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ABSTRACT
Stress initiates behavioral disturbances, which are often seen as symptoms of psychiatric
disorders, like post-traumatic stress disorder (PTSD), depression, and anxiety. While stress is
involved in the formation of disordered states, only certain individuals are vulnerable to, and
therefore experience, these outcomes. Further, females are more likely to be diagnosed with
stress-induced psychiatric disorders. Elements within stress neurocircuitry offer insight into
differential behavioral outcomes associated with stressful experiences; and the basolateral
amygdala (BLA), where pro- and anti-stress signals are integrated, is likely an important
mediator in phenotype development. The orexin system, too, while being strongly associated
with sleep, motivation, and arousal, is critical for directing stress-induced responses. Produced
in the hypothalamus, orexins (OrxA and OrxB) are released into the BLA where they target and
activate two receptor subtypes: Orx1R and Orx2R. These receptors are found on different cells
within BLA microcircuits, with Orx1R predominantly being localized to glutamatergic neurons
and Orx2R having slightly higher expression in GABAergic cells. Pharmacological inhibition of
Orx1R in the BLA rescues resilient behavior in stress vulnerable mice, while reducing fear
freezing behavior, and promoting social learning. Alternatively, Orx2R inhibition in the BLA
upsets fear learning in resilient populations, but enhances social avoidance. Alternatively,
activation of Orx2R in BLA cells reduces fear freezing and increases social preference. Female
mice exhibit unique behavioral patterns as a result of social stress compared to males, but
phenotypic responses are observed when females are administered an Orx2R antagonist. While
females have higher Orx2R expression in the BLA compared to males, pharmacological
intervention with an Orx2R antagonist reveals even further distinctions within female behavioral
phenotypes. Together, these results suggest the orexin system is important for defining
behavioral outcomes after stress, and while sexual dimorphism exists in behavior and
physiology, orexin receptor activity in the BLA appears to be a critical gating mechanism in both
male and female stress-induced phenotype development.

Dissertation Advisor __________________________
Cliff H Summers, PhD
Nolop Distinguished Professor
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Chapter 1: Counterbalanced microcircuits for Orx1R and Orx2R regulation of stress
reactivity

ABSTRACT
Orexins are hypothalamic neuropeptides regulating a range of behaviors broadly associated with
sleep, motivation, and feeding. These responses highlight the importance of orexins in
maintaining foundational biological processes, but also indicate a connection to stress-related
dysfunction, which results in aberrations to normal states of sleep, motivation, and feeding. As
such, we predict, based on clinical and preclinical evidence, that irregularities in orexin signaling
contribute to changes in affect and the formation of psychological disorders. In support of this,
orexin-producing neurons innervate several brain areas important for mediating stress responses,
including the prefrontal cortex and amygdala, where intracellular signaling results from
activation of orexin receptors (Orx1R and Orx2R). While stimulation of Orx1R and Orx2R
initiate similar intracellular pathways, signaling dynamics may be modified through receptor
location, dimerization, or genetic regulation. We further note, based on evidence from our lab,
that Orx1R and Orx2R elicit opposing stress responses after activation, suggesting the existence
of a counterbalanced mechanism for inducing physiological and behavioral stress states. Our
research and others’ demonstrate that antagonistic neurocircuits promoting either pro- or antistress responses, may be bidirectionally shifted with activation of Orx1R or Orx2R. Although
clinically approved drugs that target the orexin system, like dual orexin receptor antagonists
(DORAs), are moderately effective for the treatment of sleep- and, perhaps, addiction-related
disorders, they may inadvertently disrupt mood or exaggerate existing affective dysfunction.
We propose a novel idea for pharmacological intervention that accounts for the counterbalanced
influence of orexin receptor activity on stress-induced behaviors: selective orexin receptor
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crossover drugs (SORCOs). These SORCOs are hypothesized to potently shift signaling biases
and restore balance in stress neurocircuitry.

OREXINS – HYPOCRETINS
A novel pair of related neuropeptides/hormones was discovered in 1998 by the de Lecea,
Kilduff, Sakurai, Sutcliffe, and Yanagisawa labs [1, 2] and given different names – hypocretins
(Hcrt) or orexins (Orx) – based on what each lab was investigating. The name “orexin” refers to
the molecule’s role in feeding and appetitive behavior (from the Greek orexis, “appetite”);
“hypocretin” comes from its site of synthesis (hypothalamus) and from a molecule with which it
shares homology (secretin). Much of the early work by these labs focused on excitatory
function in feeding, arousal, and sleep-wake regulation [3-13]. The two orexins, or two
hypocretins, OrxA (Hcrt1) and OrxB (Hcrt2), are cleaved equally from a single prepro-orexin
peptide [2], and bind to two receptor subtypes derived from separate genes, Orx1R (gene:
HcrtR1) and Orx2R (HcrtR2) [14]. However, binding affinity of OrxA is high for both Orx1R
and Orx2R, but is 5-100 times greater than OrxB for the Orx1R [14, 15]. The Orx2R is bound and
activated equally well by both OrxA and OrxB [15].
Synthesis of the OrxA/OrxB neuropeptides is limited to the perifornical region of the
hypothalamus [16, 17], and is functionally divided into lateral (LH) and dorsomedialperifornical (DMH/PeF) subgroups [18]. Importantly, synthesis of Orx, and activation of LHDMH/PeF Orx neurons is greater in females [19, 20]. Most orexinergic neurons colocalize the
excitatory amino acid transmitter, glutamate (Glu), the inhibitory opiate, dynorphin (Dyn), and
the neuropeptides, neurotensin and neuronal activity-regulated pentraxin (NARP), which modify
and increase the potential actions of these neurons [21-28]. Additionally, orexin-producing
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neurons are commonly found in close proximity to cells that synthesize melanin-concentrating
hormone (MCH), which often has opposing actions [16, 29] and those that serve a similar
function, but express pyroglutamylated arginine-phenylalanine-amide peptide (QRFP) [30].
Although orexin perikarya are located exclusively in the hypothalamus, orexinergic projections
and receptors are distributed throughout the brain [31, 32]. The LH-DMH/PeF orexinergic
system has broadly projecting axons and terminals, innervating numerous limbic and cortical
structures, such as the prefrontal cortex (PFC), nucleus accumbens (NAc) shell, septum,
hypothalamus (paraventricular [PVN], anterior [AH], arcuate [ARC], dorsomedial [DMH], and
ventromedial [VMH] nuclei), bed nucleus of the stria terminalis (BNST), thalamus, and
amygdala [17, 33, 34]. These projections are reciprocated, with limbic and cortical regions
sending numerous afferents to orexinergic neurons [35, 36]. Reciprocal connections with such a
comprehensive assortment of brain regions may explain how orexins are implicated in such a
wide variety of physiological and behavioral functions [3, 14].
Orexin projections, functioning by means of Orx1R and Orx2R, promote stimulatory (for the
most part, see Receptor intracellular signaling and dimerization) influence [37] via activation of
coupled G proteins [14], which in turn promote downstream signaling pathways like cyclic
adenosine monophosphate (cAMP), phospholipase C (PLC), and extracellular signal-regulated
kinase (ERK) [14, 38, 39]. Orexin receptors have also been demonstrated to modulate molecular
systems that control neural plasticity, including Protein Kinase B (Akt), mammalian target of
rapamycin (mTOR) intracellular signaling [40, 41], and brain-derived neurotrophic factor
(BDNF) expression [39, 42, 43]. Additionally, excitatory functions of Orx may be enhanced by
Glu release as a co-transmitter, or inhibited by Dyn co-transmission [24-26].
While much of the early work on Orx focused on excitatory roles in arousal, sleep-wake
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regulation, and feeding [3-13], OrxA and/or OrxB have also been implicated in a wide variety of
physiological and behavioral functions [3, 14], which include learning [44-51], reward [18, 5256], and stress [46, 57-61]. As stress has significance in many other orexin-linked actions such
as food seeking [62, 63], reward [18, 52-56], biorhythms [64-67], and arousal [5, 55, 59, 68], it
may be that orexin’s most important roles involve “stress responsiveness.” Given that chronic
stress is a reliable predictor of depression and may be necessary for its establishment [69-71],
manipulation of the Orx system via Orx1R or Orx2R [14] could prove to hold therapeutic value
in treating depression and similarly pernicious affective disorders [72], as they have prodepressive and anti-depressive effects, respectively [73, 74]. It is important to note that while
Orx1R and Orx2R may have opposing actions relative to stress-regulation and affect in some
regions of the brain (see sections below), in other regions they may work in concordance relative
to these functions [75, 76].

QUALITIES OF OREXIN RECEPTORS
Difficult to consider, and often ignored when discussing influence over the signaling balance
of neurocircuits, are certain receptor features like location, intracellular signaling, dimerization,
and genetic regulation. While not easily evaluated for their functional contributions to
microcircuit tone, these receptor capacities support changes in neural signaling and behavioral
output. Some of these receptor attributes will go unacknowledged in our own predicted
description of Orx1R-Orx2R interplay (see COUNTERBALANCED Orx1R VS Orx2R
MODULATION), but here we recognize Orx receptor dynamics as multifaceted and important
instruments for managing stress responsiveness.
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Receptor location
Unlike Orx signaling peptides (OrxA & OrxB), which are processed from a single preproorexin molecule [2], Orx receptors are not bound by shared transcriptional and translational
processes. As such, Orx1R and Orx2R are not always found together, with mRNA [31, 33, 77]
and protein [77, 78] distributions varying based on brain location. This differential expression
suggests distinct physiological functions of the Orx receptor subtypes.
Even more specifically, Orx receptors are found on different neuronal populations.
Examples of Orx receptors concentrating on glutamatergic [79-83] and GABAergic [82, 84, 85]
neurons have been reported. Guiding system tone, Orx receptors also function directly on
serotoninergic cells [86, 87], adrenergic neurons [88, 89], histamine-producing cells [90],
dopaminergic neurons [91], microglia [92], and astrocytes [93]. In hypothalamic cell
populations, Orx1R is co-localized with numerous peptides, including Orx, corticotropin
releasing factor (CRF), and MCH [94]. Furthermore, orexin-producing neurons express Orx2R,
which may initiate a positive feedback mechanism for enhancing broadly dispersed orexinergic
tone [95]. However, more recent evidence suggests that Orx neurons do not express
autoreceptors [96], suggesting that feedback requires indirect mechanisms. These examples
demonstrate a selective influence of Orx signaling over specific neural systems and cell types
that may collectively work to balance physiological and behavioral responses.
Still more precise, Orx receptors can function on various locations on neurons. For example,
in the central amygdala (CeA) [79] and PFC [80, 81], Orx receptors have been suggested to
mediate glutamatergic signaling presynaptically. However, Orx receptors appear to also
regulate cell activity from dendrites and cell bodies [87, 95, 97]. Together, these results
demonstrate a diverse profile of Orx receptors to control neurophysiological responses through
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regional specificity at both the tissue and cellular levels. Signaling characteristics of Orx1R and
Orx2R may further expand influence over intracellular mechanisms.
Receptor intracellular signaling and dimerization
Receptor signaling cascades are intricate and while we will not go into immense detail (see
Kukkonen & Leonard, 2014 and Leonard & Kukkonen, 2014 for reviews), it is possible that
some features associated with orexin’s intracellular signaling dynamics derive from unique
qualities of the Orx1R and Orx2R subtypes, and potentially from cellular mechanisms that
modify the cascade, such as dimerization. Noteworthy, Orx receptor signaling cascades, as well
as those from other G protein-coupled receptors (GPCR), are not fully understood, in part, due
to limitations in methodologies [98]. However, we will describe some broad qualities of Orx
receptor signaling (Fig. 1) with the caveat that a complete understanding of the underlying
signaling mechanisms remains unknown.
As stimulation of Orx receptors results in elevated Ca2+ [2, 39] and PLC activation [99], it is
presumed that they work as GPCRs of the Gq variety. In support of this, Orx1R stimulation in
the prelimbic region of the PFC (PrL) leads to activation of phosophokinase C (PKC) and the
suppression of hyperpolarization-activated/cyclic nucleotide (HCN) currents [97]. However, in
human adrenal tissue, Orx2R may couple with Gq, Gs, or Gi [100, 101]. In the dorsal raphe
(DRN), locus coeruleus (LC), and pontine reticular nuclei, OrxA promotes coupling of Gi; an
effect that is suppressed with an Orx1R antagonist [102]. Further, hypothalamic Orx receptors
can couple with Gq, Gs, Go, or Gi; and during food deprivation, coupling preference shifts to
favor Gq, Gs, or Go, over Gi [103]. Specificity and coupling of G proteins may be dependent on
ligand concentration, with Gi and Gq pathways being preferred and Gs contributing only when
Orx levels are elevated [104]. Interestingly, bound Orx1R is also capable of interacting with β-
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arrestins, prompting receptor internalization [105, 106]. Also, activation of Orx1R or Orx2R in
mouse hypothalamic neurons triggers signaling cascades through the mTOR pathway [40, 41],
which may stimulate cell growth and neuroplasticity.
Cell signaling initiated by Orx receptor activation, while plastic in the ability to trigger
multiple downstream effectors, is further diversified during dimerization with other GPCRs
where signaling cascades may be altered (Fig. 1). Orexin receptor subtypes can form
homodimers/oligomers [107]. Curiously, Orx1R homodimers/oligomers may be abundant at
stable cellular states, where receptor activation leads to more dimerization and inhibition
promotes separation into the monomer formation [108]. Splice variants of Orx2R (Orx2Rα &
Orx2Rβ), with distinct C-terminus regions, also dimerize, resulting in enhanced Ca2+ signaling
[109].
It is important to note that most therapeutic drugs have not been assessed for binding affinity
to receptor dimers. Understanding the potential dimerization of these receptors is critical for
pharmacotherapeutics since these dimers may either modify the desired actions of drugs or be
required for their actions. Several heterodimers form as a result of Orx1R interacting with other
GPCRs, including Orx2R [107], Cb1 [107, 110, 111], pyroglutamylated RFamide (QRFP; an
orexin-like peptide) receptor [112], CRF1 [113], CRF2 [114], kappa opioid receptor (ΚOR)
[115], cholecystokinin type 1 (CCK1) [116], and ghrelin receptors, GHSR1a [117] and GHSR1b
[118]. Though not as heavily explored, Orx2R has been demonstrated to form heterodimers with
Cb1 [107], QRFP receptor [112], and 5-HT1A [119]. While the neurophysiological significance
of GPCR dimers remains uncertain, they are, perhaps, functioning in a way that mediates cell
signaling and downstream transcriptional changes. Further, it is not clear what effect genetic
variation imposes on receptor dimerization capabilities [120].
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Receptor genetics
In humans, genetic variants of both Orx1R and Orx2R have been linked to stress-related
dysfunction. For example, the Orx1R gene (HcrtR1) variant that leads to an amino acid
substitution at the 408th position (Ile408Val) has been linked to increased mood disorders [121,
122], elevated stress-induced aggressive behaviors [123], and polydipsic schizophrenia [124].
Similarly, the HcrtR2 variant that results in an amino acid substitution at the 308th position
(Val308Ile) is associated with panic disorders in females [125] and nicotine dependence [126].
Other HcrtR2 variants were discovered in patients experiencing daytime sleepiness (Pro10Ser)
or Tourette’s syndrome (Pro11Thr) symptoms [127]. Although it is unknown whether variants
of Orx receptors are functional [120], it is clear when the Orx system is disrupted, stress-induced
disorders become more prevalent.
Changes in transcriptional control of Orx receptors has been demonstrated in many systems,
but we focus on just a few examples related to stress and stress-provoked behavioral
abnormalities. Unpredictable chronic mild stress (UCMS) in female rodents increases Orx1R
mRNA expression [128], while chronic alcohol reduces Orx1R mRNA in the PFC [129]. Our
own lab demonstrated that Orx1R mRNA in the PrL does not change with ten days of social
defeat [130]. Single prolonged stress induces upregulation of Orx1R in both the hypothalamus
and hippocampus [131]. Further, we have demonstrated that social stress enhances Orx1R and
reduces Orx2R mRNA in the basolateral amygdala (BLA) of (susceptible) mice that demonstrate
social avoidance behavior in the Social Preference/Interaction (SIP) test [130], or animals that
demonstrate social avoidance behavior in the Social Interaction/Preference (SIP) test. In
humans, males that have committed suicide exhibit elevated Orx2R mRNA in the anterior
cingulate cortex (ACC) [128]. Interestingly, HcrtR2 expression undergoes diurnal fluctuations
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in both the hypothalamus and cortex (HcrtR1 shows this expression pattern in only the cortex),
and is correlated with expression patterns of Bmal1, a gene important in establishing circadian
rhythms [132]. Together, these examples highlight the intricacies of homeostatic and
physiological balance during periods of stress; they identify Orx receptors as important
contributors for establishing neural and behavioral normalcy.

OREXINS AND PSYCHIATRIC DISORDERS
The critical element in the relationship between Orx activity and psychiatric disorders is
stress [72]. Stress responsiveness is a crucial factor in the promotion of dysfunctional affect and
maladaptive behavior in numerous psychological conditions including attention deficit disorder
(ADD), anxiety disorders, autism spectrum disorders, bipolar disorder, major depressive disorder
(MDD), drug addiction, eating disorders, obsessive-compulsive disorder (OCD), panic, posttraumatic stress disorder (PTSD), reactive attachment disorders, schizophrenia, and sleep
disorders [133, 134]. It is significant that females and males respond differently to stress [135],
with women reported to have twice the rates of affective disorder diagnoses [136, 137]. In
addition to significantly more women being diagnosed with stress-promoted behavioral disorders
[138] such as major depression, high comorbidity with anxiety exacerbates this problem [139,
140]. What is more, human neuroimaging and animal studies suggest that neural atrophy and
other structural deficits, which play key roles in these disorders, are exacerbated by stress [141149]. The most intense stressors experienced by humans are social [150-153]. As social stress is
the most intensive [154] and unpredictable [155] of stressors, it specifically promotes
maladaptive behavior, including depression, anxiety, PTSD, sociophobia, loss of self-esteem,
and other behavioral symptoms in humans [151, 153]. The incidence rates of adult affective
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disorders steeply rise during adolescence in parallel with a structural and functional
reorganization of the neural circuitry underlying stress reactivity [156-160]. Further, stress
circuits and neuromodulatory factors are predisposing factors for human depression [161-163]
and anxiety [161, 162]. Orexin fibers heavily innervate stress-related brain regions important for
stress-induced affective disorders, including the amygdala [62, 164, 165]. This structure’s
connectome [34, 58, 164] implicates roles for Orx in arousal [1, 18, 55, 58, 166-168], food
regulation [2-4, 8, 10, 47, 62], and reward [18, 56]; but because these functions are relevant to
affective disorders, Orx is also likely to be involved in fear, anxiety [57, 130, 169-172], and
depression [73, 173-178]. Social stress is strongly influenced by Orx and Orx receptor actions,
and these data are strongly suggestive of their direct involvement in psychological disorders [72,
179].
Clinical studies and trials
Orexins appear to play a role in many psychological disorders [180-183]. Orexinergic cell
function is reliably dysregulated by depression [184]. In depressed patients, mean cerebrospinal
fluid (CSF) Orx levels are elevated, but also show reduced diurnal fluctuation [182]. Depressed
patient CSF orexin levels, however, are diminished after attempted suicide [180, 181]. Human
brain, blood, and CSF levels of orexins fluctuate with steady state disruptions occurring as a
result of childhood mistreatment [185], anxiety [172, 185], sleep disorders [186-194] panic
[172], schizophrenia [195, 196], traumatic brain injury [197, 198], Alzheimer’s Disease [186,
199, 200], and heart disease [201], as well as by depression and suicide [180-182, 185]. These
reports together suggest that reduced Orx is critically associated with depression and preclinical
depressive behavior [184, 202, 203]. This interpretation of these data is consistent with reported
effects in animal models, in which, orexins prevent depressive behavior by promoting stress
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resilience (see section Preclinical evidence) [84, 177, 204-207].
There appear to be clinically relevant sex differences in Orx function with respect to stress
and affect [208]. While there are no significant differences in plasma OrxA in healthy younger
women and men [209], among older subjects, women have higher levels of OrxA in CSF than
men [210]. Interestingly, narcolepsy which is associated with profound reductions in neural
orexinergic function, does not distinguish patients’ plasma levels of OrxA, which are more
commonly male, from those without narcolepsy [211]. Sleep disturbance appears to be divided
by sex along lines associated with Orx function. The probability of reduced Orx function and
greater narcolepsy in males, and potentially increased Orx function leading to insomnia in
females [212, 213], are suggestive of brain Orx systems differentiated by sex. Female patients
with major depression exhibit elevated OrxA in PFC [128], which is not seen in healthy females
or males [128, 209]. Interestingly, these female patients were postmenopausal, suggesting that
any sex differences were not due directly to sex hormone actions, although indirect long-term
effects may have contributed the differences. The relationship between Orx function and
affective disorders seems to be worth further investigation.
However, while Orx receptor antagonist drugs have been approved for treatment of insomnia
[214, 215], virtually no large-scale clinical examinations of Orx1R- or Orx2R-related drug
effectiveness specifically for psychiatric disorder treatment has been undertaken. The dual
orexin receptor antagonist (DORA) sleep-promoting drug, suvorexant (Belsomra), is clinically
approved as a treatment to encourage somnolence by reducing arousal and wakefulness [216]. It
will be important to clinically examine its effects on stress and affect. Suvorexant lowers stress
hormone levels of cortisol and norepinephrine, and reduces the severity of anxiety and
depression in psychiatric patients with insomnia [217], while effectively reducing sleep onset
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times and increasing sleep duration, without rebound or withdrawal [218]. These results are
consistent with the Orx1R antagonist activities of the drug, but different from those expected for
its Orx2R antagonist actions [179]. Interestingly, in a preclinical trial of the competitive Orx1R +
Orx2R antagonist, almorexant, a DORA that had been in phase II clinical trials, anxious and
depressive behavior were reduced to the same extent as with the antidepressant, fluoxetine [219].
As chronic insomnia is highly comorbid with affective disorders, and is associated with up to a
4-fold increased risk of developing major depression [220-222], it seems appropriate to test
interactions between drugs, such as DORAs, taken for insomnia and antidepressants [223]. Drug
interactions between desipramine, a tricyclic antidepressant (TCA), and almorexant, revealed
that the enzyme primarily responsible for metabolism of the antidepressant is inhibited by
almorexant. Not surprisingly, almorexant increased exposure to desipramine by nearly four
times, whereas the antidepressant had no relevant pharmacokinetic effects on almorexant. There
was, however, a slight increase in calmness in patients using almorexant. Regrettably, this
DORA with possible capacity for lowering affective symptoms was removed from clinical trials
based on its safety profile [224]. Filorexant (MK-6096) is another dual Orx receptor antagonist
in phase II trials for patients with major depression, but these were terminated early, without
showing a significant difference in depression rating [225]. One of the two most common
adverse events for filorexant was suicidal ideation, which is common in this type of patient.
Recent development and clinical trials for two new single orexin receptor antagonist (SORA)
drugs have presented potentially promising treatments for anxiety and depression through Orx1R
or Orx2R inhibition, respectively. The clinical potential for limiting Orx1R activity has been
successfully examined in phase I trials, with the Orx1R antagonist, ACT-539313, developed
specifically for the purpose of reducing anxiety [226, 227]. The other SORA drug is an Orx2R
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antagonist, seltorexant JNJ-42847922/MIN-202, designed to reduce insomnia [178, 228-230],
which was demonstrated to be safe and effective in clinical phase 1, 1b and 2 trials for that
purpose. Importantly, this Orx2R antagonist was also demonstrated to reduce self-reported
depression in some of these small sample trials. The potential antidepressant action of this
Orx2R antagonist runs counter to the primary hypothesis of this paper, that Orx2R stimulation
inhibits stress-responsive neurocircuitry to limit anxious and depressive behavior. A different
Orx2R antagonist, MK-1064, delivered icv or directly into the BLA of the mouse brain, increases
stress responsiveness and behavior [179]. We are excited by the development of these new
SORA drugs, and are anxious to test their activity on stress-related neurocircuitry with objective
measures of behavior in our animal model (see COUNTERBALANCED Orx1R VS Orx2R
MODULATION). This kind of comparison will be necessary to help determine the value of our
suggestion of a clever new type of drug or combination of drugs awaiting drug discovery,
selective orexin receptor crossover (SORCO), which makes use of the opposing functional
effects of Orx1R and Orx2R actions [72], which was derived solely from pre-clinical studies.
Preclinical evidence
The effects of OrxA peptide action in emotion-related regions of the brain (sometimes via
systemic delivery) promote anxious behavior or anxiety [204, 231-234]. The actions of OrxA
often shows similar effects to those of Orx1R agonists, suggesting that the more common Orx1R
binding is the primary transducer for OrxA. Effects of whole brain (intracerebroventricular [icv])
infusion of OrxA in mice increases anxiogenic behaviors in the Light-Dark Test (LDT) and
Elevated Plus Maze (EPM) [235]; while effective pharmacological reversal (using antagonists
selective for dopamine or serotonin receptors - haloperidol, ritanserin, or metergoline) of the
anxious behaviors stimulated by icv injection of OrxA or OrxB is highly dependent on the drug’s
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specificity for monoaminergic receptors [236]. Stress induced through corticosterone
administration in mice promotes anxious responses in EPM, commensurate with increased OrxA
[237]. Furthermore, orexin-deficient mice exhibit reduced reactivity to foot shocks, heightened
anxious behavior in open field (OF) and LDT paradigms, and an increased fear response to
predatory odors [204]. In contrast, optogenetic excitation of Orx cells in rats increases
anxiogenic aversion for a social target, enhances exploratory behaviors, and results in the
internalization of Orx1R in the paraventricular thalamus (PVT) and locus coeruleus (LC) [233].
Optogenetic stimulation of mouse hypothalamic Orx neurons or terminals activates the
noradrenergic LC, which when those Orx terminals in LC are optogenetically stimulated results
in enhanced fearful threat learning [238] and fear generalization [89, 239]. Interestingly,
optogenetic studies reveal the LC is one of the structures that Orx stimulates to promote
wakefulness [88, 240]. A combination of optogenetic and chemogenetic tools helped identify
another circuit associated with anxious behavior from GABAergic CRF and cholecystokinin
neurons in the BNST to hypothalamic Orx neurons [241]. In this circuit, optogenetic and
chemogenetic stimulation of CRF or CCK BNST neurons projecting on to Orx neurons increased
anxious behavior. Additionally, optogenetic activation of Orx neurons in the LH that target the
PVN is sufficient to stimulate hormone secretion from the HPA axis [242]. These data suggest
the hypothalamic orexinergic system is a hub for arousal of stress responses and motivation [243,
244].
Chronic corticosterone-induced stress also promotes depressive reactions in Tail Suspension
Test (TST) trials in mice, but further is associated with increased OrxA-containing cells in the
hypothalamus [237]. Wistar-Kyoto rats, a strain demonstrating depressive behaviors and
disrupted sleep patterns, possess fewer OrxA-expressing neurons, and these cells have a reduced
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size in comparison to Wistar control rats [205]. Contrastingly, in a genetic animal model of
depression, the Flinders Sensitive Line, female mice exhibit an elevated number of Orx neurons
in the hypothalamus [173]. Following traumatic stress, in a predator-odor model of PTSD,
hypothalamic OrxA and OrxB levels are significantly lower in individuals with extreme
behavioral disruption (PTSD-phenotype) compared to those with minimal disruption, who
display up-regulated OrxA and OrxB [245]. Similarly, social defeat-induced depressive behavior
in rats is accompanied by a reduction of OrxA and OrxB in tissue samples taken from the ventral
tegmental area (VTA), medial prefrontal cortex (mPFC), and hypothalamus [246]. Levels of
OrxA and OrxB may be influenced by age as well as affective state. In the clomipramine-induced
depression model, juvenile Long-Evans rats exhibit reduced Orx levels, but in adults they are
significantly enhanced [247]. Administered into distinct areas of the stress circuit, such as the
BNST [234], CeA [169], and BLA [82], Orx produces anxious and depressive behavior. In
addition, chronic social defeat epigenetically reduces prepro-orexin mRNA, but calorie
restriction thereafter enhances activation of Orx cells, which results in an antidepressive response
[177]. Similarly, early life stress dampens restraint-stimulated Orx cell activity, and produces a
depressive behavioral phenotype, all of which can be reversed by exercise in adolescent male
rats [248]. These reports together suggest that reduced Orx is critically associated with
depression and preclinical depressive behavior [203, 249, 250]. What is more, in genetic models
of depression, reduced Orx levels have also been measured [205, 206].
Downstream of Orx neurons, and OrxA + OrxB release, most work in animal models has
focused on the effects of Orx1R actions, which influence emotion-related regions of the brain
(sometimes via systemic delivery) to promote anxious behavior or panic [57, 171, 172, 204, 231234, 251]. In some regions of the brain, like the CeA, the effect of OrxA to produce anxious or
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conditioned fear behavior appears to depend only on the Orx1R [79, 252]. Rodents bred with the
Orx1R gene knocked out exhibit increased anxious responses [207], reduced depressive
behaviors [74, 207], and impaired fear conditioning in reaction to cued and contextual stimuli
[89, 253]. Injections of SB-334867 (intraperitoneal [ip]), a potent selective antagonist of Orx1R,
can mimic the response of Orx1R null mice, showing reduced depressive reactions in tests of
behavioral despair (forced swim test [FST] and TST) [74] and fear conditioning paradigms
[253]. Intra-amygdalar injections of Orx1R antagonist diminishes anxiety and fear conditioning,
but also decreases memory acquisition in a rodent model of PTSD [254]. In contrast, SB-334867
(ip) inhibits the reported antidepressive actions of whole brain (icv) OrxA in the FST, and
prevents orexin-induced proliferation in the dentate gyrus (DG) [176].
Interestingly, oral delivery of a dual Orx1R/Orx2R antagonist (SB-649868) limits elevation of
the pituitary stress hormone adrenocorticotropic hormone (ACTH) stimulated by mild cage
exchange stress, but not as effectively as a selective Orx2R antagonist (JNJ-42847922), or in
Orx2R knockout animals [255]. The authors suggest that the results are consistent with
predominant Orx2R expression in the PVN [31, 33], however, the systemic delivery makes it
unclear whether the effects were neural or hormonal.
Again, it is likely that animal models will reveal sex differences in Orx function as an
important component of stress-related responses [208]. While plasma levels of estrogens appear
to correlate positively with Orx neural activation, those of testosterone do not [208]. Further,
there appears to be a relationship between estrous cycle and expression (both mRNA and
protein) of orexins and their receptors [256-258], but neither orchidectomy nor estrogen or
testosterone replacement has an influence on Orx neuronal transcripts of prepro-orexin or Orx
receptors [20], perhaps explaining why other studies have not measured a relationship between

16

estrous cycling and hypothalamic Orx mRNA [259]. These data suggest that direct influences on
Orx synthesis due to reproductive cycling may be extra-hormonal, but Orx neuron activity is
enhanced by estrogens. Nevertheless, prepro-orexin mRNA is twice as high in female compared
to male rats [20], plus elevated hypothalamic Orx neuron activation along with higher CSF OrxA
concentrations in females [19]. Additionally, Orx1R and Orx2R mRNA have been shown to be
higher in female PVN and whole hypothalamus compared to males [20, 260]. Therefore, there is
ample evidence to suggest that there are sex differences in Orx function, that Orx plays a role in
affective disorders, and that those psychological disorders are influenced, even driven, by stress.

OREXINS IN STRESS
Orexins are important for arousal and for the reactive transition to coping with stressful
provocations because they play a critical role in modulating the neural systems that respond to
stressful stimuli [208, 261]. Stressful conditions potently modify Orx and Orx receptor
expression in the brain [254]. Beginning in the hypothalamus, where orexins are made in the
LH-DMH/PeF, these neurons are activated by acute stress [73, 262, 263], producing elevated
plasma and CSF levels of OrxA [262, 264]. Additionally, orexins have a cross-connected
interactive relationship with the primary stress neuropeptide CRF [58, 59, 265-267]. Specific
GABAergic CRF and CCK neurocircuitries form the BNST activate hypothalamic orexinergic
neurons, and influence emotional and stressful outcomes [241]. In addition to CRF, Orx neurons
link emotional stress to autonomic responses [268]. What is more, persistent pain and stress
activate Orx pathways [269]. Stressful behavioral paradigms, such as fear conditioning, increase
Orx1R in the amygdala [254]. Stress-activated Orx neurons exhibit upregulated expression of
BDNF, and another stress regulatory neuromodulator, neuropeptide Y (NPY) [245].
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The chief output region of the amygdala is the CeA, which regulates hypothalamic
neuroendocrine (hypothamo-pituitary-adrenal [HPA] axis) function, and extrahypothalamic
stress-related functions such as anxiety. In the CeA, Orx1R, but not Orx2R, activity modifies
neuronal depolarization and firing rate [79, 252]. The initial hormone in the HPA cascade, CRF
(produced and secreted as a hormone from the PVN and as a neuromodulator in the CeA and
BNST) increases Orx neuronal activity [58, 241]. Downstream, Orx2R is implicated in stressinduced secretion of adrenocorticotropic hormone (ACTH) release from the pituitary [263].
Taken together, the evidence from recent experiments suggests that Orx plays an important role
in most, if not all, stress-induced responses [58, 59, 68, 265, 270].

OREXINS AND STRESS NEUROCIRCUITRY
Orexinergic innervation of stress-related neurocircuitry is evident in both behaviorally relevant
limbic structures and, with significant overlap, limbic plus hypothalamic structures regulating
neuroendocrine stress hormone output (see previous section). Applicable to the specific
neurocircuitry necessary to produce affective behavior and fear learning, Orx neurons innervate
the thalamic terminals in mPFC. They also innervate BLA neurons receiving inputs from mPFC,
CeA neurons receiving input from BLA, and periaqueductal gray (PAG) neurons, which receives
input from the CeA. Additionally, as the regions of extended amygdala play important roles in
anxiety and depression, orexinergic projections to the BNST and the dopaminergic reward
circuitry from VTA to NAc and the surrounding ventral striatum may be important for those
affective responses. This latter relationship is evident in work linking Orx and stress to addiction
[271-276]. Recent evidence points to another specific Orx stress circuit that promotes addiction
and relapse, beginning in the Neuropeptide S (NPS) neurons of the Kölliker-Fuse nucleus of the

18

parabrachial nucleus (PBN) and the region around the LC, which directly stimulate hypothalamic
Orx neurons. These Orx neurons project to the VTA, and through binding of Orx1R and
PLC 2nd messenger, stimulate production of the endocannabinoid 2-AG, which disinhibits VTA
dopaminergic neurons by way of Cb1 receptors [277-281]. However, there are specific
additional neurocircuits for stress-related activity, from BNST, via GABAergic CRF and CCK
neurons, to hypothalamic Orx neurons [241], and then to noradrenergic neurons in the LC [89,
238, 239]. The interactive relationship between stress neurocircuitry and Orx also importantly
connects the food-seeking function of the peptide, with both reward and arousal [282-286].
These cross-linked functional roles have suggested that the primary role for Orx is motivational
[287, 288]. Further, recent work from our lab suggests Orx acts in decision-making
neurocircuitry (which also overlaps stress neurocircuitry) with definitive effects on behavioral
choice outcomes [72, 179]. As stress, arousal, reward, anhedonia, and modified decision-making
are all critical elements related to the onset of anxiety and/or depression, it seems likely that Orx
also plays a role in regulating the neurocircuitry involved in affective disorders [72, 73, 130,
179].

MEDIAL PREFRONTAL CORTEX (mPFC) AND AMYGDALA MICROCIRCUITS
The mPFC has a critical role in cognition, learning, executive control of emotional states,
stress-coping strategies, decision-making, and social interaction. Similarly, the amygdala is
involved in determining and learning emotional behavior, stress-coping strategies, and
behavioral responses to aversive and rewarding stimuli. Even though mPFC and amygdala are
involved in many overlapping functions related to emotional learning, the sub-nuclei of these
regions display unique patterns of connectivity, suggesting distinct parallel circuits between the
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mPFC and amygdala (Fig. 2) that preferentially drive behaviors and emotion-related learning.
Prelimbic (PrL) and infralimbic (IL) cortices
In the rodent brain, the mPFC is composed of three main subregions: anterior cingulate
(ACC; Brodmann Area 24 in humans), prelimbic (PrL; BA 32 in humans), and infralimbic (IL;
BA 25 in humans) cortices. In these regions, layer V pyramidal neurons provide output to
subcortical structures like amygdala, hippocampus, and striatum [289-291]. Additionally,
inhibitory interneurons containing gamma-aminobutyric acid (GABA) in the mPFC regulate the
outgoing signal of pyramidal neurons, or other interneurons.
Activity in the PrL and IL is predominantly involved in opposing aspects of emotional
learning [292]. Together, activation of terminals in the PrL and IL projecting from the BLA
causes anxiogenic behaviors and a reduction in social preference; while inhibition of these
terminals produces the opposite effect [293]. However, individual activation of the PrL and IL
promotes unique responses, suggesting each region serves distinctive functions [294-299].
These response-specific features, perhaps, derive from differential and reciprocal projection
patterns with the BLA, NAc, VTA, BNST, dorsal raphe (DRN), LC, hippocampus,
hypothalamus, and thalamus [300]. While the PrL primarily mediates cognitive-limbic functions
like decision-making, goal-directed behavior, and working memory, IL activity tends to
influence visceral/autonomic functions like heart rate, gastrointestinal functions, blood pressure,
and respiration [300].
Activity in the PrL is critical for the expression of fear, as well as forming and maintaining
fear memories, which can be enhanced or diminished upon PrL stimulation or inhibition
respectively [294-297]. Conversely, learning and maintaining behaviors related to reward,
including those associated with fear extinction, are increased with stimulation of IL and
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suppressed during IL inhibition [294-297]. Important for its role in fear extinction, IL activation
can simulate inhibitory interneurons in the ventral intercalated region of the amygdala (vITC),
which suppress medial CeA (mCeA) neurons that become disinhibited to trigger fear responses
[297, 298].
Anterior and posterior basolateral amygdala
The BLA receives input from brain structures relaying information about external and
internal sensory information, memory, and decision-making. This cortex-like structure consists
of about ~80-85% glutamatergic pyramidal projection neurons (PNs) and ~15-20% GABAergic
inhibitory interneurons [301, 302], which act together to regulate BLA signaling. In the BLA,
PNs are the main source of output, exciting cells in numerous downstream brain regions.
Interneurons act by inhibiting PNs and/or other interneurons, thereby modifying the outgoing
signal. Acquisition of a fear or reward memory occurs from the convergence of sensory
information projecting to the lateral (LA) portion of the BLA [301], which drives appropriate
projections and activity in the more basal area. Interneurons (specifically those expressing
parvalbumin [PV+]) supply inhibitory tone to pyramidal neurons in the LA, but dampen their
suppressive effect during fear conditioning [303]. The resulting excitatory signal from BLA
activates the main fear output of the amygdala, the CeA.
The CeA is a striatal-like structure almost entirely composed of medium spiny GABAergic
interneurons and inhibitory projection neurons [302]. Expression of fear is ultimately the result
of activating inhibitory neurons in the mCeA, which are usually under inhibitory control of
neurons originating in the lateral CeA (lCeA) [304]. Projections from interconnected inhibitory
circuits of the lateral capsular CeA (lcCeA), lCeA, and mCeA regulate inhibitory tone over
stress-induced behaviors, like freezing.
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Distinct populations of BLA pyramidal neurons become activated in response to either
aversive or appetitive unconditioned stimuli. Selectively activating these cells produces innate
fear or reward behaviors and can reinforce learning of either fear or reward [305]. Additionally,
“fear” neurons, projecting from the BLA to the PrL, increase their firing rate in response to fear
conditioning and decrease their activity following extinction learning; alternatively, “extinction”
neurons of the BLA become more activated in response to extinction learning, and innervate the
IL and CeA [306, 307]. During extinction learning, previously formed fear memories are not
erased (or unlearned), but rather, suppressed to allow the new extinction memory to become
expressed. A potential mechanism underlying extinction memory expression is the silencing of
BLA “fear” neurons through inhibitory signaling of PV+ interneurons [308]. These studies
identify separate BLA neuronal populations acting within microcircuits to mediate behavioral
and emotional output.
Two genetically unique populations of excitatory PNs in the BLA preferentially process
positive (rewarding) or negative (aversive) valence, as well as guide behavioral responses to
seek and avoid these types of stimuli respectively [299]. These nearly non-overlapping
populations along the anterior-posterior axis make up almost all the glutamatergic neurons
within the BLA. The anterior BLA (aBLA) contains magnocellular glutamatergic PNs that
express the genetic marker R-spondin 2 (Rspo2+), which are preferentially activated by aversive
stimuli, and, upon stimulation, decrease motivation to seek reward and increase freezing
behavior [299]. These aBLA neurons send dense projections to the capsular CeA (cCeA) and
PrL, and send ~30% of the projections from the BLA to NAc [299]. In contrast, the posterior
BLA (pBLA) preferentially contains parvocellular glutamatergic PNs that express the genetic
marker Ppp1r1b, encoding for the dopamine- and cAMP-regulated neuronal phosphoprotein
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(DARPP-32) [299]. These pBLA neurons become activated by exposure to rewarding stimuli,
and when optogenetically stimulated, disrupt aversive behavioral response [299]. Connections
from Ppp1r1b+ neurons target the lCeA, mCeA, and IL, and make up ~70% of the connections
from the BLA to the NAc [299]. Furthermore, Rspo2+ and Ppp1r1b+ neurons reciprocally
suppress each other’s activity; however, ~25% of connections from Ppp1r1b+ to Rspo2+ and
~17% from Rspo2+ to Ppp1r1b+ neurons produce excitatory effects [299].
Pro-stress microcircuits
Through reciprocal connectivity, the PrL and aBLA promote learning and expression of fearrelated behaviors and therefore describe the “pro-stress” microcircuits (Fig. 2A) [307, 309].
Projections from the BLA to the PrL are triggered during high fear states [310], providing
bottom-up negative valence processing that requires excitation of Rspo2+ PNs [299].
Furthermore, BLA neurons that target the CeA, presumably Rspo2+ cells innervating the cCeA
[299], are activated during cue-induced fear responses [307]. Interestingly, while activation of
the PrL reduces social preference, this motivational social learning is driven through PrL to NAc
connections and not PrL innervations of the amygdala or VTA [311]. Therefore, bottom-up
signaling to the PrL from specific aBLA neurons may prompt social aversion [293] through
downstream projection pathways. Collectively, these findings illustrate a pro-stress microcircuit
centered around aBLA neurons that send/receive signals to the PrL, as well as relay behavioral
output information to the CeA.
Anti-stress microcircuits
The IL and pBLA Ppp1r1b+ neurons, through reciprocal connections, are important for
consolidating fear extinction memories and driving reward-related behaviors. Although only
~8% of neurons in the IL project to the BLA in rats [312], enhanced activity in the IL and pBLA
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circuits are considered “anti-stress” microcircuits (Fig. 2B) that become activated upon exposure
to safety and rewarding cues. While BLA neurons innervating the IL display enhanced
excitation during fear extinction learning, and BLA-activated ventral PAG-projecting IL neurons
are also essential for fear extinction [313-315]. Further, activation of pyramidal neurons in the
IL results in inhibition of pro-stress PrL pyramidal neurons [316], perhaps, as a result of ILoriginating NPY-positive (NPY+) GABAergic neurons that project to the PrL [317]. In the
BLA, neurons innervating the IL are more susceptible to activity-dependent suppression than
those connecting with PrL, an effect that is mediated through endocannabinoid signaling
dynamics onto BLA interneurons (specifically cholecystokinin-positive [CCK+] cells) [310].
Additionally, social behaviors, perhaps associated with Ppp1r1b+ neurons projecting to the NAc
[299], are modulated by endocannabinoid interaction with BLA cells [318]. In sum, these
results indicate that anti-stress microcircuits are distinct from pro-stress circuits (Fig. 2), and
primarily involve signaling between the IL and pBLA.
The concept of counterbalanced microcircuits
While it is easier to consider stress reactivity in the guise of “stress on” and “stress off”
conditions, microcircuits exist in dynamic relationships where stressful events skew response
signaling to favor one behavioral state over another. When equilibrium is shifted, the
permanence associated with the manifestation of phenotypic display is largely dependent on the
degree to which the neural signaling is altered. This counterbalance theory of stress
responsiveness predicts that the realignment of pro- and anti-stress signaling to a more balanced
state may serve to correct affective dysfunction.
Amygdala hyperactivity in response to threat has been observed in clinical anxiety disorders
[319], and may serve to predict future risk of developing anxious or depressive disorders [320].
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Brain imaging and post-mortem studies show hypoactivity and reduced volumes in the PFC of
humans with depression [321]. Individuals that are better able to suppress negative emotions
display greater attenuation of amygdalar activity and higher inversive coupling between the
ventromedial PFC (vmPFC; human IL homologue) and amygdala [322]. This suggests mood
disorders may manifest due to changes in connectivity and functionality of the mPFC and
amygdala, with heightened amygdalar and reduced PFC activity upsetting executive control over
emotions. However, distinguishing specific mechanistic frameworks in BLA-mPFC pro- and
anti-stress microcircuits that work in a counterbalanced fashion may provide insight as to how
stress-related dysfunctions arise and, perhaps more importantly, how to correct them. One such
system, potent and dualistic in its physiological and behavioral provocations during periods of
stress, includes the targets of orexins: the Orx receptors.

OREXIN RECEPTORS AND STRESS RESPONSIVENESS
Stress-induced behavioral and physiological responses are mediated through complex
interactions of genetic and environmental influences that direct signaling biases in pro- and antistress microcircuits. Within these circuits, Orx receptors (Orx1R and Orx2R) gate the emergence
of stress-related behaviors. While evidence for Orx receptor modulation of stress responses
exists outside the microcircuits highlighted above (see Summers et al., 2020 for review), in this
section we will focus on findings that specifically incorporate the PFC and amygdala.
Gating stress responses through the prefrontal cortex (PFC)
The PrL and IL divisions of the PFC are heavily innervated by glutamatergic neurons
originating in the thalamus, particularly mediodorsal (MDT) and PVT nuclei [323]. Orexinproducing neurons of the hypothalamus densely project to the PVT [34] where OrxA, and OrxB
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to a greater extent, activate glutamatergic cells [324]. Direct infusions of OrxA or OrxB into the
PVT enhance anxious responses in the EPM; and EPM-related anxious behaviors can be
alleviated by blocking Orx1R [75] or Orx2R [76] in the PVT. A homeostatic consequence of
activating orexin-producing neurons is internalization of PVT-expressing Orx1R [233]; an effect
that is reversed with Orx1R antagonism in the PVT [75]. Although the Orx system can alter
PFC activity indirectly through thalamic nuclei, orexinergic projections also supply direct
signaling to the PFC [34].
Transcriptional expression of Orx1R is moderate in both the IL and PrL; however, Orx2R is
expressed minimally in the IL and appears to be absent in the PrL [33]. In the PrL, Orx1R is
localized to cell bodies and neuronal processes of pyramidal neurons of layer V [97]. Further,
Orx2R activation increases Ca2+ in the presynaptic terminals of axons projecting from the
thalamus to layer V PFC neurons [81]. Interestingly, in layer V of frontal area 2 (FA2), a large
PFC region lateral to the PrL, Orx1R is localized on intracortical glutamatergic presynaptic
terminals, but not on thalamocortical terminals [80]. Together, these findings suggest that
within the PFC, there is a regional dependence of Orx system control over signaling tone; and
this is initiated through direct activation of PFC neurons or regulation of Glu release from
thalamocortical inputs. However, social stress leads to a reduction in hypothalamic release of
OrxA and OrxB to the PFC [246], diminishing orexin-induced activation of PFC neurons.
The significance of Orx2R signaling in the PFC with respect to stress responses can only be
hypothesized (see section COUNTERBALANCED Orx1R VS Orx2R MODULATION);
however, few studies have considered the role of Orx1R-containing PFC neurons in behaviors
relevant to stress circuitry. For example, chronic alcohol exposure reduces Orx1R mRNA in the
PFC [129], which possibly contributes to alcohol- and withdrawal-induced changes in signaling
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dynamics of the PFC [325] and amygdala [326] that lead to hyperreactive stress states [327].
Also, blocking Orx1R in the PFC, specifically the ACC and orbitofrontal cortex (OFC), interferes
with stable decision-making strategies [328], a characteristic applicable to stress-induced
affective disorders [329]. Further, blocking Orx1R in the PFC abolishes cue-induced feeding
behavior [330], a response associated with stress-provoked eating [331, 332]. Systemic
administration of an Orx1R antagonist also reduces cue-induced feeding behavior and increases
neuronal activity of the IL, PrL, and PVT [333].
Gating stress responses through the amygdala
In the BLA, Orx receptors are localized to both glutamatergic and GABAergic neurons [82,
83]. Optogenetic activation of glutamatergic neurons in the perifornical region (PeF) of the
hypothalamus that project to the amygdala exaggerates the fear expression profile in rats [334].
Blocking intra-amygdalar Orx1R suppresses anxiety and fear responses in stressed rodents [83,
254]. Similarly, systemic (ip) administration of an Orx1R antagonist reduces contextual and
cued fear learning responses [253] and is associated with activation of IL-projecting BLA cells
and calbindin-expressing BLA interneurons [335]. Perhaps these effects, in part, are related to
impairments in spatial learning that are associated with intra-BLA Orx receptor antagonism
[336], which can reduce long-term potentiation (LTP) in DG granular cells [337]; however,
recent preliminary results from our lab suggest that small doses of an Orx1R antagonist into the
BLA enhances spatial learning during periods of stress [83]. This finding remains consistent
with the report that intra-BLA antagonism of Orx1R or Orx2R does not impair memory retrieval,
but does impact consolidation [336]. Systemic (ip) Orx2R inhibition has also been shown to
diminish contextual fear responses but has no effect on cued fear expression [253]. In our lab,
we demonstrated that cued fear associated with social stress can be reduced through icv infusion
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of a small dose of an Orx2R agonist [179]. Additionally, repeated restraint stress in mice
increases Orx release to the BLA, and this increase BLA Orx is associated with depressive
behaviors [82].
Orexin-producing neurons send projections to the CeA where they regulate release of Glu by
targeting presynaptic Orx1R [79]. As the CeA houses predominantly GABAergic neurons
[338,339], some of which are CRF-producing [340, 341], presynaptic Orx1R may be localized
on the terminals of BLA projection cells. Microinfusions of either OrxA or OrxB into the CeA
increases anxious behaviors in the LDT and EPM [169]. Inhibition of CeA Orx1R can reduce
conditioned fear [79].
Collectively, these examples demonstrate the ability of Orx receptor activity in PFC and
amygdala microcircuits to bias stress reactivity. Further, these data indicate that Orx1R and
Orx2R opposition is not a fundamental element of Orx functioning everywhere in the brain, and
that these two receptors can regulate stress and affect concordantly. While a complete
understanding of the cellular and molecular mechanisms employed to shift stress responses
remains an ambitious and long-term goal of ours, in the following section we will predict, based
on evidence from our lab, a counterbalanced mechanism for mediating stress-induced behaviors
via Orx1R and Orx2R interaction.

COUNTERBALANCED Orx1R VS Orx2R MODULATION
The idea of the Orx system contributing to bidirectional stress responses is not novel.
Discrete and parallel circuits, incorporating the lateral hypothalamus and orexin-producing
neurons, initiate opposing behavioral responses to emotionally relevant stimuli [241].
Furthermore, motivated behavior promoted through Orx release is antagonistic to the action of
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Dyn, an endogenous opioid that is co-expressed with Orx, in the VTA [27]. At the level of
synapses, Orx1R activation through Gq signaling can lead to the production and release of 2arachidonoylglycerol (2-AG) (Fig. 4C) [342], which may suppress the initial Orx system
stimulation in circuits tied to food-seeking and pain [343]. While these examples demonstrate
orexin’s involvement in opposing systems, we propose that dualistic Orx1R versus Orx2R
signaling within stress microcircuits shifts behavioral responses to favor maladaptive or adaptive
outcomes.
Inhibition of Orx1R in stress microcircuits
Using a test of behavioral despair, we observed a positive relationship between despair
(immobility) and amygdalar Orx1R mRNA levels [73]. Additionally, we detected elevated
Orx1R mRNA in the BLA of individuals displaying susceptibility after 10 days of social defeat
[130]. These transcription levels of Orx1R were further negatively correlated with social
preference behavior [130]. Together, these results suggest that Orx1R activity in the BLA is
important for one side of a system that balances stress reactivity.
Using a preclinical social stress paradigm designed by our lab, called the Stress Alternatives
Model (SAM), we set out to determine if pharmacological manipulation of Orx1R in the BLA
(intra-BLA) could shift stress responsivity (Fig. 3). The SAM takes advantage of the fact that
when mice are exposed to intense stress (like social stress), they diverge into behavioral
phenotypes, adopting either active or passive coping strategies [344-346]. We have
demonstrated that mice displaying the active strategy (called Escape mice) are behaviorally and
physiologically resilient to stress, while those of the passive phenotype (called Stay mice) are
susceptible to stress [179, 347]. Following phenotype commitment in the SAM, antagonism of
Orx1R in the BLA shifted behaviorally susceptible (Stay) individuals toward the resilient
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(Escape) phenotype (Fig. 3E), suggesting a positive influence of drug delivery on decisionmaking during stress [83]. Inhibition of Orx1R also reduced fear learning responses (Fig. 3A) in
mice conditioned to associate a tone with social aggression [83]. In a similar way, blocking
intra-BLA Orx1R decreased aggression-induced conflict-freezing responses, but had no effect on
fear-related startle response (Fig. 3B, C) [83]. It is noteworthy that stimulation of Orx1R in the
BLA produced opposing effects [83].
Our results support the prediction that Orx1R activity in the BLA drives pro-stress responses
and blocking these receptors biases anti-stress microcircuit signaling. Several other studies
provide complimentary findings that bolster our claim that inhibition of Orx1R promotes positive
behavioral outcomes to stressful events [74, 75, 170-172, 251, 253, 254, 330, 348-350]. We
propose that selective Orx1R inhibition may provide a potential therapeutic quality for affective
disturbances, like those observed in MDD, by correcting signaling imbalances within stress
neurocircuitry. However, our results establish an equally viable pharmacological target in the
Orx2R (Fig. 3).
Orx2R stimulation in stress microcircuits
In response to social defeat, susceptible individuals express lower levels of Orx2R mRNA in
the BLA and the level of expression is positively correlated with social preference [130]. In the
SAM, we demonstrated that inhibition of whole brain (icv) Orx2R enhanced susceptible
behaviors in previously resilient mice, including the blockade of escape behavior, enhanced
freezing, increased startle, and diminished social preference [179]. We observed similar results
with intra-BLA infusion of an Orx2R antagonist [83].
In contrast, rescue of escape behavior in susceptible (Stay) mice was possible using whole
brain [179] and intra-BLA [83] administration of an Orx2R agonist (Fig. 3E). Further, we
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observed a reduction in fear-related conditioned/conflict freezing and startle (Fig. 3B, C) [83,
179]. The SAM paradigm incorporates decision-making [344-346] and allows for measurements
of motivated behaviors that are sometimes blunted during periods of stress, like escape-seeking
behavior (called Attention Toward Escape) [83, 179]. Stimulation of Orx2R [83, 179] and
inhibition of Orx1R [83] activate this adaptive response in susceptible mice (Fig. 3D). Although
few studies have directly addressed Orx2R activity in response to stress-related behaviors, there
are those that complement our findings [74, 84]. Collectively, these observations expose a
mechanism by which Orx1R and Orx2R activity bidirectionally balances stress responsivity.
Importantly, our preclinical results illustrate that Orx receptor signaling in stress microcircuits
mediates stress reactivity by altering behavioral output related to fear, decision-making, and
motivation (Fig. 3). We posit that simultaneous antagonism of Orx1R and stimulation of Orx2R
(see section THE POTENTIAL FOR SELECTIVE OREXIN RECEPTOR CROSSOVER
DRUGS (SORCOs)) would provide a potent effect on biasing resilient behaviors in response to
stress.
Competing Orx1R and Orx2R signaling to balance pro- and anti-stress microcircuits
Focusing on a small piece of the overall stress neurocircuitry, namely distinct areas of the
mPFC (IL & PrL) and the amygdala, we can offer simplistic predictions as to how signaling
from Orx1R and Orx2R work to oppose biases in stress responsivity (Fig. 4). Expression of
Orx1R in both the IL and PrL is limited in deep cortical layers (layers V & VI) but more
abundant in layer II [33], suggesting a regional dependence on signaling that may more
effectively drive signals from interneurons within layer II/III. However, in the PrL Orx1R is
found on pyramidal cell bodies and neuronal processes [97], indicating a potentially potent prostress response upon activation (Fig. 4A).
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In the PrL, Orx2R mRNA is possibly absent; however, some expression exists within the IL
[33]. In addition, Orx2R enhances thalamocortical signaling from thalamus-projecting
presynaptic terminals [81], perhaps further potentiating IL activity (Fig. 4B). These observations
advocate a preference for anti-stress signaling upon Orx2R activation.
Amygdalar Orx receptors are less characterized; however, Orx1R signaling from presynaptic
terminals in the mCeA [79], may originate from glutamatergic projection neurons in the BLA
(Fig. 4D). This prediction is not baseless as glutamate-producing neurons in the BLA have been
shown to express Orx1R [82, 83, 351]. As antagonism of Orx1R in the BLA results in activation
of IL-projecting neurons as well as calbindin-positive (Calb+) GABA cells [335], we predict
blockade of Orx1R on CeA-projecting pyramidal neurons deactivates endocannabinoid-mediated
suppression of Calb+ GABA neurons (Fig. 4C; similar to mechanisms proposed by Berrendero,
Flores, & Robledo, 2018) and allows for Orx2R signaling bias of IL-targeting fear extinction
circuits.
Expression of Orx receptors have also been identified in GABA neurons [82] and with whole
brain Orx2R stimulation, PV+ GABA cells in intercalated/BLA regions of the amygdala (Fig. 4C)
become activated [179]. Intercalated GABA cells that suppress pro-stress responses [352] are
activated by inputs from the IL [353], so activation of Orx2R within the IL may induce anti-stress
reactivity (Fig. 4B). It is also possible that Orx2R activation of IL-projecting neurons results in a
positive feedforward of circuit control that directs adaptive stress responses.
The Orx1R-Orx2R signal balance may also be achieved through regional expression in
anterior and posterior BLA neurons. The configuration of non-overlapping aBLA and pBLA
cells that antagonistically regulate emotional responsivity [299] suggests there may be an
organizational structure from which balance of the Orx system stabilizes reactions to stress. In
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this model, Orx1R activation may selectively activate aBLA circuits, while Orx2R stimulation
shows bias towards the pBLA connections (Fig. 4C, E).
All predictions reported here may work individually or in combination to support the
opposing actions of Orx1R and Orx2R regulation of stress neurocircuitry (Fig. 4).
Counterbalance theory of stress responsiveness suggests that upsetting stable states in PFC and
BLA results in imbalances that may be corrected through opposing systems. During stressinduced disorders, including affective disorders, we argue that pro-stress microcircuits become
favorable leading to behavioral disturbances. We hypothesize, based on supporting evidence
presented here, that Orx1R-Orx2R counterbalanced systems are responsible, in part, for
establishing equilibrium during periods of stress. As such, we propose a novel idea for
therapeutic intervention of stress-related disorders through simultaneous inhibition of Orx1R and
stimulation of Orx2R.

THE POTENTIAL FOR SELECTIVE OREXIN RECEPTOR CROSSOVER DRUGS
(SORCOs)
Our proposal for a hypothetical class of drugs or combined drug treatment is based on two
important factors. The first is that the mPFC-BLA microcircuits play an important role, perhaps
even a dominant role, in the regulation of stress responsiveness and emotional behavior. To be
sure, however, mPFC-BLA are not the only stress-related specific microcircuits in the brain.
Other circuits, including those emanating from GABAergic CRF and CCK neurons in the
BNST, stimulating hypothalamic Orx neurons, which innervate important stress/arousal regions
of the brain, such as the LC [89, 238, 239, 241], and perhaps also influence the mPFC-BLA
microcircuits.
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In the mPFC-BLA reciprocal set of microcircuitries, the functions of Orx1R and Orx2R
appear to be opposing, primarily because their expression is likely segregated to functionally
distinct cell types. The critical role of the mPFC-BLA systems regulating stress-related functions
and behaviors remains to be more carefully demonstrated. The evidence thus far for its
importance, comes from experiments using icv injection of Orx2R agonist and antagonist drugs,
with a potentially pan-brain exposure suggesting that Orx2R function is primarily anti-stress.
Similarly, systemic delivery of Orx1R antagonists reduces stress-related functions and behavior,
suggesting a pro-stress function for Orx1R. It is clear however, that in some regions of the brain,
the Orx1R and Orx2R appear to function concordantly, and this may be the prevalent disposition
of these two receptors in the brain. Further clarification will be necessary to determine if the
kind of drug or drug combination that we propose below is appropriate.
The currently available Orx drugs (and those in clinical trials) are antagonists of both Orx1R
and Orx2R called DORAs as well as selective receptor antagonists (SORAs) for Orx1R or
Orx2R, which were developed for use in treatment of insomnia [178, 228-230, 354] or anxiety
[226, 227], and with some effectively yielding sleep-promoting results [178, 216, 218, 228-230],
have been suggested to be potentially useful in treatment of addiction [355] and depression [178,
228] as well. These drugs, though not selective for the Orx1R alone, have also displayed some
promise as therapeutic tools for relieving signs of affect. Orally administered DORA-12
enhances social interaction time in rats subjected to high levels of CO2 to promote a panic state
[251]. Almorexant, a competitive Orx receptor antagonist designed to treat insomnia, lowers
blood pressure (BP) in hypertensive rats, while having no impact on the resting BP of wildtype
animals [356]. Further, almorexant, in a dose-dependent fashion, reduces fear-potentiated startle
in conditioned rats, while having no myorelaxant effects [51]. When administered almorexant

34

daily, mice experience decreased anxious and depressive behaviors in an UCMS model for
depression that are comparable to fluoxetine-treated animals [219]. The effectiveness of
DORAs suggests the Orx receptors function in a similar fashion, which is often true relative to
sleep-wake cycles, insomnia, and narcolepsy, but not always, as Orx1R may oppose the sleepinducing effects of Orx2R [357], and SORA Orx2R antagonist drugs differentially increase
NREM sleep [358, 359] over REM-induction by DORAs. We make the point that it is also not
true for stress neurocircuitry and responsiveness or behavioral affect [72, 73, 83, 130, 179, 351].
Consequently, sometimes the typical, presumably Orx1R-mediated, effect is not manifest, such
as the case with the predator odor PTSD model, in which rats treated with almorexant display a
higher prevalence of the PTSD phenotype [245]. Therefore, to achieve an effective, efficient
anxiolytic or anti-depressant drug based on specific Orx1R and Orx2R functions [72, 83, 130,
179, 351] in the stress neurocircuitry that regulates enhanced responsiveness and affect, a
distinctively new kind of drug, or drug combination is necessary. The need for a singular or
dual drug with the ability to modify both pro-stress and anti-stress circuitries seems to be critical
for the treatment anxiety and/or depression [72, 73, 83, 130, 179, 351]. This new drug should
limit the output of pro-stress circuitries through inhibition of Orx1R and promote anti-stress
circuitries and actions by means of stimulation of Orx2R. A selective orexin receptor crossover
(SORCO) drug or combination of drugs would, we believe, produce a complete treatment
related to specific causes of anxiety and depression, and not just to symptomology. In the
process, SORCO actions could positively modify behavior associated with stress, arousal,
reward, anhedonia, and modified decision-making thereby limiting significant elements related
to the etiologies of those affective disorders.
We make one additional point regarding the clinical implications for DORAs and SORAs
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used for treatment of insomnia in comparison with the potential actions of a SORCO designed to
limit anxiety or depression. However, comparisons may be difficult, since the dosages used for
rodent experiments are on the order of ten-fold higher (compared only within a treatment type,
such as icv injection) in sleep- or wake-promoting treatments, than for our studies related to
stress responsiveness [72, 179]. This difference in dosage is significant for several reasons, the
first of which is that cross effects, and side effects, may be avoided, although significant further
testing would be necessary to determine this. Suggesting that some Orx system-targeting drugs
may have a wide range of efficacy, anxious, panic, and depressive behavior can be inhibited by
doses of Orx1R and Orx2R antagonists SB334867, ACT-539313 and JNJ-42847922 (seltorexant)
drugs similar to those used for sleep induction [72, 170-172, 251]. The low doses necessary to
produce anxiolytic or antidepressive actions from Orx2R agonist treatment may prove to be a
therapeutic advantage [72]. Thus, inhibition of Orx1R, and stimulation of Orx2R, both appear to
have the potential for anxiolytic and antidepressive actions. While DORA treatment confounds
the opposing actions of Orx1R and Orx2R in the mPFC-BLA microcircuits, it seems likely that
anti-panic effects derive mostly from antagonizing Orx1R actions [251], given the evidence that
blocking Orx2R is anxiogenic and pro-depressive (for icv and intra-BLA injections) [179].
Additionally, at first blush, these promising results based on the new Orx2R antagonist
seltorexant (JNJ-42847922) suggest the opposite action for Orx2R than the anti-stress function
that we suggest. It may be that our suggestion for Orx2R anti-stress function is limited to a
specific neurocircuitry (see sections above). However, results from icv injection of both Orx2R
agonist and antagonist [179] suggest that the anti-stress/anxiolytic/antidepressant role for Orx2R
is more systemic, at least within the brain. While early clinical trials with limited sample sizes
support antidepressant actions for seltorexant, which are potentially very important, there are
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also precautions that should be taken based on subjective (self-report) data that also may be
reliant on codependent physiological actions, such as sleep. As the authors of those studies note,
insomnia or sleep dysregulation powerfully predisposes subjects to depressive affect, and
resolving dysfunctional sleep, may have a potent antidepressive effect, without actually engaging
or chemically realigning the neurocircuitry that is primarily responsible for anxiety or
depression. At doses that do not affect activity or sleep, Orx2R-targeting drugs may influence
stress responsiveness and affective behavior in a way that suggests that these receptors promote
resilience in pre-clinical studies.

SUMMARY
Parallel pro-stress and anti-stress neurocircuitries exist between the prefrontal cortices and
the basolateral amygdala, and these reciprocal and interacting circuits are critical for the
development and expression of affective behaviors and disorders. Projecting neurons from the
orexin-producing region of the hypothalamus modulate both pro-stress and anti-stress elements
by means of Orx1R and Orx2R. The affect-related functions of Orx1R and Orx2R are opposing,
with Orx1R promoting anxious, panic, and despair-related behaviors, and Orx2R limiting those
responses as well as reinforcing behavior associated with stress resilience. The evidence
suggests that DORAs work at counter purposes related to affective behavior, and that a new
selective crossover drug (or combination of drugs) that inhibits type 1 Orx receptors while
stimulating type 2 receptors (SORCO) is a potentially effective method to reorient mood and
behavior associated with affective disorders.
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Table 1. Listing of clinical trials and studies using receptor antagonists for the Orx1R or Orx2R (SORAs)
or both (DORAs). For a table of preclinical results please refer to Summers et al., 2020.
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Figure 1. Dimerization of Orx receptors changes signaling dynamics. Activation of Orx1R (orange; top
left) may result in Gq (blue), Gs (green), Gi (red), or β-arrestin (pink) signaling cascades. When
stimulated, dimers of Orx1R initiate intracellular pathways that are unique from the monomers: (A)
homodimers may recruit more dimerization [108]; (B) Orx1R+Orx2R has unknown properties [107]; (C)
Orx1R+Cb1 allows for spontaneous receptor recycling [110, 111]; (D) Orx1R+QRFP-R has unknown
signaling properties but may be neuroprotective through the activation of ERK pathways [112]; (E)
Orx1R+CRF1 favors Gi and the recruitment of β-arrestin [113]; (F) Orx1R+CRF2 signals through Gi
pathways [114]; (G) Orx1R+KOR uses the Gs pathway [115]; (H) Orx1R+CCK1 enhances Gq and Gi
signaling, but also recruits signaling from G12/13 and β-arrestin pathways [116]; (I) Orx1R+GHSR1a
utilizes Gs and β-arrestin signaling [117]; and (J) GHSR1b favors Gq and β-arrestin intracellular pathways
[118]. As a monomer, Orx2R (yellow; bottom left) can signal via Gq, Gs, and Gi pathways. Dimerization
results in differential signaling patterns: (1) homodimers have unknown signaling qualities [107]; (2)
Orx2R variant dimers (Orx2α+Orx2β) displays exaggerated Gq and normal Gi signaling [109]; (3)
Orx2R+Cb1 has unknown signaling properties [107]; (4) Orx2R+QRFP-R may be neuroprotective [112],
but has not been heavily investigated; (5) Orx2R+5-HT1A returns signaling to basal conditions [119].
Note, referenced studies rely on in vitro techniques to explore signaling cascades, and results reported
here are only pathways observed when Orx peptides (OrxA or OrxB) are present. Other pathways may be
evident when the partner receptor’s ligand is present.
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Figure 2. Stress responses are initiated through counterbalanced parallel neurocircuits. (A) Pro-stress
behaviors are initiated through activation of reciprocal PrL and aBLA (Rspo2+ cells) connections that
lead to inhibition of pBLA projection neurons and activate mCeA outputs to promote “Fear On”
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signaling. (B) Anti-stress responses are promoted through reciprocally innervated IL and pBLA
(Ppp1r1b+) neurons, which suppress projection neurons in the aBLA and indirectly in the mCeA through
ITC GABAergic cells. Importantly, this represents a simplistic model of a highly complicated system;
and does not include many components that are also necessary for modulation of stress reactivity.
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Figure 3. Pro-stress behaviors are alleviated, and anti-stress responses are promoted through Orx1R
inhibition (orange arrows) or Orx2R stimulation (yellow arrows). In the SAM, mice display behaviors
consistent with a gradient of stress-induced responses [346] (dashed line), where fear-associated
behaviors (far left, red dashed line) are consistent with vulnerability, and active avoidance through escape
(far right, green dashed line) relating to stress resilience. Mice exposed to the SAM show diminished
pro-stress behaviors with treatments, including (A) fear conditioned freezing, (B) conflict freezing, and
(C) startle response. Conversely, with specific Orx receptor-targeted treatments, anti-stress responses are
increased, including (D) motivational behaviors (Attention Toward Escape) and (E) resiliency (Escape
behavior). All values are approximations combined from icv [179] and intra-BLA [83, 351] studies and
are represented as percent from control (vehicle-treated mice exposed to the social stress paradigm).
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Figure 4. Pro- and anti-stress circuits are bidirectionally mediated through Orx1R and Orx2R activity.
(A) In the PrL, Orx1R stimulation activates (increased Ca2+) aBLA-projecting neurons, and biasing
counterbalanced microcircuits to favor pro-stress behavioral responses. (B) The IL expresses Orx2R on
presynaptic thalamocortical terminals that, when activated, promote increased Glu release onto pBLAprojecting neurons. These pBLA-connecting IL neurons also express Orx2R, which, upon stimulation,
increases signaling to the pBLA and favoring anti-stress microcircuit activation. (C) The aBLA houses
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mCeA-innervating neurons that express Orx1R. When activated, Orx1R promotes excitation of projection
neurons, but also stimulates the production of 2-AG, which inhibits GABA release from interneurons
(CCK+) and leads to disinhibition (and hyper-excitability) of aBLA projection neurons, biasing pro-stress
responses. Note that Orx2R may be located on interneurons within the aBLA to help suppress pro-stress
signaling. (D) Presynaptic terminals express Orx1R in the mCeA. When activated, these receptors
increase glutamate release onto mCeA neurons and promote pro-stress responsivity. (E) The pBLA
contains Orx2R on pyramidal projection neurons that signal in support of anti-stress pathways.
Interneurons in the pBLA may also express Orx1R, which would suppress anti-stress signaling if
stimulated. Noteworthy, these are predicted interactions of Orx receptors in pro- and anti-stress
microcircuits. The precise locations and functions of these receptors within these areas of stress
neurocircuitry remains largely unknown.
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Chapter 2: Orexin 1 receptor antagonism in the basolateral amygdala shifts the balance
from pro- to anti-stress signaling and behavior

ABSTRACT
BACKGROUND: Stress produces differential behavioral responses through select molecular
modifications to specific neurocircuitry elements. The orexin system targets key components of
this neurocircuitry in the basolateral amygdala (BLA).
METHODS: We assessed the contribution of BLA Orexin 1 receptors (Orx1R) in the
expression of stress-induced phenotypes. Using the Stress Alternatives Model (SAM), a social
stress paradigm that produces two behavioral phenotypes, we characterized the role of BLA
Orx1R using acute pharmacological inhibition (SB-674042) and genetic knockdown (AAV-U6Orx1R-shRNA) strategies.
RESULTS: In the BLA, we observed that Orx1R (HCRTR1) mRNA is predominantly expressed
in CamKIIα+ glutamatergic neurons and rarely in GABAergic cells. While there is a slight
overlap in Orx1R and Orexin 2 receptor (Orx2R; HCRTR2) mRNA expression in the BLA, we
find that these receptors are most often expressed in separate cells. Antagonism of intra-BLA
Orx1R after phenotype formation shifted behavioral expression from stress sensitive (Stay) to
resilient (Escape) responses, an effect that was mimicked by genetic knockdown. Acute
inhibition of Orx1R in the BLA also reduced contextual and cued fear freezing responses in Stay
animals. This phenotype-specific behavioral change was accompanied by biased molecular
transcription favoring HCRTR2 over HCRTR1, and MAPK3 over PLCB1 cell signaling cascades
and enhanced BDNF mRNA.
CONCLUSIONS: The functional reorganization of intra-BLA gene expression after Orx1R
antagonism promotes elevated HCRTR2, to greater MAPK3, yielding increased BDNF
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expression. Together, these results provide evidence for a receptor-driven mechanism that
balances pro- and anti-stress responses within the BLA.

INTRODUCTION
Stress-induced alterations in neurocircuitry result in divergent behavioral responses. Enhanced
stress reactivity (pro-stress) in rodent models is similar to human affective dysfunction in mood
disorders like depression, fear-/anxiety-related disorders, or post-traumatic stress disorder
(PTSD) [1]. Current pharmacotherapies for affective disorders have limited success, and a
mechanistic understanding remains elusive.
Balance within key stress circuits may be disrupted during periods of intense or prolonged
stress to shift signaling dynamics in pro- or anti-stress pathways [2-4]. Stressful stimuli are
interpreted, in part, through converging signals in the basolateral amygdala (BLA), where
glutamatergic projection neurons are influenced by distinctive GABAergic interneurons, to
direct behavioral responses [5]. Additionally, activity in the BLA is modified by hypothalamic
orexinergic neurons, which are critical for panic [6, 7] and motivation [8, 9].
Orexin A (OrxA) and orexin B (OrxB), neuromodulators derived from a single prepropeptide, activate two G-coupled protein receptors: orexin 1 receptors (Orx1R), having greater
affinity for OrxA, and orexin 2 receptors (Orx2R), which binds equally well to OrxA and OrxB
[10]. These receptors stimulate heterotrimeric Gq proteins which increase intracellular Ca2+ [11]
to activate phospholipase C (PLC) pathways [12]. The PLCβ1 isozyme variant is transcribed in
the amygdala [13], and its dysfunction is linked to psychopathologies like depression [14],
bipolar disorder [15], addiction [16], and schizophrenia [17, 18].
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Stimulation of Orx1R can also activate extracellular signal-regulated protein kinase (ERK).
In the amygdala, recruitment of ERKs is important for consolidation, reconsolidation, and
extinction of fear memories [19, 20]. While Orx1R in the BLA are important in regulating fear
[21, 22], depression [23, 24], and anxiety [25], it is unclear how shifts in molecular signaling
cascades mediate such responses and initiate stress-induced phenotype development.
Utilizing the Stress Alternatives Model (SAM), a behavioral paradigm that separates
individuals into social stress resilient (Escape) and vulnerable (Stay) populations [26], we
explored how Orx1R activity in the BLA is involved in the formation of stress-related
phenotypes. As a social interaction and avoidance paradigm in which smaller subjects encounter
intense attacks from larger novel aggressors over a four-day period, the SAM produces two
separate subsets of animals, exhibiting social avoidance or enhanced fear conditioned responses
[27, 28]. Unlike a traditional social defeat outcome, the SAM provides mice an opportunity to
avoid social aggression by exiting the arena through one of two escape tunnels only large
enough for the smaller mouse. By the end of the second day of social interaction, test subjects
stably commit to a phenotype: Escape or Stay. These stable phenotypes may be altered through
pharmacological manipulations administered on the third day of the SAM [28-30]. Thus, the
SAM is a useful tool for studying the development of stress-induced phenotypes, while
providing an opportunity to explore physiological and clinically relevant molecular mechanisms.
We investigated if inhibition of intra-BLA Orx1R, alters the formation of social stressinduced behavioral phenotypes. We predict that pharmacological inhibition or genetic
knockdown will shift behavioral patterns in vulnerable (Stay) populations toward resilience
(Escape). Further, we explored if Orx1R inhibition affects conditioned fear responses and alters
the expression of genes responsible for balancing signaling in pro- and anti-stress
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neurocircuitries. Together, these results allow us to propose a neurocircuit model that defines
the role of intra-BLA Orx1R signaling in the balance of pro- and anti-stress states.
METHODS & MATERIALS (see also COMPLETE METHODS & MATERIALS)
Social Stress and Decision-Making Paradigm

Aggressive social interactions between larger novel CD1 and smaller male C57BL/6NHsd mice
dyads in the SAM apparatus (Fig. 1) involve four trials, lasting up to five minutes each, allowing
test animals the opportunity to shorten stressful encounters by making use of size-restricted
tunnels at the apical end of the oval open field interaction arena. A tone given during isolation in
the SAM apparatus prior to social interaction permits comparisons between cued and contextual
fear conditioning. The escape routes provide a decision-making opportunity, producing two
stable phenotypes: active avoidance (Escape) and enhanced fear conditioning (Stay), which may
be modified by drug treatment on Day 3. The treatment regimen allows for statistical
comparisons between groups, and within subjects, by comparing responses to SAM interactions
before and after treatment. All procedures were performed in accordance with the Guide for the
Care and Use of Laboratory Animals (NIH Publications No. 80-23) and approved by the
University of South Dakota Institutional Animal Care and Use Committee.
Experimental Overview (see also Supplemental Information)
The primary treatment for these experiments is inhibition of BLA Orx1R, via the antagonist SB674042 (0.3 nmol/0.3 μL delivered bilaterally intra-BLA, 1h prior to interaction on Day 3) or
short-hairpin knockdown (bilateral intra-BLA transduction beginning 30 days prior to SAM
interaction). Considering the difference in timing of delivery, these treatments were done and
analyzed separately, with unique hypotheses. All behavioral measures were performed during
the dark cycle, and included Escape (use of the apical tunnels), Stay (remaining in the SAM
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arena with the novel aggressor), time spent attentive to the escape hole, latency to escape (for
Escape mice), fear conditioned freezing (measured in response to the tone and context, prior to
the social interaction unconditioned stimulus [US], and as a conditioned response [CR on Day 5]
in the absence of the US), and food intake. Thus, treatment groups included home cage controls,
intra-BLA vehicle injection, and intra-BLA SB-674042 injection of Escape and Stay mice. In
addition, local knockdown treatment groups included home cage controls, intra-BLA AAVOrx1R-shRNA injection, and intra-BLA AAV-scramble-shRNA injection. Brains and blood
were collected for visual representations of gene expression (using RNAscope) of HCRTR1,
HCRTR2, calbindin (CALB1), Ca++/Calmodulin Kinase type 2 alpha (CAMKIIα), Glutamate
Decarboxylase (GAD1), and parvalbumin (PVALB) in the BLA, as well as to measure plasma
concentrations of the stress hormone corticosterone (by enzyme linked immunosorbent assay).
Gene expression (using qRT-PCR) of HCRTR1, HCRTR2), PLCB1, MAPK1, MAPK3, BDNF,
and GAPDH (housekeeping gene) were measured in BLA tissue. All experimental designs and
statistical analyses were based on a priori hypotheses, using two-way repeated measures
ANOVA, two-way ANOVA, one-way ANOVA, regression analyses, and t-test, followed (where
appropriate) by post hoc analyses.

RESULTS (see also COMPLETE RESULTS)
Orx1R are expressed in BLA glutamatergic neurons
The glutamatergic marker, CamKIIα, was identified in the vast majority of BLA neurons (~80%;
Fig. S2) as well as those expressing HCRTR1 [31, 32], though the signal was also found in some
calbindin-expressing GABAergic neurons (Fig. 2). Few (<20%) BLA HCRTR1-possessing cells
express GAD1 (GABAergic marker) and co-express parvalbumin (PV, ~10%; Figs. 2I-J). While
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Orx1R are localized predominantly on glutamatergic neurons in the BLA (Fig. 2P), our results
suggest HCRTR1 is expressed in 10-15% of BLA glutamatergic neurons and ~5% of GABA
cells (Fig. 2K).
Intra-BLA Orx1R inhibition and knockdown increase motivation for active avoidance
(Escape)
In the SAM, typically animals evenly self-select one of two stable [27-29, 33] behavioral
phenotypes, Escape or Stay (Figs. 1A) [26, 27, 29, 33, 34], 44.7% Escape and 55.3% Stay (Figs.
S1B, C).
We wished to determine if inhibition of Orx1R (SB-674042) in BLA [2] stimulated
motivation for active avoidance. Time spent investigating the escape route is both a predictor of
active avoidance and an indicator of motivation to escape [28]. Time spent attentive to the hole
was significantly greater in vehicle-treated Escape mice (Fig. 3A), but intra-BLA infusion of the
Orx1R antagonist (Escape: Figs. 3B, C; Stay: Figs. 3B, D) or AAV-U6-Orx1R-shRNA (Fig. 3E)
increases attention to the escape route. Further, receptor activation with OrxA reduced the time
Escape mice spent investigating the escape route (Fig. S3). Together these results characterize
an important function of BLA Orx1R in modulating adaptive motivation in a social stress
environment (Fig. 3F), where inhibition or knockdown promote increased motivation to Escape.
Inhibition and knockdown of BLA Orx1R promote active avoidance (Escape)
As motivation to escape was enhanced, we wished to determine if inhibition of Orx1R in BLA
also resulted in more proactive anxiolytic behavior (Escape). Upon intra-BLA injections of an
Orx1R antagonist on SAM Day 3, a substantial number of Stay mice exhibited Escape behavior
(Fig. 4A), with a 30% shift that day, and a significant increase the day after (Day 4 = 70%
increase). Interestingly, intra-BLA activation of both Orx receptors with OrxA or biased
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activation of Orx1R with duel delivery of OrxA and an Orx2R antagonist blocked Escape
behavior in a small proportion of mice on Days 3 and 4 (Fig. S4), and though not statistically
significant, does support the pro-stress role of Orx1R.
As knockdown reduced Orx1R expression prior to stressful interactions experiments, we did
not expect a dramatic change in behavior over the course of SAM trials, but while scramble
control mice remained stable, those treated with AAV-U6-Orx1R-shRNA selected to Escape
incrementally (though not significantly) more on the last two days of SAM exposure (Fig. 4B).
By the end of Day 4, 72.7% of AAV-U6-Orx1R-shRNA-treated mice displayed the Escape
phenotype compared to 54.5% of those that received the scramble control.
Escape mice spent significantly less time in the SAM arena with the CD1 mouse on Days 2
through 4 [26, 27, 29, 33, 35], thus escape latency was reduced (Fig. 4C). Stay mice remain
submissively for the entire 5 min period, unless treated with the Orx1R antagonist, significantly
reducing the time spent with the aggressive CD1 mouse on Day 4 (Fig. 4D). Neither Orx1R
inhibition nor knockdown influenced escape latency in Escape animals (Figs. 4D, E). These
results, in combination, suggest that intra-BLA Orx1R promote coping strategies associated with
responses to increased stress, and acute inhibition of these receptors allows for greater expression
of behavior derived from reduced output of pro-stress neurocircuitry (Escape; Fig. 4F).
Importantly neither of the Orx1R manipulations, antagonist or knockdown treatments,
influenced arousal/locomotion (Figs. S5), but did result in small but significant decreases in food
intake and body weight (Figs. S6).
BLA Orx1R inhibition reduces cued and contextual fear conditioning
As motivation for and actual active stress-avoidance were promoted by intra-BLA Orx1R
inhibition, we probed whether SAM social stress exposure (US+) could be associated with fear
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conditioning (tone = CS; freezing behavior =CR; absence of social aggressor = US-; Fig. 1A).
Cued fear responses significantly enhanced freezing in both Escape and Stay phenotypes (Figs.
5A, B), and Stay mice displayed heightened freezing behavior to context (CS-, opaque cylinder
divider) as well (Fig. 5B). Although inhibition of intra-BLA Orx1R did not affect the fear
freezing profile in Escape mice (Figs. 5A, D), antagonist-treated Stay mice exhibited
significantly reduced contextual (CS-) and cued (CS+) fear responses (Figs. 5A, H). Like mice of
the Escape phenotype, knockdown of BLA Orx1R (AAV-U6-Orx1R-shRNA) did not affect
conditioned freezing behavior (Fig. S7). Importantly, activation of intra-BLA Orx receptors with
OrxA did not change the fear freezing profile in Escape or Stay mice compared to Vehicle control
(Figs. 5A, E, I). However, biased stimulation of Orx1R in the BLA with a combination of OrxA
and an Orx2R antagonist eliminated the conditioned response in Escape (Figs. 5A, F), but not
Stay mice (Figs. 5A, J).
Corticosterone levels are reduced with intra-BLA Orx1R antagonism
As intra-BLA Orx1R inhibition increased motivation for, and promoted, stress-avoidance, as well
as reducing conditioned fear, we hypothesized that this treatment would also reduce plasma
concentrations of the stress hormone, corticosterone (Fig. 5C). Social stress in SAM interactions
increases corticosterone concentrations in both Escape and Stay animals [27, 28, 33], although
Stay mice have higher levels of corticosterone compared to Escape. Inhibition of BLA Orx1R
decreased Stay corticosterone concentrations compared to vehicle-treated Stay animals; and did
not differ significantly from non-stressed mice (Fig. 5C). Treatments with OrxA or the
combination of OrxA and an Orx2R antagonist did not change corticosterone levels relative to
vehicle-treated controls, however, the differences between Escape and Stay were eliminated and
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levels were elevated compared to Orx1R antagonist-treated mice (Fig. 5C). Inhibition of BLA
Orx1R not only reduces social fear responses, but also reverses social stress responsiveness.
Antagonism of intra-BLA Orx1R recruits alternative signaling
With Orx1R antagonism in the BLA, we predicted orexin receptor gene (HCRTR1 & HCRTR2)
expression may be influenced by phenotype and treatment (Figs. 6). Although HCRTR1 expression was
unaltered following vehicle treatment, Orx1R antagonism reduced intra-BLA HCRTR1 in Escape mice
compared to non-stressed cage controls (Fig. 6A), and simultaneously elevated HCRTR2 expression in
Stay mice compared to Escape and vehicle-treated Stay mice (Fig. 6B). In vehicle controls HCRTR2
expression was higher in Escape mice compared to both Stay and Orx1R antagonist-treated Escape mice
(Fig. 6B). Changes in both HCRTR1 and HCRTR2 expression due to Orx1R inhibition appear to occur in
a phenotype-dependent way in the BLA.
Transcription of BLA PLCβ1 (PLCB1) mRNA [13] is likely important for Orx1R signaling [36] in the
BLA, so we predicted Orx1R antagonist might limit PLCB1 expression levels (Fig. 6C). Interestingly,
Escape mice in both vehicle and Orx1R antagonist groups expressed lower amounts of PLCB1 compared
to Stay animals (Fig. 6C). Escape mice in both vehicle- and Orx1R antagonist-treated groups had lower
PLCB1 mRNA compared to cage control animals (Fig. 6C). These data suggest adaptive physiological
shifts in intra-BLA PLCB1 expression may play a role in, or result from, phenotype development,
without identifying how Orx1R antagonism is involved.
Alternative molecular pathways recruited during Gq activation are driven by ERK genes (MAPK1 &
MAPK3). Although ERK2 (MAPK1) mRNA was unaffected (Fig. S8), Orx1R antagonism in Stay mice
resulted in a significant increase in MAPK3 expression compared to similarly treated Escape, vehicletreated Stay, and non-stressed cage control mice (Fig. 6D). These results suggest potential links amongst
Orx1R inhibition, phenotype plasticity, and PLCβ1 and ERK1 signaling recruitment in behaviorally
distinctive groups, which also differ in stress sensitivity.
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The transcription of brain-derived neurotrophic factor (BDNF) is tied to neuroplasticity [37, 38] and
behavioral changes like extinction of fear memories [39], so we predicted an increase in BDNF might be
associated with intra-BLA Orx1R inhibition (Fig. 6E). As hypothesized, intra-BLA Orx1R antagonism
resulted in elevated BDNF in Stay compared to Escape mice and vehicle-treated Stay mice (Fig. 6E). As
Stay mice treated with an Orx1R antagonist experienced shifts from stress-vulnerable to resilient
behavioral responses, the alterations in gene expression reported here (Fig. 6F) may be implicit in this
behavioral plasticity.

Molecular restructuring following intra-BLA Orx1R inhibition is related to fear
responsiveness
As altered transcription coincided with behavioral change produced by intra-BLA Orx1R antagonist
treatment, we hypothesized that correlations would exist between them. Expression levels of HCRTR2 in
both vehicle- and Orx1R antagonist-treated mice are negatively correlated with cued freezing (Figs. 7A,
B). Relative expression levels of PLCB1 were positively correlated with cued freezing behavior in
vehicle-treated mice (Fig. 7C); however, this relationship is not observed after intra-BLA Orx1R
inhibition (Fig. 7D). Contextual freezing behavior was associated with MAPK3 expression in only
vehicle-treated mice (Figs. S9I). By contrast, intra-BLA antagonism of Orx1R cued freezing behavior
was negatively correlated to MAPK3 expression (Fig. 7F), but not in vehicle-treated mice (Fig. 7E). The
lack of gene expression correlations with cued fear freezing when phenotypes were assessed
independently (Figs. S10), indicates that behavioral and transcriptional relationships exist within
collective operational adaptations that link behavioral change to molecular modification. Together, these
results suggest a functional connection between Orx1R antagonist-induced shifts in gene expression and
fear-related behaviors.

Cells expressing Orx1R in the BLA do not co-express Orx2R
Given that Orx1R antagonism within the BLA alters expression of Orx2R (HCRTR2) mRNA, and
is related to cued fear responses, we decided to investigate whether both orexin receptor subtypes
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are expressed within the same amygdalar neurons (Fig. 2). In BLA cells, mRNA for HCRTR1
and HCRTR2 largely do not overlap, as ~80% of HCRTR1+ cells do not co-express HCRTR2
(Figs. 2L-O). Importantly, even when BLA Orx1R are inhibited, native OrxA and OrxB will bind
Orx2R. Previous research from our lab suggests Orx2R may be predominantly localized to
specific GABAergic neurons within the BLA [28].
Fear response after Orx2R inhibition is phenotypically different from Orx1R antagonism
As blocking Orx1R in the BLA produced major effects on conditioned fear freezing in Stay mice
(Fig. 5H), and increased HCRTR2 gene expression (Figs. 6B, 7B), we predicted antagonism of
Orx2R (MK-1064) might affect fear behavior in Escape mice. Acute inhibition of Orx2R in the
BLA eliminated the cued (CS+) freezing response in Escape mice observed in vehicle control
animals and significantly reduced freezing during the post-tone (CS+) period (Figs. 5A, G). Stay
mice treated with an Orx2R antagonist displayed no statistical differences in the levels of
contextual (CS-) and cued (CS+) freezing compared to animals in the vehicle control group (Figs.
5A, K). These results suggest Orx receptor activity in the BLA influences social stress-induced
fear behavior in receptor type and phenotype dependent fashions.
Transcriptional changes after Orx2R antagonism contrast those observed after Orx1R
inhibition
Since blocking Orx1R produced changes in mRNA expression relevant to BLA cell signaling
dynamics, we predicted Orx2R antagonism to induce opposing changes to these transcriptional
relationships (Fig. 6). While Orx1R inhibition resulted in a reduction in HCRTR1 gene
expression in Escape mice, Orx2R antagonism presented a similar decrease, but only in Stay
animals (Fig. 6A). Expression of HCRTR2 in the BLA was reduced in both Escape and Stay
phenotypes after blocking Orx2R, contrasting with Orx1R antagonism, which enhanced HCRTR2
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mRNA levels in Stay mice (Fig. 6B). Further, intra-BLA Orx2R inhibition muted the reduction
in PLCB1 observed in Escape mice under Vehicle treatment conditions (Fig. 6C) while having
no effect on MAPK3 gene expression (Fig. 6D). Finally, Orx2R antagonist treatment enhanced
BDNF expression in Escape mice, while diminishing transcription in Stay animals, an effect that
is phenotypically opposite to that observed after Orx1R inhibition (Fig. 6E). Importantly, no
relationships between gene expression and conditioned fear freezing were observed for any of
the tested cell signaling markers after Orx2R antagonism except for BDNF, in which a significant
negative correlation was revealed (Fig. S12E).
Gene expression uncovers a potential molecular mechanism behind intra-BLA Orx1R
antagonism
To help generate a theoretical mechanism to explain the physiological basis surrounding the observed
behavioral (and phenotypic) shifts resulting from intra-BLA inhibition of Orx1R, we explored
transcriptional relationships in systems that exhibited similar regression patterns (Fig. 8). With
antagonism of Orx1R, there is a steeply positive relationship between HCRTR2 and MAPK3 expression
(Fig. 8A). Importantly, this association does not exist after vehicle or Orx2R antagonist treatment (Fig.
S11A). While there are no observed relationships between BDNF and HCRTR2 expression levels (Figs.
8B, S13), BDNF expression is positively correlated to MAPK3 expression in animals treated with an
Orx1R antagonist (Fig. 8C). Notably, no relationships exist between HCRTR1 expression and the other
genes of interest (Figs. S13D-I). These data allowed us to predict a working model to explain how BLA
Orx1R may function to establish behavioral patterns consistent with stress-induced phenotype
development (Fig. 9).

DISCUSSION
Antagonism of Orx1R in the BLA can reverse or diminish expression of stress-related behavior. Our
results suggest BLA Orx1R play a central role in stress responsiveness [40, 41] and related behavioral,
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physiological, and molecular outcomes that are important components of affective disorders [42, 43],
such as anxiety [7], depression, and PTSD. Acute inhibition of intra-BLA Orx1R promotes Escape over
Stay responses and limits freezing during fear conditioning in a phenotype-dependent way. Further,
inhibition of Orx1R alters gene expression associated with critical signaling cascades. Following intraBLA Orx1R antagonism, transcription for receptors and intracellular signaling becomes biased toward
Orx2R (HCRTR2) over Orx1R (HCRTR1), and ERK1 (MAPK3) over PLCβ1 (PLCB1) pathways. The
relationship of these behavioral and molecular changes to enhanced expression of HCRTR2 mRNA,
largely in BLA neurons that do not contain Orx1R (Figs. 2L-O), suggests receptor-mediated mechanisms
that balance pro- and anti-stress responses in BLA microcircuits.
Aggressive social interactions in the SAM produced two behavioral phenotypes that represent risk
assessment and decision-making: Escape and Stay. These phenotypes, like those exposed to social defeat
paradigms [44, 45], exhibit resilience (tightly linked to Escape) and susceptibility (highly correlated with
Stay) in the Social Interaction/Preference (SIP) test [28]. However, unlike traditional social defeat,
SAM-separated phenotypes are expressed early in the behavioral paradigm, providing insight into the
development and progression of stress-induced behavior and pathophysiology. Anxiolytic drugs (such as
CRF1 receptor antagonist antalarmin and the Orx2R agonist [Ala11, d-Leu15]–OrxB) promote escape, while
anxiogenic drugs (such as the α2 antagonist yohimbine and the Orx2R antagonist MK-1064) delay and/or
block escape behavior [28, 29]. Surprisingly, neither the Orx1R antagonist (Fig. 4D) nor knockdown
(Fig. 4E) influenced escape latency, although it is reduced by anxiolytic factors such as exercise,
Neuropeptide S, antalarmin, and increased by anxiogenic factors like yohimbine [29]. We posit that
enhanced escape on Day 4, following BLA Orx1R inhibition (on Day 3, drug treatment), is a reflection of
the shift toward anti-stress signaling indicated by downregulation in pro-stress signaling (HCRTR1), and
upregulation of anti-stress systems (HCRTR2, MAPK3, BDNF). These stress-induced effects are paired
with important learning and motivational components during SAM interactions [27, 29, 33, 35], and in
human affective disorders [46].
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In addition to species-specific anxious behavior and learning, social stress promotes behavioral
inhibition, depressed behavioral drive and motivation in some individuals [47], plus a lower rate of
adaptive behavior [48]. Behavioral depression reveals two distinctive phenotypes related to stress
responsiveness in humans and other animals [45, 49, 50]. In SAM social interaction trials, Stay animals
exhibit significantly less interest in exploring/investigating the escape route (Fig. 3A) and indecisiveness
relative to escape [35]. Measuring motivation in the SAM is derived from a simple decision-making
process, Escape or Stay [26, 27]. Antagonism and knockdown of Orx1R increases interest in the escape
route for both Stay and Escape mice (Figs. 3C, D). Thus, BLA Orx1R regulate stress-induced
motivational behaviors; greatest in Escape mice, but marking a dramatic behavioral reversal in Stay mice
that typically avoid the escape route (Figs. 3B-C). The complementary results of intra-BLA knockdown
of Orx1R (Fig. 3E) supports the notion that during periods of stress, intra-BLA Orx1R activity may
provoke behavioral depression. Attention to the escape route happens prior to escape, and is thus the first
evidence of phenotypic differentiation in the SAM [28, 35]. Latency to escape, and escape behavior also
are influenced by motivation, although as previously demonstrated, these behaviors are strongly affected
by stress and fearfulness associated with familiarity of the SAM or social interaction [27-29, 33, 35].
Our results, like those of others, suggest Orx activity plays a fundamental role in motivation [8, 51], and
in this case, specifically in the BLA for behaviors associated with stress-related motivation and decisionmaking.
Understanding the development of decision-making and motivation in the SAM is enhanced by
pairing aversive aggression (US) with a non-threatening stimulus (tone CS) prior to interaction,
promoting potent cued and contextual conditioned responses (CR) similar to standard fear conditioning
approaches that utilize foot shock as a US [52]. While the CRs elicited are similar, e.g. freezing [53], the
ethological and ecological relevance of the US to the subject are not. By associating naturally aversive
US with a benign stimulus [54], the SAM allows views into development of fear learning as it relates to
the etiology of stress-provoked neurocircuitry changes, and demonstrates a connection between stressinduced fear expression and phenotype (Fig. 5). While early work suggested only Stay animals exhibited
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cued fear learning [27, 33], it is now clear both Stay and Escape respond to auditory cues with enhanced
freezing compared to pre-tone freezing, and Stay mice also show contextual (prior to the cue) fear
conditioning (Fig. 5B). Additionally, BLA Orx activity modulates associative fear learning [22], with
Orx1R, but not Orx2R, inhibition reducing both contextual and cued conditioned fear responses in Stay
animals (Figs. 5H, K). Antagonizing Orx1R reduces fear/panic-induced freezing [7, 55, 56], with Orx2R
antagonism appearing to eliminate all fear learning in Escape mice; and our results demonstrate a
phenotype-dependent effect (Figs. 5D, H). Stimulation of intra-BLA Orx1R and Orx2R receptors using
OrxA in Stay mice produces no reduction in contextual or cued fear conditioning (Fig. 5I), suggesting that
the inhibition of both types of learned fear responses result specifically from Orx1R inhibition in Stay
mice. To clarify the roles of Orx1R and Orx2R, we administered OrxA while concurrently inhibiting
Orx2R (MK1064), leaving Orx1R stimulated, and again there was no statistically significant reduction in
either type of fear conditioning response (Fig. 5J). Interestingly, knockdown of Orx1R did not affect the
fear freezing profile (Fig. S7). As knockdown occurred before the introduction of social stress, activity
levels of Orx1R after SAM exposure allowed for fear learning (higher freezing after CS), but did not
diminish freezing as observed with acute antagonism after stress and phenotype development (Fig. 5H).
Molecular gene expression during SAM fear conditioning and phenotype development indicated
potential shifts in receptor-linked intracellular signaling cascades (Fig. 6). Acute inhibition of intra-BLA
Orx1R lowered HCRTR1 expression in Escape mice while enhancing HCRTR2 in Stay animals (Figs. 6A,
B). Antagonism of Orx2R in BLA did the opposite, reducing HCRTR1 only in Stay mice, and reducing
HCRTR2 in both phenotypes (Figs. 6A, B). Mice exhibiting escape and reduced fear freezing, expressed
lower PLCB1 compared to the Stay phenotype; an effect unaltered by SB-674042 treatment, but reversed
by Orx2R antagonism (Fig. 6C). However, intra-BLA Orx1R antagonism increased MAPK3 and BDNF
expression in Stay animals only, with Orx2R inhibition having no effect on expression of MAPK3, and
enhancing BDNF, but only in Escape mice, while reducing BDNF in Stay mice (Figs. 6D-G). These
results suggest social stress disrupts gene expression, and potentially alters BLA signaling pathways
depending on an individual’s stress state. Therefore, pharmacological interventions (like acute Orx1R
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antagonism) may functionally amend behavior through signaling adaptations that are phenotype
dependent.
Fear conditioning responses appear to be related to specific transcriptional reorganization taking
place during/after intra-BLA Orx1R inhibition (Fig. 7). In treated animals, negative regressions exist
between cued fear freezing behavior and HCRTR2 as well as MAPK3 [57] transcriptional changes (Figs.
7B, F). Without treatment (vehicle), cued freezing was positively linked to PLCB1 gene expression (Fig.
7C), an effect not observed with Orx1R antagonism (Fig. 7D). These associations provide evidence for
potential mechanistic remodeling (Fig. 9) in the BLA during periods of stress that is tied to phenotype
formation and involves Orx receptor activity. This balancing act between Orx1R and Orx2R creates an
influence over BLA microcircuits, which further defines downstream signaling dynamics, in a way that
can modify stress-induced behavior [2]. Since changes in HCRTR2 expression after intra-BLA Orx1R
inhibition are positively associated with MAPK3 but not BDNF transcription levels (Figs. 8A, B), it
appears the adjusted bias of Orx2R over Orx1R activity favors ERK1 signaling (Fig. 9). Amplification of
ERK1, in turn, may lead to enhanced BDNF expression (Fig. 8C) and plastic changes within BLA
microcircuits (Fig. 9) [57, 58]. Importantly, these findings highlight a role of intra-BLA Orx1R in
establishing pro-stress behavioral states; but exposes a receptor-driven balance that takes part in the fluid,
not static, appearance of phenotype-specific behavior.
Conclusions
Modulation of BLA stress-regulatory pathways via Orx1 receptors found predominantly on
glutamatergic pyramidal neurons modifies gene expression and behavior. Modulation of pro-stress BLA
microcircuits via Orx1R inhibition reduces stress-induced behavior. In the process, Orx1R BLA
inhibition modifies gene expression of HCRTR2 which impedes pro-stress responses. Concurrently,
transcription levels for downstream molecular signaling systems associated with Orx receptor signaling
are also tilted toward increased ERK1 (MAPK3), rather than PLCβ1 (PLCB1) signaling pathways,
potentially altering behavior.
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Figure 1. The Stress Alternatives Model (SAM) is used to assess the development of stress-induced
phenotypes. (A) The SAM is a 4-day behavioral paradigm in which (I) a test mouse is placed into an
opaque cylinder, (II) presented a tone, (III) exposed to social aggression, and commits to a phenotype:
(IV) Escape or (V) Stay. (B) The behavioral timelines for (I) pharmacology and (II) genetic knockdown
experiments (mice are the same age at testing) include surgeries targeting the BLA, SAM exposure (Days
1-4), and the testing of contextual and cued fear responses (Day 5).
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Figure 2. In the untreated BLA, Orx1R are expressed predominantly in glutamatergic neurons and are
rarely co-expressed with Orx2R. (A) Imaged sections containing BLA cells (LA = lateral amygdala)
stained with probes targeting mRNA of (B) HCRTR1 (red), (C) CamKIIα (green), and (D) Calb
(Magenta) revealed when (E) merged (with DAPI) that (F) Orx1R+ cells mostly co-express the
glutamatergic cell marker, CamKIIα (N = 4, F2,9 = 54.4, p < 0.001; CamKIIα+ vs Calb+: t6 = 10.4, p <
0.001; CamKIIα+ vs Other: t6 = 5.2, p < 0.001; Calb+ vs Other: t6 = 5.2, p < 0.001; bars are statistically
different from one another as illustrated with unique letters, e.g. A is significantly different from B and
C; p < 0.001). (G) Expression of HCRTR1 (red) GAD67 (GAD1) mRNA (yellow) infrequently overlap
with (H) most HCRTR1+ cells being absent of the GABAergic marker (N = 5, t8 = 29.5, *p < 0.001). (I)
While a subset of BLA GABAergic neurons produce the calcium-binding protein parvalbumin (Pvalb+),
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(J) HCRTR1+ (red) cells are mostly absent of Pvalb expression (light blue) with less than 10% being both
HCRTR1+ and Pvalb+ (N = 4, t6 = 23.1, *p < 0.001). (K) Further, more BLA glutamatergic (CamKIIα+)
neurons (compared to GABAergic → GAD1+) also express HCRTR1 (N = 9, t7 = 3.2, *p ≤ 0.015). (L)
Images of BLA cells with fluorescent markers labeling (M) HCRTR1 mRNA (red) and HCRTR2 mRNA
(green) demonstrate (N) most BLA cells express neither HCRTR1 nor HCRTR2 (N = 4, F2,9 = 42.1, p <
0.001; HCRTR1+ vs Other, t6 = 7.5, p < 0.001; HCRTR2+ vs Other, t6 = 8.4, p < 0.001; bars are
statistically different from one another as illustrated with unique letters, e.g. A is significantly different
from B). (O) Most HCRTR1+ cells in the BLA do not express HCRTR2 (N = 4, t6 = 10.1, *p < 0.001), as
depicted in (P) showing Orx1R on glutamatergic neurons.
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Figure 3. Motivation toward Escape behavior is impacted through inhibition of intra-BLA Orx1R. (A)
Escape mice, as compared to those expressing the Stay phenotype, spend a greater % of time
investigating the SAM escape routes (N = 19, Phenotype Effect: F1,51 = 16.4, p < 0.001; Escape vs Stay:
Day 1, t17 = 2.6, *p ≤ 0.018; Day 2, t17 = 2.5, *p ≤ 0.017; Day 4, t17 = 4.2, *p < 0.001). (B) While Escape
mice, in general, explore the escape routes more often, (C) inhibition of intra-BLA Orx1R promotes even
more attention toward the escape tunnels (N = 34, Treatment Effect: F1,30 = 7.7, p ≤ 0.019; Day 3 Vehicle
Escape vs Orx1R Ant. Escape, t10 = 2.5, +p ≤ 0.018). (D) Antagonism of intra-BLA Orx1R only slightly
stimulates escape route exploration in Stay mice (Day 4 Vehicle x Orx1R Ant., t20 = 2.1, +p ≤ 0.05). (E)
Knockdown of intra-BLA Orx1R temporarily and minimally increases attention toward escape on Day 3
of the SAM (N = 22, Day 3 Scramble vs AAV-Orx1R-shRNA, t20 = 2.4, +p ≤ 0.024). (F) Illustration
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demonstrating inhibition of intra-BLA Orx1R on predominantly on glutamatergic neurons promotes
attention toward the escape route in the SAM arena. In Pharmacological Experiments, drug treatment is
administered on Day 3 as designated by the bold square.
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Figure 4. Intra-BLA Orx1R mediates stress-related behavioral phenotype development. (A) Infusion of
an Orx1R antagonist (SB-674042) into the BLA promotes Escape behavior in Stay mice (N = 22, Day 4,
χ2: F1 = 9.3, *p < 0.001). (B) Knockdown of Orx1R (AAV-Orx1R-shRNA) upsets normal Day 2
phenotype commitment behavior (as observed with AAV-Scramble-shRNA controls), inducing more
Escape behavior on Days 3 and 4 (N = 22). (C) Escape animals learn to efficiently utilize the escape
route to avoid social aggression over the course of 4 days while Stay mice submit to the aggressor (N =
19, Phenotype Effect: F1,45 = 175.3, p < 0.001; Time Effect: F3,45 = 26.1, p < 0.001; Interaction Effect:
F3,45 = 26.1, p < 0.001; Escape vs Stay: Day 2, t17 = 5.8, *p < 0.001; Day 3, t17 = 10.6, *p < 0.001; Day 4,
t17 = 11.9, *p < 0.001; Within Escape phenotype comparison, F3,18 = 17.8, p < 0.001, Day 1 vs Day 3, t6 =
5.7, p < 0.001; Day 1 vs Day 4, t6 = 6.5, p < 0.001; Day 2 vs Day 3, t6 = 2.9, p ≤ 0.009; Day 2 vs Day 4, t6
= 3.7, p ≤ 0.002; p < 0.05 for Days marked with unique lettering, e.g. A is different from B and C). (D)
Antagonizing intra-BLA Orx1R promotes aggressor avoidance in Stay mice (N = 34, Time Effect: F3,54 =
2.9, p ≤ 0.043; Interaction Effect: F3,54 = 2.9, p ≤ 0.043; Day 4 Vehicle Stay vs Orx1R Ant. Stay, t20 = 3.4,
+

p < 0.001), but has no effect on those animals exhibiting the Escape phenotype. (E) Knockdown of

intra-BLA Orx1R does not impact the overall latency of aggressor avoidance (N = 22). Overall, (F)
inhibition of Orx1R in the BLA appears to prompt Escape behavior. In Pharmacological Experiments,
drug treatment is administered on Day 3 as designated by the bold square.
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Figure 5. (A) Antagonism of intra-BLA Orx1R reduces conditioned fear responses in Stay animals while
Orx2R inhibition diminishes fear freezing in Escape mice (N = 71). (B) Although both Escape and Stay
phenotypes learn to associate a cue (tone, CS+) with social aggression (Phenotype Effect: F1,17 = 7.6, p ≤
0.013; CS Effect: F1,17 = 47.7, p < 0.001; Escape CS- vs CS+, t6 = 3.9, #p ≤ 0.008; Stay CS- vs CS+, t11 =
5.7, #p < 0.001), Stay mice exhibit heightened freezing behavior to both context (CS-; t17 = 2.8, *p ≤
0.011) and tone (CS+; t17 = 2.3, *p ≤ 0.033). Baseline measurements of freezing are represented by a
dotted line. Treatments of (D) Orx1R Ant. (CS Effect: F1,10 = 24.7, p < 0.001; Orx1R Ant. Escape CS- vs
CS+, t4 = 3.4, #p ≤ 0.026) or (E) OrxA (CS Effect: F1,9 = 26.8, p < 0.001; OrxA Escape CS- vs CS+, t3 = 3.5,
p ≤ 0.039) do not alter conditioned fear behavior in Escape mice. However, (F) Escape animals treated

#

with a drug cocktail (OrxA + MK-1064) designed to stimulate Orx1R (Orx1R Stim.; CS- vs CS+, t5 = 1.8, p
≥ 0.140) or (G) an Orx2R antagonist (CS Effect: F1,11 = 11.6, #p ≤ 0.006; Interaction Effect: F1,11 = 7.5, p
≤ 0.019; CS- vs CS+, t5 = 0.7, p ≥ 0.533; Vehicle vs Orx2R Ant., t11 = 2.7, +p ≤ 0.019) do not display
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conditioned fear responses. (H) In Stay animals, antagonism of Orx1R (Treatment Effect: F1,20 = 8.8, p ≤
0.008) reduces contextual (CS-; Vehicle Stay vs Orx1R Ant. Stay, t20 = 2.6, +p ≤ 0.017) and cued (CS+;
Vehicle Stay vs Orx1R Ant. Stay, t20 = 2.7, +p < 0.001) fear freezing but does not prevent the ability to
associate the tone with social stress (CS Effect: F1,20 = 29.6, p < 0.001; Orx1R Ant. Stay CS- vs CS+, t9 =
3.8, #p < 0.001). Stay mice treated with (I) OrxA (CS- vs CS+, t4 = 4.2, #p ≤ 0.014), (J) Orx1R Stim. (CSvs CS+, t8 = 4.0, #p ≤ 0.004), or (K) Orx2R Ant. (CS Effect: F1,15 = 22.6, #p < 0.001) do not differ from
vehicle controls in terms of fear freezing profile. (C) Mice exposed to social stress produce elevated
levels of stress hormone (N = 39, F2,12 = 24.3, p < 0.001; Cage Control vs Vehicle Escape, t5 = 3.1, ^p ≤
0.028; Cage Control vs Vehicle Stay, t9 = 9.9, ^p < 0.001); however, Stay animals have the highest
concentration (Vehicle Escape vs Stay, t10 = 2.6, _p ≤ 0.025). Inhibition of intra-BLA Orx1R reduces
corticosterone levels in Stay mice (Vehicle Stay vs Orx1R Ant. Stay, t10 = 5.1, +p < 0.001; Orx1R Ant.
Stay vs OrxA Stay, t6 = 3.3, !p ≤ 0.002).
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Figure 6. Transcriptional changes in the BLA after Orx1R or Orx2R antagonism shifts signaling profile.
(A) Antagonism of Orx1R in the BLA reduces HCRTR1 expression (N = 45, Treatment Effect: F2,27 = 3.5,
p ≤ 0.043), but only significantly so in animals expressing the Escape phenotype (Cage Control vs Orx1R
Ant. Escape, t11 = 2.2, ^p ≤ 0.050); whereas infusion of an Orx2R antagonist in the BLA reduces HCRTR1
expression in Stay mice compared to vehicle animals of the same phenotype (t10 = 2.2, +p ≤ 0.044). (B)
While Escape mice (Treatment Effect: F2,27 = 9.8, p < 0.001; Interaction Effect: F2,27 = 8.6, p < 0.001)
treated with vehicle express higher HCRTR2 levels compared to Stay mice (t9 = 3.0; *p ≤ 0.016) and
Orx1R- or Orx2R-antagonist-treated Escape animals (Vehicle vs Orx1R Ant., t7 = 2.6, +p ≤ 0.035; Vehicle
vs Orx2R Ant.: t7 = 4.5, +p < 0.001; Orx1R Ant. vs Orx2R Ant.: t8 = 3.5, !p < 0.001), Orx1R antagonism
results in elevated levels (Escape vs Stay, t10 = 2.2, *p ≤ 0.05; Vehicle vs Orx1R Ant., t12 = 2.4, +p ≤ 0.034)
while Orx2R inhibition leads to a reduction (Vehicle vs Orx2R Ant.: t10 = 3.5, +p ≤ 0.002; Orx1R Ant. vs
Orx2R Ant.: t10 = 4.7, !p < 0.001) of HCRTR2 in Stay mice. (C) A reduction of PLCB1 (Phenotype
Effect: F1,27 = 19.1, p < 0.001; Interaction Effect: F2,27 = 4.3, p ≤ 0.023) that is found in Escape mice under
control conditions (Cage control vs Vehicle Escape, t10 = 5.1, ^p < 0.001; Escape vs Stay, t9 = 5.0, *p <
0.001) and Orx1R antagonism (Escape vs Stay, t10 = 3.1, *p ≤ 0.012; Cage Control vs Orx1R Ant., t11 = 3.3,
p ≤ 0.007) is eliminated with intra-BLA Orx2R antagonism (Vehicle vs Orx2R Ant.: t7 = 2.8, +p ≤ 0.017).

^

(D) While Stay mice treated with an Orx1R antagonist express higher levels of MAPK3 (Phenotype Effect:
F1,27 = 11.3, p ≤ 0.002; Treatment Effect: F2,27 = 4.3, p ≤ 0.023; Interaction Effect: F2,27 = 5.1, p ≤ 0.013) in
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the BLA compared to Vehicle controls (t12 = 3.1, +p < 0.001), administration of an Orx2R antagonist does
not induce the same transcriptional response (Orx1R Ant. vs Orx2R Ant.: t10 = 2.7, !p ≤ 0.022). (E)
Expression of BDNF in the BLA after treatment (Interaction Effect: F2,27 = 10.6, p < 0.001) with an Orx2R
antagonist is enhanced in Escape mice (Orx2R Ant. Escape vs Stay: t8 = 2.9, *p ≤ 0.019; Vehicle vs Orx2R
Ant.: t7 = 2.7, +p ≤ 0.013; Orx1R Ant. vs Orx2R Ant.: t8 = 2.5, !p ≤ 0.017) and reduced in Stay animals
(Vehicle vs Orx2R Ant.: t10 = 2.2, +p ≤ 0.05; Orx1R Ant. vs Orx2R Ant.: t10 = 3.9, !p < 0.001); a
phenotypically opposite effect is observed after Orx1R antagonism (Escape vs Stay, t10 = 2.8, *p ≤ 0.018;
Orx1R Ant. Stay vs Vehicle Stay, t12 = 2.2, +p ≤ 0.049). Transcriptional changes after (F) intra-BLA
Orx1R antagonism and (G) Orx2R inhibition are differentially regulated in a phenotype-dependent fashion.
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Figure 7. Conditioned fear freezing response is related to gene expression changes resulting from intraBLA Orx1R antagonism. In both (A) vehicle- (N = 11, F1,9 = 16.1, R2 = 0.6419, p ≤ 0.003) and (B) Orx1R
antagonist-treated animals (N = 12, F1,10 = 7.2, R2 = 0.4197, p ≤ 0.023) a negative correlation exists
between HCRTR2 expression and cued fear freezing. (C) With vehicle treatment, relative PLCB1
expression is positively associated with cued fear freezing (F1,9 = 6.4, R2 = 0.417, p ≤ 0.0319). (D) This
relationship is not observed in mice that were administered an Orx1R antagonist (F1,10 = 0.7, R2 = 0.0625,
p ≥ 0.4333). (E) While there is not a significant association between MAPK3 expression and cued fear
freezing after vehicle treatment (F1,9 = 3.8, R2 = 0.2973, p ≥ 0.0828), (F) a significant negative
correlation is observed after Orx1R antagonism (F1,10 = 6.3, R2 = 0.3877, p ≤ 0.0306).
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Figure 8. The BLA transcriptional changes that result from Orx1R antagonism form relationships that hint
at molecular timelines and signaling dynamics. (A) While relative gene expression of MAPK3 is positively
correlated to the transcriptional changes of HCRTR2 (N = 12, F1,10 = 8.3, R2 = 0.4532 p ≤ 0.0164), (B) there
is no association between BDNF and HCRTR2 (F1,10 = 0.3, R2 = 0.0313, p ≥ 0.5822). However, (C) a
positive relationship emerges when comparing BDNF expression to that of MAPK3 (F1,10 = 8.2, R2 =
0.4517, p ≤ 0.0167).
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Figure 9. Predicted circuit demonstrates the influence of intra-BLA Orx1R antagonism, during
endogenous stimulation through OrxA and OrxB release, on microcircuit dynamics in a phenotypedependent fashion. (A) Escape mice treated with an Orx1R Antagonist (SB-674042) undergo molecular
shifts, including reduced HCRTR1 and PLCB1 transcription, leading to diminished orexin activity on
glutamatergic neurons in the BLA. Escape mice also have decreased HCRTR2 expression, potentially via
(un-diagrammed) negative circuit feedback, even while Orx2R are stimulated. (B) While OrxB and OrxA
maintain stimulation of some GABAergic neurons through Orx2R, antagonism of some pyramidal
neurons via intra-BLA Orx1R inhibition differentially modifies molecular mechanisms in Stay mice
through enhancement of Orx2R (HCRTR2), ERK1 (MAPK3), and BDNF transcription and increased
orexin activity in Orx2R-containing neurons (likely GABAergic cells).

107

COMPLETE METHODS & MATERIALS
Animals
Male C57BL/6NHsd mice (6-8 weeks old for pharmacology studies and 4-6 weeks old for
shRNA studies) weighing ~22-26 g (Envigo, Indianapolis, IN; N = 108 [pharmacology
experiment] & N = 32 [knockdown experiment]) were housed in groups (4-5 mice per cage) for
a 5-day acclimatization period. For pharmacological studies (N = 92), bilateral stereotaxic
surgeries were performed to implant guide cannula (26 ga cut to 4.0 mm) directed at the
basolateral amygdala (intra-BLA). In orexin 1 receptor knockdown studies (N = 27), the
insertion of an adeno-associated virus (AAV-U6-Orx1R-shRNA or AAV-scramble-shRNA) was
performed stereotaxically by direct injection/perfusion. Following surgery, all animals were
caged individually for the remainder of the experiments, including cage controls (N = 16 for
pharmacology experiment; N = 5 for knockdown study). A separate cohort of retired male
breeder Hsd:ICR (CD1) mice weighing ~50 g (Envigo) were housed in a similar fashion. These
animals were used to provide aggression during social interaction in the Stress Alternatives
Model (SAM), as they act aggressively towards C57BL/6N mice [59]. All mice were
maintained on a 12:12 light-dark cycle (lights off at 6 pm) in rooms held at 22°C (35% Relative
Humidity) and given ad libitum food and water. All behavioral experiments were performed
during the animals’ active phase (scotophase). Mice (C57BL/6N) were handled daily 48 hours
after stereotaxic surgery for 7 days (pharmacological studies) or for the last 7 days of a 30-day
viral incubation period (shRNA studies), followed by social engagement/aggression and
behavioral testing for 5 days. Surgeries and behavioral experiments were all performed in a
manner that minimized suffering and the number of animals used was in accordance with the
National Institutes of Health’s Guide for the Care and Use of Laboratory Animals (NIH
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Publications No. 80-23) and approved by the Institutional Animal Care and Use Committee of
the University of South Dakota.
Stereotaxic Surgery
During stereotaxic surgery, mice were anesthetized using isoflurane (2% at 1.0 L/min flow rate)
to allow for bilateral intra-BLA guide cannula (PlasticsOne, Roanoke, VA; 26 ga cut to 4.0 mm)
implantation or AAV-U6-Orx1R-shRNA administration, then given a recovery period (7 days
for pharmacological experiments; 30 days for AAV-U6-Orx1R-shRNA experiments which
included time for virus incubation) before behavioral testing. Bilateral intra-BLA cannula
placement and AAV-shRNA infusion were performed using the following stereotaxic
coordinates: -1.35 mm AP, ± 3.30 ML, and -4.90 mm DV. During surgery, mice were kept on a
warming pad to maintain core body temperature. After surgery, all animals were placed into
home cages resting on a warming pad for post-surgery recovery and monitoring. Mice were
injected subcutaneously with the analgesic ketorolac (5 mg/kg) immediately following surgery
and 24 hours after receiving the first injection for a total of 48 hours post-surgery pain relief.
Following behavioral experiments, brain tissue was dissected, fixed or frozen and later sectioned
to distinguish correct injection placement directed at the BLA (Fig. S1A). Only animals in
which the BLA was successfully targeted bilaterally (Fig. S1A; 71 mice out of 92 attempts for
pharmacology experiment & 22 mice out of 27 attempts for shRNA study) were used for data
analysis.
Drugs & Drug Infusions
An Orx1R antagonist (SB-674042, IC50 = 3.76 nM for Orx1R and 531 nM for Orx2R [60];
MedChemExpress, Monmouth Junction, NJ), Orexin A (OrxA; Tocris, Minneapolis, MN), OrxA
plus an Orx2R antagonist for biased activation of Orx1R, an Orx2R antagonist (MK-1064, IC50 =
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18 nM for Orx2R and 292 nM for Orx1R (61); MedChemExpress) , or vehicle (artificial
cerebrospinal fluid [aCSF] + DMSO) were bilaterally administered into the BLA (300 nL/side)
on Day 3 (Fig. 1A), an hour before social interaction in the SAM. Dilutions for both treatments
were prepared using a 3:1 ratio of aCSF to dimethylsulfoxide (DMSO). The dose of intra-BLA
Orx1R antagonist (SB-674042; 0.3 nmol/0.3 μL) was adjusted from intracerebroventricular (icv)
Orx receptor-targeting drugs with similar affinities, and preliminary results [28, 62]. The dose
for the Orx2R antagonist (MK-1064; 0.1 nmol/0.3 μL) was 3x lower than previously used
concentrations that produced anxiogenic effects when administered to the whole brain (icv) [28].
Similarly, the intra-BLA doses chosen for OrxA (0.1 nmol/0.3 μL) and the Orx1R activating
cocktail (OrxA+MK-1064; 0.1 nmol/0.3 μL) were selected and adjusted based on icv
administrations that produced anxious behaviors in mice [62]. After mixing, aCSF (8.59 g
NaCl, 0.201 g KCl, 0.279 g, CaCl2, 0.16 g MgCl2, 0.124 g NaH2PO4, 0.199 g Na2HPO4/L H2O)
was brought to a physiological pH (7.33) using NaOH, and then was filtered, degassed, and
stored at 4°C. Drugs were administered by placing cannula (33 ga cut to 4.9 mm, extending 0.9
mm below each guide cannula) into the surgically implanted guide cannula, and injecting at a
rate of ~0.5 μL/min using a 1.0 µL digital syringe (Model 7101 Zero Dead Volume, Knurled
Hub 2.75”, 22GA Needle; Hamilton Company, Reno, NV). After injections, the injector and
syringe were left in place for 90 seconds. Home cage mobility was measured an hour later to
assess locomotion changes that might be associated with drug interactions.
Short-hairpin Knockdown of Orx1R (AAV-U6-Orx1R-shRNA)
The genetic reduction of Orx1R in adult mice was accomplished by intra-BLA injection of shorthairpin RNA packaged into an adeno-associated virus (serotype 2) vector. Preparations of
Orx1R knockdown virus (AAV-U6-Orx1R-shRNA, sense target sequence:
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CCAAAGGTCCCCACAGACATATTC) and scrambled control virus (AAV-scramble-shRNA,
scrambled control sequence: CGGAATTTAGAAACCCGGCTCCAC) were performed at the
Yale School of Medicine Virus Core (New Haven, CT). The oligonucleotides had SapI and
XbaI overhangs to allow for ligation downstream of the mU6pro region of a modified pAAVMCS vector, pAAV-shRNA. This vector was designed to co-express hairpin RNAs, under the
control of a mouse U6 promoter and an SV40 polyadenylation site, as well as EGFP controlled
by an independent CMV promoter and hGH polyadenylation sequence [25]. During stereotaxic
surgery, mice were infused bilaterally using a 1.0 µL syringe (Neuros Model 7001 KH Syringe,
point style 3, 32GA; Hamilton Company, Reno, NV) with 400 nL of virus at a rate of ~0.25
μL/min. After administration, the syringe was left in place for 5 min before being removed.
Dental cement was used to seal the holes made in the skull before the incision was sutured
together. Knockdown was validated using in situ hybridization (RNAscope) and was analyzed
using ImageJ [63]. We observed a 59.4% knockdown (F2,13 = 35.4, p < 0.001) of Orx1R (Fig.
S1D-G). Home cage mobility was performed after 30 days of recovery/viral incubation and
animal weights were taken every week to assess virus-mediated changes in mobility and body
weight, respectively (Fig. S5, S6D). Food weights were taken every day to assess changes in
appetite or food-seeking behaviors that might have resulted from intra-BLA Orx1R knockdown
(Fig. S6A-C).
Behavioral Design
All behavioral measures were performed during the dark cycle when the animals are active,
under red light (~700 nm λ). A GoPro (Hero 3 or Hero 7) video camera was used to record all
behavioral interactions and testing for later analysis. Animal groups for pharmacological studies
included home cage controls (N = 16), for comparisons of food intake, corticosterone levels, and
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mRNA levels), vehicle-treated (N = 19), SB-674042-treated (N = 15), OrxA-treated (N = 9),
OrxA+MK-1064-treated (N = 15), and MK-1064-treated animals (N = 13). Animal groups for
shRNA knockdown experiments included cage controls (N = 5), AAV-U6-Orx1R-shRNA (N =
13), and AAV-scramble-shRNA (N = 9). All pharmacology treatment groups were subjected to
4 days of social aggression (Days 1-4; Fig. 1B) in the SAM with intra-BLA drug injections on
Day 3. Virus-mediated knockdown experiments also included 4 days of aggressive social
interaction (Days 1-4; Fig. 1B) in the SAM. All mice, excluding cage controls, were exposed to
a fear conditioning (FC) paradigm after being inserted into the SAM (Fig. 1A) on the first 4 days
of behavioral testing, using a tone (2500 Hz at 75 dB) as a conditioned stimulus (CS), but before
exposure to an aggressive CD1 mouse, the unconditioned stimulus (US+), and at the end of test
day (Day 5 for both pharmacology and AAV-shRNA experiments; Fig. 1B) to measure freezing
behavior as a conditioned response (CR) in the absence of a CD1 mouse (US-). After
undergoing the CR testing for FC, mice were anesthetized using isoflurane (5% at 1.0 min/L for
2 min) and rapidly decapitated. Whole brains and trunk blood plasma were collected and stored
at -80°C until further analysis.
Stress Alternatives Model (SAM)
The SAM apparatus (Fig. 1A) consists of a white rectangular box (91 cm x 22 cm x 30 cm) and
two curved opaque dividers (r = 10.25 cm) that separate the box into three parts: an oval open
field area (length = 71 cm, width = 22 cm, height = 30 cm) with two enclosed safety areas (10
cm x 22 cm x 30 cm) on both sides which are accessible via escape holes only the smaller
C57BL/6N mice can fit through (Fig. 1A). Before social interaction in the SAM begins, an
opaque cylinder (diameter = 15 cm, width = 20 cm) is positioned in the center of the open field,
then the CD1 mouse is placed outside the cylinder in the open arena of the SAM. A C57BL/6N
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mouse is put into the cylinder and subjected to a fear conditioning paradigm (see Fear
Conditioning (FC) Paradigm section below).
After the cylinder is lifted, C57BL/6N mice are presented with the novel (novel on first day
only) open field arena, containing two escape holes on both ends of the arena, and subjected to
social aggression from a novel aggressive CD1 male, for 5 min. By the end of day 2 of the
SAM, C57BL/6N mice will choose one of two phenotypes that they will express for the
remaining days in the SAM (Days 3 & 4) [26-29]. Mice either utilize the escape holes which
lead to the enclosed (safe) areas of the apparatus where they cannot be attacked by the CD1
mouse (Escape), or they remain in the open field arena and submit to social aggression (Stay).
Previous studies from our laboratory show that Escape mice exhibit significantly lowered
physiological and behavioral measurements of stress when compared to Stay mice [26-29],
despite both groups of animals receiving high levels of social aggression from CD1 mice.
In instances where social aggression from a CD1 mouse was life threatening to a C57BL/6N
mouse, a clear, perforated divider (15 cm wide and 20 cm high) was placed over the CD1 mouse
to briefly interrupt the intense aggressive bouts, which include repeated bites to the head, neck,
or underside of the test C57BL/6N mouse. After 5 min of SAM interaction each day, both mice
were removed from the apparatus and placed back into their home cages. If a C57BL/6N mouse
escaped, they were left in the enclosed area for the remainder of the 5 min, with a clear
perforated sheet of plastic positioned in front of the escape hole in the open field to prevent the
test mouse from going back into the SAM arena.
SAM Behavioral Analysis
Behavioral analysis during the SAM was measured starting when the cylinder was lifted, until
the 5 min of interaction ended, or when a test mouse utilized the escape routes. Mice self-
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selected groups after the first two days of the SAM, being considered the Stay phenotype if the
mouse did not escape on Days 1 or 2, or Escape if the mouse utilized the escape routes on Days 1
or 2. Behaviors recorded included time spent attentive to the escape holes and latency to escape.
Time spent attentive to the hole is defined as the amount of time that a mouse’s head is
within a 3 cm radius of either of the two escape holes and includes sniffing the holes or placing
their head or body inside the escape route. This measurement is an indicator of stress-sensitive
novelty exploration [28, 64, 65]. Even though the entire SAM apparatus is initially novel on Day
1, the escape routes are distinct in that they require a different physical path for movement, and
the enclosed area on the other side of the escape routes remains unknown unless the mouse
utilizes them. This measure provides a novel indicator of anxious behavior and decision-making
that is unique to the SAM [27, 29], and tightly linked to Social Interaction/Preference (SIP)
susceptible (for Stay) and resilient (for Escape) outcomes [28, 30]. Other studies from our lab
show similar results for rainbow trout, suggesting an evolutionary conservation of the circuitry
underlying these behaviors [35]. The Escape and Stay phenotypes are thought to be the result of
decision-making as early responses are initially variable, then become stabilized with experience,
and can be altered with learning or administration of anxiolytic or anxiogenic drugs [27-29, 33,
35, 66].
Latency to escape (or time spent with social aggressor) is determined by measuring the time
it takes an animal to utilize an escape route once the cylinder has been lifted and social
interaction begins. Previous experiments have shown that once an animal escapes, their latency
to escape declines as escape becomes familiar, indicative of spatial and social learning [27, 29,
33].
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Video recordings of the behavioral tests were analyzed using ANY-maze Video Tracking
Software (Version 6.0, Stoelting Co., Wood Dale, IL). Between each animal trial, the arena was
cleaned thoroughly using 70 % ethanol, disinfectant wipes, and dried using clean paper towels.
SAM Validation
The SAM is a tool for assessing stress-related behavior that may be appropriately described as
anxious and depressive behaviors, and as such has been progressively subjected to accepted
validation testing, using the specific criteria for Construct, Predictive, and Face Validities [67].
Through incorporation of social defeat elements as well as active avoidance, the SAM construct
combines elements of fear and anxiety [68-71], social stress and depression [72, 73], but also
alleviation of these stress-related outcomes through Escape. This approach is both ecologically
and ethologically relevant [26, 74, 75] and maintains similarities to relevant human disorders
[76, 77], suggesting a degree of Construct Validity. Predictive validation of the SAM has been
demonstrated through the induction of behavioral changes, including phenotype reversal, using
known anxiolytic, antidepressive, or anxiogenic drugs (NPS, antalarmin, and yohimbine) [27,
29, 33]. The SAM has also been used in conjunction with, and produces comparable results to,
the Social Interaction/Preference (SIP) Test [28, 66]. This additional test (SIP) has been
validated as translationally and predictively reliable in demonstrating the effectiveness of
pharmacotherapies used to treat anxiety (benzodiazepines) and depression (SSRIs) [7, 78-81].
Furthermore, elevated glucocorticoid levels establish an enhanced physiological stress response
in animals encountering social aggression in the SAM, with the Stay phenotype expressing the
greatest increase [26-29, 33]. With respect to Face Validity, SAM exposure results in behavioral
outcomes, largely examples behavioral inhibition (FC freezing) and social avoidance (Escape,
Escape Latency, and SIP test), that reflect those seen in human anxiety and depression. In 13
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published papers on the Stress Alternatives Model, covering 43 experiments and approximately
1,032 animals sampled, the relationship between the number of Escape and Stay animals is very
close to 50% for each phenotype. In most of these experiments, the SAM trials have been
limited to 4 days, with fear conditioning tested on Day 5, and within these parameters,
approximately 98% of phenotypes are stable after Day 2. In experiments to test the stability of
these phenotypes, based on changes in the physical or social environment (prior exposure to the
escape route, exercise, testing in the absence of a CD1 aggressor, or social stress prior to SAM)
as well as the use of anxiolytic or anxiogenic drugs administered on Day 3, modification of
phenotype expression can only be affected through manipulations that alter the stressful
experience.
Fear Conditioning (FC) Paradigm
Training and testing for FC took place in an opaque cylinder where C57BL/6N mice were placed
prior to initiation of social aggression (unconditioned stimulus, US) in the open field of the SAM
(4 days), and on test day (Day 5) in the absence of the US (US-). Freezing was measured in
response to a conditioned stimulus (CS) tone, which indicated that an aggressive conspecific
(US+) would appear shortly (after the divider was pulled). Before social interaction in the SAM
on days 1-4, an opaque cylinder (diameter = 15 cm, width = 20 cm) was placed in center of the
open field, and a novel CD1 mouse was placed in the arena outside of the cylinder. A
C57BL/6N mouse was then introduced into the opaque cylinder to undergo a FC paradigm that
consisted sequentially of a 30 sec acclimation period, the presentation of a 5 sec tone (2500 Hz at
75 dB, CS+), a 10 sec trace period, and the removal of the cylinder, exposing the test mouse to
aggressive interactions from a CD1 mouse (US). On Day 5, the CS was presented without the
US (US-) and freezing to the context and tone alone (CR) were measured.
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FC Behavioral Analysis
Freezing behavior analysis was performed using ANY-maze (Ver. 6.0) software. Measurements
of freezing time were separated into time prior to the tone (30 sec acclimation period), which
provides an indication of contextual conditioning (CS-), and after the tone (15 sec total: 5 sec
tone and 10 sec trace), reflecting conditioning in response to the tone (CS+). Freezing behavior
is often used to determine fear conditioning (28, 82), and was defined as bouts of immobility
excluding normal breathing behavior, for one second or longer.
RNAscope
Coronal slices of fresh frozen brains (N = 16; 16 µm) from AP -1.50 to -1.80 relative to bregma
and incubated in cold (4°C) 10% formalin for 20 min before being washed (2x for 1 min) in 1x
phosphate buffer solution (PBS). The sections then were dehydrated using sequential washes in
ethanol (50%, 70%, and 100%; 5 min each). A final ethanol (100%) incubation period was
performed overnight at -20°C. The next day, sections were processed. In short, proteins were
digested using a protease treatment followed by rinses with distilled water. Sections were then
bathed in RNAscope (Advanced Cell Diagnostics, Newark, CA) probes (HCRTR1, Cat. No.
466631; HCRTR2, Cat. No. 460881; CALB1, Cat No. 428431; CAMKIIα, Cat. No. 445231;
GAD1, Cat. No. 400951; PVALB, Cat. No. 421939) and allowed to incubate for 1 h in a
hybridization oven (ACD HybEZ II oven, Cat. No. 321711) set to 40°C. Subsequent washes
(RNAscope Wash Buffer Reagents [310091]: Wash Buffer 50x diluted to 1x) and incubation
periods with amplification buffers (RNAscope Fluorescent Multiplex Detection Reagents
[320851]: AMP1 [320852], AMP2 [320853], AMP3 [320854], AMP4 ALT A [320855], AMP4
ALT B [320856], AMP4 ALT C [320857]) linked fluorophores and enhanced signaling of
targeted mRNA molecules. Tissue sections on microscope slides (Fisher Scientific, Pittsburgh,
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PA; Superfrost Plus, Cat. No. 12-550-15) were stained with DAPI (20 sec) before adding a drop
of mounting medium (Fisher Scientific; Prolong Gold Antifade Mountant, Cat. No. P10144) and
a coverslip.
Images were visualized and captured using a fluorescence microscope (Nikon NIE with a
Photometrics CoolSNAP MYO camera or Leica DM RA2 with Leica DFC3000 G camera).
Regions of interest were identified from images and analyzed for fluorescence using ImageJ
software. Colocalization of mRNA for cell markers and/or receptors were recognized as overlap
of fluorescence signal or as distinct puncta overlaying DAPI signaling, suggesting mRNA
expression in a single cell.
Stress Hormone (Corticosterone) Analysis
After behavioral testing on day 5 (immediately following FC test), trunk blood was collected and
centrifuged for 10 min in heparinized tubes to separate blood plasma. The plasma was then
frozen immediately on dry ice and later transferred to a -80 °C freezer for storage until analysis
could be completed. Concentrations of plasma corticosterone [B] were quantified in duplicate in
a single run using corticosterone enzyme linked immunosorbent assay kit (Enzo Life Sciences,
Farmingdale, NY).
qRT-PCR
After behavioral testing on Day 5, mice brains were dissected and immediately frozen on dry ice.
Brains were stored in a freezer set to -80°C until the tissue was processed. Fresh frozen brains
were sectioned (Leica Biosystems, Buffalo Grove, IL; Leica CM1850 Clinical Cryostat, Cat. No.
047131148) to 200 μm, the BLA (AP -0.95 mm to -2.45 mm relative to Bregma) was
microdissected on a cold plate using 25 GA punches (Stoelting Co., Wood Dale, IL; Brain Punch
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Set, 0.25 to 1.25 mm; Cat. No. 57401) and immediately placed into 500 μL of Trizol reagent
(Thermo Fisher Scientific, Waltham, MA; Invitrogen TRIzol Reagent, Cat. No. 15-596-018).
Extraction of RNA took place using the Trizol method as previously described [83], but with
some adjustments. In brief, BLA tissue was incubated in 500 μL Trizol at room temperature for
5 min before the phase separation step which included the addition of 100 μL of 1-bromo-3chloropropane and centrifugation (4°C, 7,500xg, 15 min). The top aqueous layer was removed
and used in the RNA precipitation step by mixing it with 250 μL of isopropanol and 1 μL glycol
blue (Thermo Fisher Scientific, Waltham, MA; GlycoBlue Coprecipitant, Cat. No. AM9516) for
pellet formation and identification. The RNA pellet was formed at the bottom of the tube by
centrifugation (4°C, 12,000xg, 20 min). The fluid around the pellet was removed before it was
washed with 75% ethanol and centrifuged at 16,000xg (4°C, 5 min). Most of the ethanol was
removed while the remaining ethanol was evaporated by placing the sample in a hot plate oven
set to 65°C for 20-40 min. The RNA pellet was then concentrated with 25 μL RNase-free water
and quantified using a nanodrop (Implen Inc., Westlake Village, CA; Nanophotometer N50
Spectrometer). Aliquots of RNA samples diluted to 20 ng/μL were created for PCR analysis
before the samples were stored at -80°C.
Assays for the PCR analyses performed in this study were purchased from Thermo Fisher
Scientific (Waltham, MA) and include HCRTR1 (4351370, Mm01185776_m1), HCRTR2
(4351370, Mm01179312_m1), PLCB1 (4351370, Mm01329382_m1), MAPK1 (4448892,
Mm00442479_m1), MAPK3 (4351370, Mm01278702_gH), BDNF (4351370,
Mm04230607_s1), and GAPDH (4453320, Mm99999915_g1) as the housekeeping gene. Onestep RT-qPCR kits (Cat. No. 4392653) were used to build a master mix for each mRNA target
and was combined with RNA samples in individual PCR tubes (MIDSCI, Valley Park, MO;
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Pryme Ergonomic PCR Tubes; Cat. No. B77201). Tubes were loaded into Applied Biosystems
QuantStudio 3 No. B77201 (Thermo Fisher Scientific, Waltham, MA; Cat. No. A28131) and, per
vendor recommendations for Taqman Assays, were subject to 40 cycles at the following thermal
cycling conditions: reverse transcription (48°C for 15 min), activation of DNA polymerase (95°C
for 10 min), denaturation (95°C for 15 sec), and annealing/extension (60°C for 1 min).
Controls lacking either enzyme or template were used to identify possible contamination
during PCR runs. Samples from 45 individuals (12 cage control mice, 11 vehicle-treated mice [4
Escape, 7 Stay], 12 Orx1R Antagonist-treated mice [5 Escape, 7 Stay], and 10 Orx2R Antagonisttreated mice [5 Escape, 5 Stay) were used for PCR analysis. Each sample was run in duplicate,
where the average Ct value was subtracted from the average housekeeping gene (GAPDH) Ct to
give the ΔCt for analysis. Relative gene expression levels were determined using the 2-ΔΔCt
method [84] and compared to the average ΔCt of the untreated controls (cage controls). Data are
presented in graphical form as the average fold change.
Statistical Analysis
All experimental designs and statistical analyses were based on a priori hypotheses. For
conditions that changed over 4 days of SAM social interaction, we compared outcomes using a
two-way repeated measures ANOVA (Orx receptor-targeting drug x behavioral phenotype x
time in SAM interaction design), where phenotype was either Stay or Escape. In addition, twoway ANOVA (Orx receptor-targeting drug x Phenotype design) was utilized to determine the
influence of manipulating activity of Orx receptors (Treatment Effects) relative to the expression
of behavioral phenotypes (Stay vs Escape; Phenotype Effects) and Phenotype by Conditioning
(Interaction Effects). Regression analyses were used for correlations of gene expression and
behavioral (fear conditioning) responses, as well as for correlations between receptor or BDNF
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gene expression and that of intracellular molecular signaling pathways. To compare changes
occurring within a treatment group across SAM interaction days, a one-way repeated measures
ANOVA (Orx receptor-targeting drug x day of SAM interaction design) was performed. Cage
controls were necessary for interpretation of hormonal corticosterone levels and relative gene
expression levels, because samples from SAM treatments were compared to baseline levels
determined by the mean values of home-cage control animals. Therefore home-cage controls
were added for specific one-way ANOVA comparisons. Comparison of locomotion in the home
cage after drug treatment was also accomplished by one-way ANOVA. Comparisons between
two treatments (Vehicle or Orx receptor-targeting drug) within a given phenotype (Escape or
Stay) were analyzed by Student’s t-tests. To determine differences in percentage of escape, chisquare and Fischer Exact statistical analyses were performed, where results from previous days
were utilized as expected values.
Each animal was a singular sample source, from which multiple measures and analyses were
taken. Five assumptions of parametric statistics were applied to the data, which were
transformed when necessary, but also compared to non-parametric analyses, and graphed in their
raw form. Analyses with both non-parametric and parametric statistics were performed along
with examination for multiple comparisons using the Holm-Sidak method, and when the
statistical analyses match, as they do for the data herein, we report the parametric results without
α adjustment [85-90]. Significant effects between groups for one-way analyses were examined
with Student–Newman–Keuls post hoc analyses (to minimize Type I error) and Duncan's
Multiple Range Test (to minimize Type II error).
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COMPLETE RESULTS
Orx1R are expressed in BLA glutamatergic neurons
Using RNAscope in situ hybridization, we identified neurons in the BLA which expressed
Orx1R, CamKIIα, and calbindin mRNA (Fig. 2). Consistent with previous reports in rodents [31,
32], we identified the majority (~80%) of BLA cells to express the glutamatergic marker,
CamKIIα (Fig. S2; F2,9 = 3,311.7, p < 0.001; CamKIIα+ vs Calb+: t6 = 25.2, p < 0.001; CamKIIα+
vs Other: t6 = 20.8, p < 0.001). While Orx1R (HCRTR1) mRNA were observed in both
glutamatergic (CamKIIα-expressing [CamKIIα+]) and calbindin-expressing (Calb+) GABAergic
neurons, the vast majority of Orx1R was expressed in CamKIIα+ cells (>60%; Fig. 2; F2,9 =
386.8, p < 0.001; CamKIIα+ vs Calb+: t6 = 12.0, p < 0.001; CamKIIα+ vs Other: t6 = 4.3, p ≤
0.005; Calb+ vs Other: t6 = 6.0, p < 0.001). Further analyses revealed very few (<20%) of
Orx1R+ cells in the BLA to also express the gene for glutamate decarboxylase (GAD1 →
GAD67), a GABAergic neuron marker (Figs. 2G, H; t8 = 29.5, p < 0.001). Additionally, a small
number (~10%) of Orx1R+ cells also express parvalbumin mRNA (PVALB → PV+), a calciumbinding protein found in a proportion of BLA GABA neurons [91] (Figs. 2I, J; t6 = 23.1, p <
0.001). Importantly, our analyses suggest HCRTR1 is expressed in 10-15% of BLA
glutamatergic neurons, which is significantly more than expression in GAD1+ (GABAergic)
neurons (Fig. 2K; t7 = 3.2, p ≤ 0.015). Together, these results reveal Orx1R to be localized
predominantly on glutamatergic neurons in the BLA (Fig. 2P).
SAM social interactions produce Escape and Stay phenotypes
In the SAM, animals self-select one of two behavioral phenotypes, Escape or Stay (Fig. 1A, S1B
& C), which are typically divided evenly within a population [26, 27, 29, 33, 34]. However, in
some cohorts of animals this may be skewed [28, 30]. For the mice subjected to the
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pharmacological experiments, we observed 39.4% Escape and 60.6% Stay phenotypes (Fig.
S1B). The genetic knockdown experiments yielded Escape and Stay phenotype expression at the
expected 50:50 ratio (Fig. S1C).
Intra-BLA Orx1R inhibition and knockdown increase attention toward the escape route
Previous research from our laboratory demonstrated that the amount of time test subjects spend
investigating the escape tunnel is an indicator of motivation to escape [28]. Similarly, time spent
attentive to the escape hole was significantly different between phenotypes in vehicle-treated
mice (Fig. 3A; Phenotype Effect: F1.51 = 16.4, p < 0.001; Time Effect: F3,51 = 1.3, p ≥ 0.299;
Interaction Effect: F3,51 = 1.5, p ≥ 0.235; Escape vs Stay: Day 1, t17 = 2.6, p ≤ 0.018; Day 2, t17 =
2.5, p ≤ 0.017; Day 3, t17 = 1.6, p ≥ 0.125; Day 4, t17 = 4.2, p < 0.001). Infusion of an Orx1R
antagonist (SB-674042) stimulates attention to the escape hole on treatment day (Day 3)
compared to vehicle-treated Escape mice (Figs. 3B, C; Treatment Effect: F1,30 = 7.7, p ≤ 0.019;
Time Effect: F3,30 = 2.3, p ≥ 0.098; Interaction Effect: F3,30 = 0.9, p ≥ 0.470; Day 3 Vehicle
Escape vs Orx1R Antagonist Escape, t10 = 2.5, p ≤ 0.018). In Stay mice, pharmacological
inhibition of Orx1R (SB-674042) increases the time attentive to the escape route (Figs. 3B, D;
Day 4 Vehicle x Orx1R Antagonist, t20 = 2.1, p ≤ 0.05), however, the effect is smaller compared
to that observed in Escape mice (Fig. 3C). Knockdown of Orx1R (AAV-Orx1R-shRNA)
significantly increased attention toward the escape hole on the third day of the SAM relative to
scramble controls (AAV-Scramble-shRNA) of the same phenotype (Fig. 3E; Day 3 Scramble vs
AAV-Orx1R-shRNA, t20 = 2.4, p ≤ 0.024).
Further analyses demonstrate changes in the time animals investigate the escape routes after
alternative treatments (Fig. S3; Escape: Treatment Effect, F4,23 = 7.9, p < 0.001; Day 3:
Phenotype Effect, F1,61 = 36.1, p < 0.001, Treatment Effect, F4,61 = 7.3, p < 0.001, Interaction
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Effect, F4,61 = 4.9, p ≤ 0.002; Day 4: Phenotype Effect, F1,61 = 46.0, p < 0.001, Treatment Effect,
F4,61 = 5.2, p < 0.001, Interaction Effect, F4,61 = 3.2, p ≤ 0.019). For Escape mice, OrxA
treatment reduced attention toward escape on Day 4 relative to Vehicle-treated animals of the
same phenotype (Figs. S3A & B; t9 = 2.6, p ≤ 0.013). Additionally, on both Days 3 and 4,
Escape mice treated with an Orx1R antagonist displayed higher attention toward escape
compared to animals in the OrxA (Figs. S3A & B, Day 3: t7 = 2.8, p ≤ 0.007; Day 4: t7 = 4.3, p <
0.001) and Orx1R stimulation (Figs. S3A & D; Day 3: t9 = 2.7, p ≤ 0.023; Day 4: t9 = 3.1, p ≤
0.003) treatment groups. Infusion of an intra-BLA Orx1R antagonist also produced greater Day
4 attention toward escape behavior in Escape mice compared to those administered an Orx2R
antagonist (Figs. S3A & F; Day 4: t9 = 2.5, p ≤ 0.015). In Stay mice, investigation of the Escape
route was higher on Day 4 for animals treated with an Orx1R antagonist relative to those infused
with OrxA (Figs. S3A & C; t13 = 2.3, p ≤ 0.036) or an Orx2R antagonist (Figs. S3A & G; t15 =
2.3, p ≤ 0.034). Attention toward escape on Day 3 was lower in Stay mice of the Orx1R
stimulation (OrxA + MK-1064) treatment group compared to those treated with an Orx1R
antagonist (Figs. S3A & E; p ≤ 0.017). Together these results characterize an important function
of intra-BLA Orx1R in modulating adaptive motivation in a social stress environment, where
inhibition or knockdown of these receptors promote increased motivation for Escape behavior
and indirectly more avoidance behavior (Fig. 3F).
Inhibition and knockdown of BLA Orx1R promote escape
In the pharmacological experiments, behavioral phenotypes for both Escape and Stay vehicletreated animals were stable as demonstrated previously [27-29, 33]. However, intra-BLA
injections of an Orx1R antagonist (SB-674042) resulted in a substantial number of Stay mice
exhibiting Escape behavior on Days 3 and 4 of the SAM (Fig. 4A), with a 30% shift on the day
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of treatment (χ2: F1 = 2.0, p ≥ 0.078) and a significant increase the day after (70% increase; χ2:
F1 = 9.3, p < 0.001). Interestingly, intra-BLA activation of both Orx receptors with OrxA or
biased activation of Orx1R with a combination of OrxA and an Orx2R antagonist (MK-1064)
blocked Escape behavior in a small proportion of mice on Days 3 and 4 (Fig. S4), and though
not statistically significant does support the pro-stress role of Orx1R. Treatment with an Orx2R
antagonist did not affect Escape behavior (Fig. S4).
In knockdown experiments, scramble control animals, like vehicle-treated mice, committed
to Escape or Stay on the second day of SAM interaction and did not deviate from these selfselected behavioral phenotypes on the third and fourth days (for both: χ2: F1 = 0.2, p ≥ 0.64).
While 54% of animals treated with AAV-Orx1R-shRNA chose to Stay in the SAM arena with
the aggressive CD1 mouse on Day 2 of social stress, this number decreased incrementally on the
last two days of SAM exposure (Fig. 4B; χ2: F1 = 0.0, p ≥ 1.0; χ2: F1 = 0.2, p ≥ 0.69). By the end
of Day 4 of SAM interaction, 72.7% of AAV-Orx1R-shRNA-treated mice displayed the Escape
phenotype compared to 54.5% of those that received the scramble control (Fig. 5B; χ2: F1 = 0.0,
p ≥ 0.87).
For Escape and Stay phenotypes, the duration of social interaction with the aggressive CD1
mouse was significantly different (Phenotype Effect: F1,45 = 175.3, p < 0.001; Time Effect: F3,45
= 26.1, p < 0.001; Interaction Effect: F3,45 = 26.1, p < 0.001; Escape vs Stay: Day 1, t17 = 1.1, p ≥
0.259; Day 2, t17 = 5.8, p < 0.001; Day 3 t17 = 10.6, p < 0.001; Day 4 t17 = 11.9, p < 0.001) and
changed for Escape mice over the four-day course of the experiments (Fig. 4C; F3,18 = 17.8, p <
0.001). As Escape mice learned to use one of two escape tunnels provided [26, 27, 29, 33, 35],
they spent significantly less time in the SAM arena with an aggressive CD1 mouse on Days 2
through 4; i.e. escape latency was reduced (Fig. 4D; Day 1 vs Day 2, t6 = 2.8, p ≤ 0.011; Day 1
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vs Day 3, t6 = 5.7, p < 0.001; Day 1 vs Day 4, t6 = 6.5, p < 0.001; Day 2 vs Day 3, t6 = 2.9, p ≤
0.009; Day 2 vs Day 4, t6 = 3.7, p ≤ 0.002; Day 3 vs Day 4, t6 = 0.8, p ≥ 0.437); whereas vehicletreated Stay mice remained submissively within the SAM arena for the entire 5 min period (Fig.
4D). Stay animals treated with the Orx1R antagonist (SB-674042), however, spent significantly
less time with the aggressive CD1 mouse on Day 4 of the SAM paradigm compared to those
administered vehicle (Fig. 4D; Treatment Effect: F1,54 = 2.8, p ≥ 0.111; Time Effect: F3,54 = 2.9,
p ≤ 0.043; Interaction Effect: F3,54 = 2.9, p ≤ 0.043; Day 4 Vehicle Stay vs Orx1R Antagonist
Stay, t20 = 3.4, p < 0.001).
Treatment of the Orx1R antagonist (SB-674042) administered on the third day of the SAM
had no effect on latency to escape in animals exhibiting the Escape phenotype compared to
vehicle-treated mice (Fig. 4D; Treatment Effect: F1,30 = 0.2, p ≥ 0.675; Time Effect: F3,30 = 26.9,
p < 0.001; Interaction Effect: F3,30 = 0.3, p ≥ 0.856). Knockdown of intra-BLA Orx1R (AAVOrx1R-shRNA) had no effect on the latency to escape compared to the scramble control (AAVScramble-shRNA) group, although there was a similar decrease over interaction days (Fig. 4E;
Treatment Effect: F1,60 = 0.0, p ≥ 0.960; Time Effect: F3,60 = 5.5, p ≤ 0.002; Interaction Effect:
F3,60 = 0.0, p ≥ 0.995). These results, in combination, suggest that intra-BLA Orx1R promote
coping strategies associated with responses to increased stress, and acute inhibition of these
receptors allows for greater expression of behavior that is derived from reduced output of prostress neurocircuitry (Escape).
BLA Orx1R regulate weight gain and food-seeking behavior, but do not increase
locomotion
As the orexin system is important for motivated behaviors, such as food-seeking, we assessed
food intake throughout these experiments to determine if the combination of stress and Orx1R
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treatments infused into the BLA would alter normal feeding behavior. In the pharmacological
experiments, social stress caused fluctuations in feeding behavior throughout four days of SAM
exposure (Fig. S6A). While vehicle-treated mice exhibited lower food consumption on Day 1 of
the SAM compared to Day 2 (Treatment Effect: F1,99 = 1.9, p ≥ 0.177; Time Effect: F3,99 = 7.9, p
≤ 0.001; Interaction Effect: F3,99 = 1.6, p ≥ 0.192; t18 = 3.0, p ≤ 0.008) and Day 3 compared to
Days 2 (t18 = 4.2, p ≤ 0.001) and 4 (t18 = 2.8, p ≤ 0.012), there were no significant differences
between cage control animals (not exposed to social stress), which consumed relatively equal
amounts of food throughout all four days of the SAM (Fig. S6A). Inhibition of Orx1R resulted in
greater food consumption on treatment day (Day 3), and less intake on Day 4 compared to
vehicle-treated mice (Fig. S6B; Treatment Effect: F1,96 = 0.001, p ≥ 0.974; Time Effect: F3,96 =
12.0, p ≤ 0.001; Interaction Effect: F3,96 = 6.0, p ≤ 0.001; Orx1R Antagonist Day 1 vs Day 2, t14 =
4.2, p ≤ 0.001; Orx1R Antagonist Day 2 vs Day 3, t14 = 3.3, p ≤ 0.005; Orx1R Antagonist Day 2
vs Day 4, t14 = 6.7, p ≤ 0.001; Day 3 Vehicle vs Orx1R Antagonist, t32 = 2.4, p ≤ 0.021; Day 4
Vehicle vs Orx1R Antagonist, t32 = 3.1, p ≤ 0.004). Further, home cage locomotion was
unaltered by the dose of the Orx1R antagonist (SB-674042) or the other treatments (OrxA, Orx1R
Stimulation [OrxA + MK-1064], & Orx2R antagonist) used in this set of experiments (Fig. S5A;
t32 = 1.1, p ≥ 0.299), nor was it upset by knockdown of Orx1R (Fig. S5B; F2,24 = 1.4, p ≥ 0.267).
Since the administration of adeno-associated viruses aimed to knockdown Orx1R in the BLA
was followed by 30 days to allow for viral incubation (Fig. 1B), animal weights were taken
weekly to assess the influence of intra-BLA Orx1R on this metabolic process as it relates to foodseeking behavior. No differences in body weight gain were observed between cage control
animals, which did not undergo surgery, and scramble controls; however, Orx1R knockdown
(AAV-U6-Orx1R-shRNA) resulted in a reduction in weight gain that became more prominent as
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the incubation period progressed with Days 1 and 5 revealing significant decreases compared to
the cage control group (Fig. S6D; Treatment Effect: F2,120 = 1.9, p ≥ 0.172; Time Effect: F5,120 =
142.5, p ≤ 0.001; Interaction Effect: F10,120 = 2.2, p ≤ 0.022; Day 1 Cage Control vs AAV-Orx1RshRNA, t16 = 2.8, p ≤ 0.014; Day 5 Cage Control vs AAV-Orx1R-shRNA, t16 = 2.7, p ≤ 0.017).
Food consumption in scramble control animals, which experienced social stress, differed from
cage controls only after four days of SAM social interaction (Fig. S6C; Treatment Effect: F2,120 =
4.7, p ≤ 0.019; Time Effect: F5,120 = 1.2, p ≥ 0.302; Interaction Effect: F10,120 = 2.6, p ≤ 0.007;
Day 5 Cage Control vs AAV-Scramble-shRNA, t12 = 2.8, p ≤ 0.016). While modest reductions
in food intake were observed in AAV-U6-Orx1R-shRNA animals compared to scramble controls,
a significant difference was only detected after introduction of social stress (Day 1) of the
experimental protocol (Fig. S6C; Day 1 AAV-Scramble-shRNA vs AAV-Orx1R-shRNA, t20 =
2.8, p ≤ 0.005; Day 5 Cage Control vs AAV-Orx1R-shRNA, t16 = 4.1, p ≤ 0.001). Together these
results identify a role of intra-BLA Orx1R in maintaining normal feeding behavior and weight
gain.
Activity of Orx1R in the BLA regulates cued fear responses
On test day (Day 5 for both pharmacological and knockdown experiments; Fig. 1B), after four
days of SAM social stress exposure (US+) paired with a conditioned stimulus (tone; Fig. 1A),
fear conditioning was assessed in mice by measuring freezing behavior (CR) in the absence of a
social aggressor (US-). While cued fear responses (enhanced freezing associated with the CS)
were observed in both Escape and Stay phenotypes under control conditions (Figs. 5A, B; CS
Effect: F1,17 = 47.7, p < 0.001; Escape CS- vs CS+, t6 = 3.9, p ≤ 0.008; Stay CS- vs CS+, t11 = 5.7,
p < 0.001), Stay mice displayed heightened freezing behavior to both context (CS-, opaque
cylinder divider) and cue (CS+) compared to Escape animals (Fig. 5B; Phenotype Effect: F1,17 =
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7.6, p ≤ 0.013; Escape vs Stay: CS-, t17 = 2.8, p ≤ 0.011; CS+, t17 = 2.3, p ≤ 0.033). Inhibition of
intra-BLA Orx1R (SB-674042) did not affect the fear freezing profile in Escape mice (Figs. 5A,
D; Treatment Effect: F1,10 = 1.1, p ≥ 0.313; CS Effect: F1,10 = 24.7, p < 0.001; Interaction Effect:
F1,10 = 0.3, p ≥ 0.574; Orx1R Antagonist Escape CS- vs CS+, t4 = 3.4, p ≤ 0.026); however,
antagonist-treated Stay mice exhibited significantly reduced contextual (CS-) and cued (CS+) fear
responses (Figs. 5A, H; Treatment Effect: F1,20 = 8.8, p ≤ 0.008; CS Effect: F1,20 = 29.6, p <
0.001; Interaction Effect: F1,20 = 0.0, p ≥ 0.869; CS- vs CS+: Vehicle Stay, t11 = 3.9, p < 0.001;
Orx1R Antagonist Stay, t9 = 3.8, p < 0.001; CS- Vehicle Stay vs Orx1R Antagonist Stay, t20 = 2.6,
p ≤ 0.017; CS+ Vehicle Stay vs Orx1R Antagonist Stay, t20 = 2.7, p < 0.001). Like mice of the
Escape phenotype, knockdown of BLA Orx1R (AAV-Orx1R-shRNA) did not affect conditioned
freezing behavior (Fig. S7; Treatment Effect: F1,20 = 0.1, p ≥ 0.776; CS Effect: F1,20 = 19.3, p <
0.001; Interaction Effect: F1,20 = 0.1, p ≥ 0.747; CS- vs CS+: AAV-Scramble-shRNA, t8 = 2.6, p ≤
0.016; AAV-Orx1R-shRNA, t12 = 3.7, p < 0.001). Importantly, activation of intra-BLA Orx1R
and Orx2R with OrxA did not change the fear freezing profile in Escape (Treatment Effect: F1,9 =
0.9, p ≥ 0.364; CS Effect: F1,9 = 26.8, p < 0.001; Interaction Effect: F1,9 = 0.2, p ≥ 0.655) or Stay
mice (Treatment Effect: F1,15 = 0.1, p ≥ 0.733; CS Effect: F1,15 = 47.7, p < 0.001; Interaction
Effect: F1,15 = 1.2, p ≥ 0.295) compared to Vehicle control (Figs. 5A, E, & I). However, biased
stimulation of Orx1R in the BLA with a combination of OrxA and an Orx2R antagonist (MK1064) eliminated the conditioned response in Escape (Figs. 5A & F; Treatment Effect: F1,11 =
1.0, p ≥ 0.332; CS Effect: F1,11 = 16.4, p ≤ 0.002; Interaction Effect: F1,11 = 3.6, p ≥ 0.084; Orx1R
Stim. CS- vs CS+: t8 = 2.1, p ≤ 0.073), but not Stay mice (Figs. 5A & J; Treatment Effect: F1,19 =
4.1, p ≥ 0.060; CS Effect: F1,19 = 45.1, p < 0.001; Interaction Effect: F1,19 = 0.0; p ≥ 0.955; Orx1R
Stim. CS- vs CS+: t7 = 4.6, p ≤ 0.003).
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Corticosterone levels are reduced with intra-BLA Orx1R antagonism
Immediately following assessment of conditioned fear (within 5 min of each trial), trunk blood
plasma was collected and used to measure the concentration of rodent stress hormone,
corticosterone, which was released in response to exposure of conditioned fear stimuli (Fig. 5C).
As in previous studies [27, 28], corticosterone levels were elevated in both Escape and Stay
animals relative to unstressed cage controls (Fig. 5C; F2,13 = 32.7, p < 0.001; Cage Control vs
Vehicle Escape, t11 = 8.1, p < 0.001; Cage Control vs Vehicle Stay, t12 = 8.1, p < 0.001);
however, Stay mice have higher levels of B compared to those of the Escape phenotype (Fig. 5C;
Vehicle Escape vs Vehicle Stay, t10 = 2.8, p ≤ 0.015). Inhibition of Orx1R (SB-674042) in the
BLA, while having no effect on Escape stress hormone concentrations, decreased Stay B levels
compared to vehicle-treated animals of the same phenotype (Fig. 5C; F1,16 = 17.5, p < 0.001;
Phenotype Effect: F1,16 = 1.2, p ≥ 0.298; Interaction Effect: F1,16 = 6.3, p ≤ 0.023; Vehicle Escape
vs Stay, t10 = 2.7, p ≤ 0.015; Orx1R Antagonist Escape vs Stay, t6 = 0.9, p ≥ 0.358; Vehicle
Escape vs Orx1R Antagonist Escape, t6 = 1.1, p ≥ 0.283; Vehicle Stay x Orx1R Antagonist Stay,
t10 = 5.1, p < 0.001). Although antagonist-treated Escape animals had significantly higher B
levels compared to non-stressed cage controls (F2,9 = 7.9, p ≤ 0.010; Cage Control vs Orx1R
Antagonist Escape t6 = 6.1, p < 0.001), Orx1R antagonist-treated Stay mice B levels did not
differ significantly from B levels in non-stressed mice (Fig. 5C; Cage Control x Orx1R
Antagonist Stay, t6 = 2.3, p ≥ 0.062). No correlations, however, between corticosterone
concentrations and fear freezing were observed (Vehicle: F1,10 = 2.4, p ≥ 0.1525; Orx1R Ant.: F1,6
= 0.006, p ≥ 0.9402). Activation of Orx1R and Orx2R with OrxA or selective stimulation of
Orx1R (OrxA + MK-1064) did not impact corticosterone levels relative to vehicle controls
(Treatment Effect, F3,28 = 1.1, p ≥ 0.351; Phenotype Effect, F1,28 = 4.9, p ≤ 0.034; Interaction
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Effect, F3,28 = 0.8, p ≥ 0.489); however, the phenotypic separation that is witnessed under control
conditions was not observed after these treatments (Fig. 5C). Further, these stimulation
treatments resulted in elevated corticosterone levels relative to cage control mice (Fig. 5C; OrxA
Escape vs Cage Control, t5 = 3.7, p ≤ 0.014; OrxA Stay vs Cage Control, t5 = 3.2, p ≤ 0.025;
Orx1R Stim. Escape vs Cage Control, t5 = 5.0, p ≤ 0.004; Orx1R Stim. Stay vs Cage Control, t5 =
5.1, p ≤ 0.004). These results highlight a role for BLA Orx1R in mediating the expression of
behavioral and physiological fear responses.
Antagonism of intra-BLA Orx1R recruits alternative signaling pathways
To determine how the shift in behavioral patterns observed with intra-BLA Orx1R inhibition
coincides with adjustments to transcriptional levels for molecular mechanisms associated with
Orx1R signaling, we performed RT-qPCR analyses of specific genes of interest within the BLA.
As phenotype and treatment may influence receptor gene (HCRTR1 & HCRTR2) expression, we
analyzed levels in BLA tissue (Figs. 6A & B). While vehicle treatment did not result in changes
in HCRTR1 expression (Phenotype Effect: F1,19 = 0.3, p ≥ 0.585; Treatment Effect: F1,19 = 5.5, p
≤ 0.03; Interaction Effect: F1,19 = 0.2, p ≥ 0.690), Orx1R antagonist-treated mice of the Escape
phenotype exhibited significantly reduced HCRTR1 gene expression compared to non-stressed
cage controls (Fig. 6A; t11 = 2.2, p ≤ 0.050). Escape animals in the vehicle control group
exhibited elevated HCRTR2 expression (Phenotype Effect: F1,19 = 2.8, p ≥ 0.111; Treatment
Effect: F1,19 = 1.6, p ≥ 0.221; Interaction Effect: F1,19 = 14.1, p < 0.001) relative to control Stay
mice (t9 = 3.0; p ≤ 0.016) and Escape animals treated with an Orx1R antagonist (Fig. 6B; t7 =
2.6, p ≤ 0.035). However, antagonist treatment resulted in elevated HCRTR2 expression in Stay
mice compared to those that escaped (t10 = 2.2, p ≤ 0.05) and vehicle-treated animals of the same
phenotype (Fig. 6B; t12 = 2.4, p ≤ 0.034). Changes in both HCRTR1 and HCRTR2 gene
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expression following Orx1R inhibition appear to occur in a phenotype-dependent way in the
BLA.
Since PLCβ1 mRNA (PLCB1) is expressed in the amygdala [13], and its protein product
likely plays a dominant role in Orx1R signaling [36] in the BLA, we quantified relative fold
changes in cage control, vehicle-, and Orx1R antagonist-treated mice (Fig. 6C). In both vehicle
and Orx1R antagonist groups, Escape mice expressed significantly lower amounts of PLCβ1
(PLCB1) compared to Stay animals of the same treatment (Fig. 6C; Phenotype Effect: F1,19 =
27.8, p < 0.001; Treatment Effect: F1,19 = 1.4, p ≥ 0.259; Interaction Effect: F1,19 = 0.2, p ≥
0.664; Vehicle Escape vs Stay, t9 = 5.0, p < 0.001; Orx1R Antagonist Escape vs Stay, t10 = 3.1, p
≤ 0.012). Further, while Stay animals had similar expression levels of PLCB1 compared to nonstressed controls (F2,19 = 0.3, p ≥ 0.723), Escape mice in both vehicle- and Orx1R antagonisttreated groups had lower levels compared to these cage control animals (Fig. 6C; F2,14 = 11.2, p
< 0.001; Cage Control vs Vehicle, t10 = 5.1, p < 0.001; Cage Control vs Orx1R Antagonist, t11 =
3.3, p ≤ 0.007). These data seem to suggest that adaptive physiological shifts in intra-BLA
PLCB1 expression may play a role in, or result from, phenotype development, without
identifying how Orx1R antagonism is involved.
As ERK signaling is one of the alternative molecular pathways that can be recruited during
Gq receptor activation, we evaluated intra-BLA transcriptional shifts in ERK genes (MAPK1 &
MAPK3) that result as an effect of Orx1R antagonism (Figs. 6D & S8). There were no
significant differences in relative ERK2 (MAPK1) mRNA in any group (Fig. S8; Phenotype
Effect: F1,19 = 0.3, p ≥ 0.611; Treatment Effect: F1,19 = 2.8, p ≥ 0.113; Interaction Effect: F1,19 =
0.0, p ≥ 0.97). However, in Stay mice treated with an Orx1R antagonist (SB-674042), we
observed a robust increase in ERK1 (MAPK3) expression that was significantly different
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compared to Escape animals in the same treatment group (Phenotype Effect: F1,19 = 13.5, p ≤
0.002; Treatment Effect: F1,19 = 6.3, p ≤ 0.021; Interaction Effect: F1,19 = 4.9, p ≤ 0.039; Orx1R
Antagonist Escape vs Stay, t10 = 3.5, p ≤ 0.006), vehicle-treated animals of the Stay phenotype
(Stay Vehicle vs Orx1R Antagonist, t12 = 3.1, p < 0.001), and non-stressed cage control mice
(Fig. 6D; t13 = 4.1, p < 0.001). The results for molecular signaling pathways suggest potential
links amongst Orx1R inhibition, phenotype plasticity, and the relationship between PLCβ1
(PLCB1) and ERK1 (MAPK3) signaling recruitment in behaviorally distinctive groups, which
also differ in stress sensitivity.
Since brain-derived neurotrophic factor (BDNF) is tied to neuroplasticity [37, 38] that may
result in behavioral changes, like extinction of fear memories [39], we assessed its relative gene
expression which we predicted would be increased with intra-BLA Orx1R antagonist treatment
(Fig. 6E). As hypothesized, intra-BLA Orx1R inhibition resulted in elevated BDNF (Phenotype
Effect: F1,19 = 8.4, p ≤ 0.009; Treatment Effect: F1,19 = 3.5, p ≤ 0.077; Interaction Effect: F1,19 =
1.9, p ≤ 0.181) in Stay compared to Escape mice (t10 = 2.8, p ≤ 0.018) and vehicle-treated Stay
mice (Fig. 6E; t12 = 2.2, p ≤ 0.049). As Stay mice treated with an Orx1R antagonist (SB-674042)
experienced shifts from stress-vulnerable to resilient behavioral responses, the alterations in
gene expression reported here may be implicit in this behavioral plasticity.
Molecular restructuring following intra-BLA Orx1R inhibition is related to fear
responsiveness
Expression levels of HCRTR2 in vehicle- (Regression Analysis: F1,9 = 16.1, p ≤ 0.003) and
Orx1R antagonist-treated mice were negatively correlated to cued freezing (Figs. 7A & B;
Regression Analysis: F1,10 = 7.2, p ≤ 0.023). Relative expression levels of PLCB1 were
positively correlated to cued freezing behavior in vehicle-treated mice (Fig. 7C; Regression
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Analysis: F1,9 = 6.4, p ≤ 0.032); however, this relationship is not observed following intra-BLA
Orx1R inhibition (Fig. 7D; Regression Analysis: F1,10 = 0.7, p ≥ 0.433). Contextual freezing
behavior was associated with MAPK3 expression in only vehicle-treated mice (Figs. S9I & J;
Vehicle, F1,9 = 5.5, p ≤ 0.044; Orx1R Antagonist, F1,10 = 2.6, p ≥ 0.137). Unlike contextual
freezing behavior (Fig. S9J; Orx1R Antagonist, F1,10 = 2.6, p ≥ 0.137), intra-BLA antagonism of
Orx1R cued freezing behavior is negatively correlated to ERK1 (MAPK3) expression (Fig. 7F;
Regression Analysis: F1,10 = 6.3, p ≤ 0.031). This relationship is not observed in vehicle-treated
mice (Fig. 7E; F1,9 = 3.8, p ≥ 0.083). Finally, there are no associations of HCRTR1 (Vehicle, F1,9
= 0.7, p ≥ 0.416; Orx1R Antagonist, F1,10 = 1.2, p ≥ 0.302) and BDNF (Vehicle, F1,9 = 0.2, p ≥
0.639; Orx1R Antagonist, F1,10 = 0.9, p ≥ 0.369) expression with respect to fear freezing
behavior (see also Figs. S9 & S10). Overall, gene expression was not largely correlated with
cued fear freezing when phenotypes were assessed independently (Fig. S10); however, after
intra-BLA Orx1R antagonism, HCRTR2 expression was negatively correlated with cued fear
freezing only in Stay animals (Fig. S10D; F1,5 = 13.7, R2 = 0.7324, p ≤ 0.014). Mostly these
results indicate that behavioral and transcriptional relationships exist within collective
operational adaptations that link behavioral change to molecular modification. These
relationships suggest a function-related connection between Orx1R antagonist-induced shifts in
HCRTR2 and MAPK3 gene expression and fear-related behaviors.
Cells expressing Orx1R in the BLA do not co-express Orx2R
Given that Orx1R antagonism within the BLA alters expression of Orx2R (HCRTR2) mRNA, a
change which is related to cued fear behavioral responses in mice, we decided to investigate
whether both orexin receptor subtypes are expressed within the same amygdalar cells using in
situ hybridization (Figs. 2L-O). Most cells within the BLA express neither HCRTR1 nor
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HCRTR2 (Fig. 2N, F2,9 = 42.1, p < 0.001; Orx1R+ vs Other, t6 = 7.5, p < 0.001; Orx2R+ vs Other,
t6 = 8.4, p < 0.001). However, in BLA cells, HCRTR1 and HCRTR2 mRNA largely do not
overlap (Fig. S11; t16 = 192.4, p < 0.001), and approximately 80% of Orx1R+ cells do not coexpress Orx2R (Figs. 2L, M, & O; t6 = 10.1, p < 0.001).
Fear response after Orx2R inhibition is phenotypically different from Orx1R antagonism
As blocking Orx1R in the BLA produced a dominant effect on conditioned fear freezing in Stay
mice (Fig. 5H), an effect that is linked to an increase in HCRTR2 gene expression (Fig. 6B), we
predicted antagonism of Orx2R (MK-1064) might have a more prominent effect on fear behavior
in Escape mice. Effects of intra-BLA Orx2R antagonism on fear responses were compared to
vehicle- (Escape Mice: Treatment Effect: F1,11 = 2.1, p ≥ 0.178; CS Effect: F1,17 = 12.4, p ≤
0.005; Interaction Effect: F1,17 = 8.0, p ≤ 0.017; Stay Mice: Treatment Effect: F1,17 = 0.1, p ≥
0.719; CS Effect: F1,17 = 37.0, p < 0.001; Interaction Effect: F1,17 = 0.5, p ≥ 0.476) animals (Figs.
5A, G, & K).
In Escape mice, acute inhibition of Orx2R in the BLA eliminated the cued-induced (CS+)
freezing response observed after vehicle treatment (Figs. 5A & G; t5 = 0.7, p ≥ 0.533). Further,
during the post-tone period (CS+), Orx2R antagonist-treated Escape mice exhibited reduced
freezing compared to vehicle-treated animals of the same phenotype (Figs. 5A & G; t11 = 2.3, p ≤
0.045).
While the slope of the freezing profile was steeper in Stay mice treated with an Orx2R
antagonist directed at the BLA compared to Stay animals in the vehicle control group, there were
no statistical differences in the levels of contextual (CS-) and cued (CS+) freezing observed (Figs.
5A & K). These results suggest Orx receptor activity in the BLA influences social stress-
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induced fear behavior in a phenotype dependent way.
Transcriptional changes after Orx2R antagonism contrast those observed after Orx1R
inhibition
Since blocking Orx1R produced changes in mRNA expression relevant to BLA cell signaling
dynamics, we predicted Orx2R antagonism to induce opposing changes to these transcriptional
relationships (Fig. 6). While Orx1R inhibition (Treatment Effect: F2,27 = 3.5, p ≤ 0.043) resulted
in a reduction in HCRTR1 gene expression in Escape mice (Cage Control vs Orx1R Ant. Escape,
t11 = 2.2, p ≤ 0.050), Orx2R antagonism presented a similar decrease, but only in Stay animals
(Fig. 6A; Vehicle vs Orx2R Ant.: t10 = 2.2; p ≤ 0.044). Expression of HCRTR2 in the BLA
(Treatment Effect: F2,27 = 9.8, p < 0.001; Interaction Effect: F2,27 = 8.6, p < 0.001) was reduced
in both Escape (Vehicle vs Orx2R Ant.: t7 = 4.5, p < 0.001; Orx1R Ant. vs Orx2R Ant.: t8 = 3.5, p
< 0.001) and Stay phenotypes (Vehicle vs Orx2R Ant.: t10 = 3.5, p ≤ 0.002; Orx1R Ant. vs Orx2R
Ant.: t10 = 4.7, p < 0.001) after blocking Orx2R, which contrasts with Orx1R antagonism which
enhanced mRNA levels in Stay mice (Fig. 6B; Orx1R Ant. Escape vs Stay: t10 = 2.2, p ≤ 0.05;
Vehicle Stay vs Orx1R Ant. Stay: t12 = 2.4, p ≤ 0.034). Further, intra-BLA Orx2R inhibition
muted the reduction in PLCβ1 (PLCB1; Phenotype Effect: F1,27 = 19.1, p < 0.001; Interaction
Effect: F2,27 = 4.3, p ≤ 0.023) observed in Escape mice under Vehicle treatment (t7 = 2.8, p ≤
0.017) conditions (Fig. 6C) while having no effect on MAPK3 gene expression (Phenotype
Effect: F1,27 = 11.3, p ≤ 0.002; Treatment Effect: F2,27 = 4.3, p ≤ 0.023; Interaction Effect: F2,27 =
5.1, p ≤ 0.013), which was increased in Stay mice after Orx1R antagonist treatment (Fig. 6D;
Vehicle vs Orx1R Ant.: t12 = 3.1, p < 0.001; Orx1R Ant. Vs Orx2R Ant.: t10 = 2.7, p ≤ 0.022).
Finally, Orx2R antagonist treatment enhanced BDNF expression (Interaction Effect: F2,27 = 10.6,
p < 0.001) in Escape mice (Orx2R Ant. Escape vs Stay: t8 = 2.9, p ≤ 0.019; Vehicle Escape vs
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Orx2R Ant. Escape: t7 = 2.7, p ≤ 0.013; Orx1R Ant. Escape vs Orx2R Ant. Escape: t8 = 2.5, p ≤
0.017), while diminishing transcription in Stay animals (Vehicle vs Orx2R Ant.: t10 = 2.2, p ≤
0.05), an effect that is phenotypically opposite to that observed after Orx1R inhibition (Fig. 6E;
Orx1R Ant. Escape vs Stay: t10 = 2.8, p ≤ 0.018; Vehicle Stay vs Orx1R Ant. Stay: t12 = 2.2, p ≤
0.049; Orx1R Ant. Stay vs Orx2R Ant. Stay: t10 = 3.9, p < 0.001). Importantly, no relationships
between gene expression and conditioned fear freezing were observed for any of the tested cell
signaling markers after Orx2R antagonism except for BDNF (Figs. S12A-D), in which a
significant negative correlation was revealed (Fig. S12E; F1,8 = 15.2, R2 = 0.6548, p ≤ 0.0046).
Gene expression uncovers a potential molecular mechanism behind intra-BLA Orx1R
antagonism
To help generate a theoretical mechanism to explain the physiological basis surrounding the
observed behavioral (and phenotypic) shifts resulting from intra-BLA inhibition of Orx1R, we
explored transcriptional relationships in systems that exhibited similar regression patterns (Figs.
6, 7, & 8). With antagonism of Orx1R, there is a strongly positive relationship between
HCRTR2 and MAPK3 expression (Fig. 8A; Regression Analysis: F1,10 = 8.3, p ≤ 0.016).
Importantly, this association does not exist after vehicle treatment (Fig. S13A; F1,9 = 1.1, p ≥
0.322). While there are no observed relationships between BDNF and HCRTR2 expression
levels in either treatment group (Fig. 8B & S13B; Vehicle, F1,9 = 0.1, p ≥ 0.732; Orx1R Ant.,
F1,10 = 0.3, p ≥ 0.582), BDNF expression is positively correlated to ERK1 (MAPK3) expression
in animals treated with an Orx1R antagonist (Fig. 8C; Vehicle [Fig. S13C], F1,9 = 0.0, p ≥ 0.951;
Orx1R Ant., F1,10 = 8.2, p ≤ 0.017). Importantly, no relationships exist between HCRTR1
expression and the other genes of interest (Fig. S13D-I). The connections reported here allowed
us to predict a working model to help explain how Orx1R function within the BLA to establish
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behavioral patterns consistent with stress-induced phenotype development (Fig. 9).
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Figure S1. (A) Injection sites for pharmacology (top & middle rows) and viral infusions (bottom row)
successfully targeted BLA in test mice. In the SAM, (B) pharmacological experiment groups selfselected into a 40:60 split of Escape and Stay animals, respectively, by the end of Day 2 (N = 71); while
(C) mice of the genetic knockdown experimental group more evenly (50:50) divided into Escape and
Stay phenotypes by the end of Day 2 of the experimental design (N = 22). Expression levels of intraBLA Orx1R (HCRTR1) mRNA in (D) Cage Controls, (E) Scramble Controls, and (F) Orx1R-shRNA
animals revealed an (G) approximately 60% knockdown of Orx1R with viral treatment (N = 16, F2,13 =
35.4, p < 0.001; bars are statistically different from one another as illustrated with unique letters, e.g. A is
significantly different from B; p < 0.001).
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Figure S2. In the BLA, the majority of cells express the glutamatergic cell marker, CamKIIα, and very
few cells express mRNA for the calcium-binding protein, calbindin (N = 4, F2,9 = 3,311.7, p < 0.001;
CamKIIα+ vs Calb+, t6 = 25.2, p < 0.001; CamKIIα+ vs Other, t6 = 20.8, p < 0.001; bars are statistically
different from one another as illustrated with unique letters, e.g. A is significantly different from B; p <
0.001).
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Figure S3. The amount of time mice spend attentive to the escape route is influenced by Orx receptor
activity in the BLA. (A) While Stay mice, in general, spend less time attentive to SAM escape routes,
investigation of the Escape routes on Days 3 & 4 is heightened in both Escape and Stay mice after Orx1R
antagonism and reduced with OrxA treatment (N = 71; Day 3: Phenotype Effect, F1,61 = 36.0, p < 0.001,
Treatment Effect, F4,61 = 7.3, p < 0.001, Interaction Effect, F4,61 = 4.8, p ≤ 0.002; Day 4: Phenotype
Effect, F1,61 = 46.0, p < 0.001, Treatment Effect, F4,61 = 5.2, p < 0.001, Interaction Effect, F4,61 = 3.2, p ≤
0.019). Individual analyses based on a priori hypotheses reveal significant reductions in attention toward
escape in (B) Escape (Treatment Effect, F2,39 = 5.8, p ≤ 0.016; Interaction Effect, F6,39 = 3.0, p ≤ 0.016;
Day 3: Orx1R Ant. vs OrxA, t7 = 2.8, !p ≤ 0.007; Day 4: Vehicle vs OrxA, t9 = 2.6, +p ≤ 0.013; Orx1R Ant.
vs OrxA, t7 = 4.3, !p < 0.001) and (C) Stay mice after intra-BLA OrxA administration (Day 4: Orx1R Ant.
vs OrxA, t13 = 2.3, !p ≤ 0.036). (D) Escape mice in the Orx1R Stim. group exhibited lower attention
toward escape compared to animals treated with an Orx1R Ant. (Treatment Effect, F2,45 = 3.8, p ≤ 0.045;
Day 3: Orx1R Ant. vs Orx1R Stim., t9 = 2.7, p ≤ 0.023; Day 4: Orx1R Ant. vs Orx1R Stim., t9 = 3.1, #p ≤
0.003). (E) Stay mice administered the Orx1R Stim. treatment presented lower attention toward escape
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on Day 3 compared to animals in the Orx1R Ant. group (#p ≤ 0.017). Mice treated with an Orx2R
antagonist displayed lower attention toward escape on Day 4 compared to Orx1R Ant. treatment in both
(F) Escape (Treatment Effect, F2,45 = 3.8, p ≤ 0.045; Orx1R Ant. vs Orx2R Ant., t9 = 2.5, $p ≤ 0.015) and
(G) Stay (t15 = 2.3, $p ≤ 0.034) phenotypes. Symbols represent significant differences compared to
Escape mice in the same treatment group (*), Vehicle (+), OrxA (!), Orx1R Stim. (#), and Orx2R Ant. ($).
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Figure S4. Activation of intra-BLA Orx1R and Orx2R with OrxA or biased stimulation of Orx1R (Orx1R
Stim. = OrxA + Orx2R Ant.) promotes Stay behavior in a small, though not significant, percentage of
Escape mice (N = 23).
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Figure S5. Intra-BLA Orx1R activity does not influence home cage mobility. (A) In the BLA, infusion
of an Orx1R antagonist, OrxA, biased activation of Orx1R (Orx1R Stim.), or an Orx2R antagonist does not
affect locomotion in the animal’s home cage environment (N = 71, F4,66 = 0.813, p ≥ 0.813). (B)
Similarly, genetic knockdown of intra-BLA Orx1R has no influence over home cage mobility (N = 27,
F2,24 = 1.4, p ≥ 0.267).
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Figure S6. Intra-BLA Orx1R activity plays a role in controlling weight gain. (A) While social stress
impacts an animal’s eating patterns (N = 35, Time Effect: F3,99 = 7.9, p ≤ 0.001; Vehicle Day 1 vs Day 2,
t18 = 3.0, p ≤ 0.008; Vehicle Day 2 vs Day 3, t18 = 4.2, p ≤ 0.001; Vehicle Day 3 vs Day 4, t18 = 2.8, p ≤
0.012) (B) acute inhibition of intra-BLA Orx1R modifies this cycle on the day of treatment (Day 3) and
the day after (N = 34, Day 4; Time Effect: F3,96 = 12.0, p ≤ 0.001; Interaction Effect: F3,96 = 6.0, p ≤
0.001; Orx1R Ant. Day 1 vs Day 2, t14 = 4.2, p ≤ 0.001; Orx1R Ant. Day 2 vs Day 3, t14 = 3.3, p ≤ 0.005;
Orx1R Ant. Day 2 vs Day 4, t14 = 6.7, p ≤ 0.001; Day 3 Vehicle vs Orx1R Ant., t32 = 2.4, +p ≤ 0.021; Day
4 Vehicle vs Orx1R Ant., t32 = 3.1, +p ≤ 0.004; unique letters indicate significant differences, e.g. A is
different from B). (C) Knockdown of Orx1R in the BLA does not influence food consumption behavior
(N = 27, Treatment Effect: F2,120 = 4.7, p ≤ 0.019; Interaction Effect: F10,120 = 2.6, p ≤ 0.007) until social
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stress is introduced (Day 1; AAV-Scramble-shRNA vs AAV-Orx1R-shRNA, t20 = 2.8, +p ≤ 0.005), at
which point knockdown temporarily reduces food intake, an effect that is matched by scramble controls
only after 4 days of social stress (Day 5) relative to non-stressed cage control animals (^p < 0.05; Day 5
Cage Control vs AAV-Orx1R-shRNA, t16 = 4.1, ^p ≤ 0.001; Cage Control vs AAV-Scramble-shRNA, t12
= 2.8, ^p ≤ 0.016). (D) While body weight gain is reduced in knockdown mice, this effect becomes
significant (relative to cage controls) only after they are subjected to social stress (N = 27, Days 1-5;
Time Effect: F5,120 = 142.5, p ≤ 0.001; Interaction Effect: F10,120 = 2.2, p ≤ 0.022; Day 1 Cage Control vs
AAV-Orx1R-shRNA, t16 = 2.8, ^p ≤ 0.014; Day 5 Cage Control vs AAV-Orx1R-shRNA, t16 = 2.7, ^p ≤
0.017).
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Figure S7. Knockdown of intra-BLA Orx1R prior to social stress-induced fear conditioning, does not
affect an animal’s fear learning response (N = 22, CS Effect: F1,20 = 19.3, #p < 0.001).

154

Figure S8. Treatment with intra-BLA Orx1R antagonist did not change expression levels of MAPK1 (N
= 31, Phenotype Effect, F1,19 = 0.3, p ≥ 0.611; Treatment Effect, F1,19 = 2.8, p ≥ 0.113; Interaction Effect,
F1,19 = 0.001, p ≥ 0.970).
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Figure S9. Molecular changes in BLA signaling dynamics as a result of intra-BLA Orx1R antagonism
are not related to contextual fear response. Transcription levels of HCRTR1, HCRTR2, PLCB1, and
MAPK1 are not related to contextual fear freezing in (A, C, E, & G) Vehicle- (N = 11) or (B, D, F, & H)
Orx1R Antagonist-treated animals (N = 12). While a significant positive relationship was observed
between contextual fear freezing and ERK1 (MAPK3) mRNA in (I) Vehicle-treated mice, (J) this positive
relationship is absent (becomes more closely resembling a negative relationship) in animals infused with
the Orx1R Antagonist. Contextual fear freezing is not associated with BDNF transcription levels in (K)
Vehicle- or (L) Orx1R Antagonist-treated mice.
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Figure S10. Phenotype-dependent cued fear learning is not correlated to changes in transcription levels.
There are no phenotype-specific relationships observed between relative transcription levels of HCRTR1,
HCRTR2, PLCB1, MAPK1, MAPK3, and BDNF and cued fear freezing response in (A, C, E, G, I, & K)
Vehicle-treated mice (N = 11). While this trend holds true mostly for animals treated with an (B, F, H, J,
L) Orx1R antagonist as well (N = 12), (D) there is exists a significant negative relationship between
HCRTR2 expression and cued fear freezing in only Stay mice administered the Orx1R antagonist (F1,5 =
13.7, R2 = 0.7324, p ≤ 0.014).
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Figure S11. The proportion of BLA cells that express both HCRTR1 and HCRTR2 is small (~2%)
compared to those that do not express the mRNA for both Orx receptors (N = 9, t16 = 192.4, p < 0.001).
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Figure S12. Inhibition of Orx2R in the BLA is not reveal correlations between cued fear freezing and
transcription of (A) HCRTR1, (B) HCRTR2, (C) PLCB1, or (D) MAPK3 (N = 10). (E) However, after
intra-BLA Orx2R antagonism, a significant negative relationship between BDNF and fear freezing was
observed (N = 10, F1,8 = 15.2, R2 = 0.6548, p ≤ 0.0046).
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Figure S13. Statistical correlations of molecular changes in the BLA associated with Orx1R antagonism
(Fig. 11) are not present in Vehicle-treated animals. (A) With vehicle administration, intra-BLA changes
in MAPK3 and HCRTR2 mRNA levels are not correlated (N = 11). Similarly, in vehicle-treated mice (N
= 11), relationships in BLA transcription levels do not exist for (B) BDNF and HCRTR2 or (C) BDNF
and MAPK3. Further, BLA analyses of mice administered vehicle (N = 11) did not reveal relationships
between HCRTR1 and (D) HCRTR2, (E) MAPK3, or (F) BDNF. After intra-BLA Orx1R antagonism (N
= 12), HCRTR1 gene expression levels in the BLA were not correlated with (G) HCRTR2, (H) MAPK3,
or (I) BDNF.
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Chapter 3: Orexin receptor modulation in basolateral amygdala reveals generalization of
social stress learning

ABSTRACT
Fear-associated memories and behavior are often expressed in contexts/environments
distinctively different from those in which they are created. This generalization process
contributes to psychological disorders, particularly PTSD. Stress-related neurocircuits in the
basolateral amygdala (BLA) receive inputs from hypothalamic orexin (Orx) neurons. These
neurons mediate activity by targeting orexin 1 (Orx1R) and orexin 2 (Orx2R) receptors which
govern opposing behavioral functions. In the BLA, inhibition of Orx1R or activation of Orx2R
ameliorate stress responsiveness and behavior. We discovered that most Orx1R+ cells also
express CamKIIα, while a majority of Orx2R+ cells are colocalized with GAD67. Further,
HCRTR1 expression was positively correlated, and HCRTR2 expression was negatively
correlated with freezing in a phenotype-dependent fashion (Escape vs Stay) in the Stress
Alternatives Model (SAM). The SAM consists of 4-days of social interaction trials between test
mice and novel larger aggressors. Exits positioned at opposite ends of the SAM oval arena
provide opportunities to actively avoid aggression. By Day 2, mice commit to a behavioral
phenotype: Escape or Stay. Pharmacologically manipulating Orx receptor activity in the BLA,
before Day 3 of the SAM, was followed with standard tests of anxiety: Open Field (OF) and
Elevated Plus Maze (EPM). Freezing and locomotion during SAM interaction were generalized
to the non-social OF environment. This transference of behaviors was blocked by intra-BLA
Orx1R antagonism, but not Orx2R antagonism in Stay mice. Moreover, the pattern of social
avoidance in the SAM for Escape and Stay mice were recapitulated in the OF test, with
behavioral transference being mediated by Orx1R and Orx2R activity.
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INTRODUCTION
Fear learning plays an important role in many psychological disorders, including anxiety,
depression, and PTSD. In these disorders, particularly PTSD and related animal models, fearassociated memories and behavior are often expressed in contexts and/or environments that are
distinctively different from those in which they are generated, a learning process known as
generalization or transference [1-6]. Preclinical models for these disorders often use
environmental or social stressors [7], and frequently demonstrate specific fear learning
mechanisms, such as Pavlovian conditioning [8, 9]. However, several classical tests for anxiety
and/or depression (such as Elevated Plus Maze [EPM] or Open Field [OF] Test) in rodents have
failed to faithfully translate to successful clinical trials [10, 11]. We suggest that more
efficacious models should carefully include ecologically and ethologically designed applications
[7, 12] that specifically consider learning in the production of behavioral outcomes and decisionmaking [13].
During socially stressful interactions, such as aggression, behavioral responses are
influenced by previous experience, environmental options, and the intensity of the social contact
[8, 9, 14, 15]. These behavioral dynamics are controlled by neural and endocrine reactivity to
stress. We designed the Stress Alternatives Model (SAM) to allow for a window onto the
development of anxious and depressive behavior, and the mechanisms of decision-making that
produce resilient and susceptible phenotypes. In an oval arena with apical escape routes, novel
larger aggressive individuals interact with a smaller adult test subjects. Test animals self-select
one of two phenotypes: Escape or Stay, which exhibit stress resilient and susceptible responses
to social interaction/preference tests (SIP) and in plasma glucocorticoid concentrations [9, 16,
17]. Anxiolytic drugs (corticotropin releasing factor type 1 receptor [CRF1] antagonist
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antalarmin, orexin 1 receptor [Orx1R] antagonist SB-674042, and orexin 2 receptor [Orx2R]
agonist [Ala11, ᴅ-Leu15]–OrxB) prompt resilient Escape behavior in susceptible Stay animals [9,
16, 17]. Alternatively, anxiogenic drugs (Yohimbine, an α2 adrenoreceptor antagonist, and
Orx2R antagonist MK-1064) promote Stay behavior in Escape phenotype mice. Behaviors
reflecting motivation to escape the SAM are also modified by stress-related neuromodulatory
events [16, 17]. A fear conditioning protocol (tone = conditioned stimulus [CS]) precedes the
aggressive interaction (unconditioned stimulus [US]) in the SAM, in which the cued conditioned
response (CR = freezing) in Stay mice is reduced by intra-basolateral amygdala (intra-BLA)
injection of an Orx1R antagonist [17].
Orexins (hypocretins) are comprised of two peptides, OrxA (HCrt1)and OrxB (HCrt2),
cleaved from the same pro-peptide produced in equal proportions in the lateral, dorsomedial
hypothalamus perifornical area (LH-DMH/PeF) [18, 19]. While OrxA has equally high binding
affinity for Orx1R and Orx2R, OrxB has a modestly higher affinity for Orx2R over Orx1R [20,
21]. In the BLA, and in other regions such as the paraventricular thalamus, the two receptor
types are functionally opposed [22-25]. We suspect therefore, that specific receptor binding is
defined by cellular localization [17], such that functions of the Gq-linked Orx receptors are
married to the output of the neuronal types in which each primarily exists. During experiments
examining the anti-stress properties of Orx1R antagonism in the BLA, it became clear that the
classical fear conditioning we expected for stress-susceptible animals alone [9, 26], was more
complex than originally hypothesized [17]. Instead of classical fear conditioning being limited
to susceptible Stay mice, both Stay and Escape mice exhibit cued CRs. Moreover, Stay mice
also exhibit enhanced contextual conditioning (freezing prior to tone in opaque divider) during
the same SAM protocol [17]. Additionally, intra-BLA injection of an Orx1R antagonist and icv
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delivery of an Orx2R agonist reduce cued fear conditioning [16, 17]. Although Escape
individuals experience significantly reduced neural and endocrine reactivity to stress, as well as
diminished stress-related behavior compared to Stay animals [9, 16, 26] they undergo classical
and contextual conditioning. While the phenotypes are fundamentally different in the magnitude
of responses (such as freezing), the fear learning processes can be induced in resilient (Escape)
animals [17].
In addition to the Orx1R antagonist inhibiting secretion of the stress hormone corticosterone
in both vulnerable (Stay) and resilient (Escape) mice, there were also specific alterations of
signaling-related gene expression [17]. Specifically, inhibition of Orx1R in BLA promoted
increased Orx2R (HCRTR2) gene expression in non-glutamatergic, presumably GABAergic,
neurons [17]. In BLA, following Orx1R inhibition (likely in pyramidal neurons) there was also a
significant increase in ERK1 (MAPK3) and Brain-Derived Neurotrophic Factor (BDNF)
transcripts [17]. We hypothesized that these changes occurred primarily in GABAergic cells
containing Orx2R. This potential cross-neuron stimulation of Orx2R, ERK1, and BDNF mRNA
production was only evident in vulnerable Stay mice following intra-BLA administration of an
Orx1R antagonist. The data suggest the Orx system not only modifies behavioral activity
through actions in the BLA, it also acts to shift the signaling systems that underlie those
behaviors [17]. We surmised that if behavior and signaling systems were both altered following
intra-BLA Orx1R antagonism, then the learning and memory systems that allow and support
those behaviors might also be changed.
As inhibition of Orx1R in the BLA corresponded with transcriptional changes in Orx
receptors and conditioned fear responses [17], we first predicted that mRNA levels of Orx
receptors in the BLA would be related to phenotype-dependent socially induced freezing
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behavior in the SAM arena. Additionally, we noticed adaptive adjustment of specific selfpositioning strategies during avoidance of the aggressor appear during SAM trials. That is to
say, resilient Escape mice seemed to make more use of SAM arena edge space on the way to
using the escape route at the apical edge, even though the CD1 aggressors primarily patrol there.
Not surprisingly, susceptible Stay mice make greater use of center areas. Those observations
lead us to examine if the development of unique Escape and Stay coping strategies were being
translated into equivalent behavior in subsequent trials using alternative testing models posttreatment. Since the open field (OF) and elevated plus (EPM) tests have uniquely defined
movement strategies that have been associated with anxious responses [11,27,28], our surprising
results suggested that the typical OF and EPM outcomes can be overridden. Based on these
findings, we hypothesized that social stress-induced fear freezing behavior will be generalized
(learned transfer of the adaptive response from one context to another) to a novel OF Test
environment, and that Orx1R inhibition or Orx2R stimulation would mute this learning response.
As intra-BLA Orx receptors are important for generalization of fearful responses, we also
hypothesized that specific learning of environmental self-positioning strategies during social
aggressor avoidance in the SAM may be transferred/generalized to the non-social OF Test with
pharmacological manipulation of Orx receptor activity. Finally, we proposed that measures of
anxious behavior in the classical EPM after social stress and behavioral testing may be
unreliable and inconsistent with results from the SAM and OF Test learning trials.
MATERIALS & METHODS
Social Stress and Decision-Making Paradigm
In the SAM paradigm (Fig. 1A), social conflict between a larger novel CD1 mouse and smaller
C57BL/6NHsd male mouse takes place for five minutes over four days, during which test animals
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may shorten interaction with the aggressor by escaping out of size-limited tunnels at the ends of
an oval open field arena. A tone given during isolation in the SAM apparatus prior to arena
exposure conditions test subjects to the upcoming social interaction. As distinct and stable
phenotypes (Escape & Stay) are established on Day 2, drug manipulation on Day 3 allows for
behavioral comparisons between phenotypes and drug controls (vehicle) during the SAM (Days
3 & 4) and in tests of anxiety that follow SAM exposure (Open Field and Elevated Plus Maze).
All procedures were performed in accordance with the Guide for the Care and Use of Laboratory
Animals (NIH Publications No. 80-23) and approved by the USD Institutional Animal Care and
Use Committee.
Experiment Overview (see also COMPLETE MATERIALS & METHODS)
For these experiments, Orx receptor-targeting drugs (Orx1R antagonist: SB-674042, Orx2R
antagonist: MK-1064, OrxA, concoction of OrxA & MK-1064 [for biased stimulation of Orx1R],
and Orx2R agonist: YNT-185) were directed at the BLA 1h prior to SAM interaction on Day 3
(Fig. 1B). After SAM interaction on Day 4, mice were exposed to the OF Test (Day 4) and
EPM (Day 5). Behavioral measurements were taken the active phase (dark cycle), and included
freezing (conflict-associated [SAM] or generalized [OF Test]), locomotion (SAM, OF Test, and
home cage), time spent in center area (SAM and OF Test), and standard EPM measurements
(time in open/closed arms and intersection zone). Brains were collected and used for visual
representations of mRNA (using RNAscope) or relative changes in gene expression (rt-qPCR)
of Orx1R (HCRTR1) and Orx2R (HCRTR2) receptors, Ca++/Calmodulin Kinase type 2 alpha
(CAMKIIα; glutamatergic cell marker), Glutamate Decarboxylase (GAD1; GABAergic cell
marker), and parvalbumin (PVALB; calcium-binding protein found in a subset of GABA
neurons). All statistical analyses were built from a priori hypotheses and performed using two-
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way repeated measures ANOVA for SAM freezing behavior across days (Phenotype x Day),
two-way ANOVA for in situ cellular localization studies and SAM, OF, or EPM behaviors
(Phenotype x Treatment), Regression analyses where correlations between SAM and OF
behaviors were made, and t-test, followed (where appropriate) by post hoc analyses.

RESULTS (see also COMPLETE RESULTS)
Social stress-induced freezing linked to specific Orx receptors in specific neurons
Freezing in response to social conflict is common and most pronounced on Day 4 of the SAM
paradigm (Fig. 2A; Phenotype Effect: F1,168 = 4.8, p ≤ 0.033; Time Effect: F3,168 = 4.2, p ≤
0.007; Interaction Effect: F3,168 = 4.1, p ≤ 0.008; Day 4 Escape vs Stay: t56 = 3.8, p < 0.001).
This freezing behavior exhibits phenotype specific positive (Escape mice) and negative (Stay)
regression relationships with HCRTR1 (Escape; Fig. 2B; F1,8 = 7.8, R2 = 0.4946, p ≤ 0.0233) and
HCRTR2 (Stay; Fig. 2C; F1,12 = 9.7, R2 = 0.4481, p ≤ 0.0088). The Orx1R and Orx2R are found
in a minority of BLA neurons (Fig. 2D; F3,44 = 134.0, p < 0.001), suggesting that the strong
functional relationship to freezing is determined by specific neurocircuits, presumably including
CamKII-positive glutamatergic pyramidal cells for Orx1R effects on freezing in Escape mice
(Figs. 2E-G; Interaction Effect: F2,30 = 37.4, p < 0.001; Orx1R+ CamKIIα+ vs CamKIIα-: t10 =
6.4, p < 0.001; Orx2R+ CamKIIα+ vs CamKIIα-: t10 = 5.8, p < 0.001; CamKIIα+ Orx1R+ vs
Orx2R+: t10 = 5.9, p < 0.001; CamKIIα+ Orx1R+ vs Orx1R+ & Orx2R+: t10 = 2.8, p ≤ 0.009), and
likely GAD67-positive GABAergic neurons for Orx2R relationship with freezing in Stay mice
(Figs. 2H-J; GAD67 Expression Effect: F1,24 = 322.9, p < 0.001; Interaction Effect: F2,24 = 73.3,
p < 0.001; Orx1R+ GAD67+ vs GAD67-: t8 = 18.0, p < 0.001; GAD67+ Orx1R+ vs Orx2R+: t8 =
8.4, p < 0.001; GAD67+ Orx1R+ vs Orx1R+ & Orx2R+: t8 = 2.9, p ≤ 0.008; Orx1R+ & Orx2R+
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GAD67+ vs GAD67-: t8 = 12.3, p < 0.001; GAD67- Orx1R+ vs Orx1R+ & Orx2R+: t8 = 2.9, p ≤
0.008; GAD67- Orx2R+ vs Orx1R+ & Orx2R+: t8 = 5.5, p < 0.001).
Orx receptor-dependent generalization of freezing and locomotion are phenotype specific
Importantly, freezing in response to social conflict in the SAM is generalizable to the OF test for
vehicle treated Stay mice (Fig. 3; Antagonist groups: Phenotype Effect, F1,43 = 16.0, p < 0.001;
Stimulation groups: Drug Effect, F3,46 = 17.1, p < 0.001; Phenotype Effect, F1,46 = 9.1, p ≤
0.004). These Stay mice exhibit significantly more conflict freezing than Escape mice (Fig. 3A;
t19 = 2.67, p ≤ 0.015). The distinctive phenotype difference in behavior is eliminated by Orx1R
antagonist treatment, but not by Orx2R antagonist (Fig. 3A; t15 = 2.8, p ≤ 0.014). Further,
phenotype differences are abolished with OrxA and Orx1R stimulation as a result of Escape mice
displaying more freezing, and after Orx2R agonist as both phenotypes experience a reduction in
freezing (Fig. 3B; Escape Vehicle vs OrxA: t10 = 3.4, p ≤ 0.007; Stay Vehicle vs OrxA: t16 = 3.3,
p ≤ 0.005; Stay Vehicle vs Orx1R Stim.: t21 = 3.0, p ≤ 0.008; Escape Vehicle vs Orx2R Stim.: t9
= 2.3, p ≤ 0.047; Escape OrxA vs Orx2R Stim.: t5 = 3.2, p ≤ 0.023; Stay Vehicle vs Orx2R Stim.:
t17 = 3.3, p ≤ 0.004; Stay OrxA vs Orx2R Stim.: t9 = 8.7, p < 0.001; Stay Orx1R Stim. vs Orx2R
Stim.: t13 = 8.5, p < 0.001).
Generalization of locomotion is also transferable from SAM to OF for Escape mice (Fig. 4;
Antagonist groups: Phenotype Effect, F1,43 = 9.0, p ≤ 0.005; Stimulation groups: Phenotype
Effect, F1,46 = 8.2, p ≤ 0.006), with significant positive regressions between OF and SAM
locomotion for Orx1R antagonist, but also for OrxA and the Orx2R agonist (Figs. 4E-H; Orx1R
Ant.: F2,3 = 15.9, p ≤ 0.028; OrxA: F2,2 = 49.4, p ≤ 0.02; Orx2R Stim.: F2,1 = 351.5, p ≤ 0.034).
Escape mice (vehicle treated) exhibit significantly more locomotion in the SAM and OF (Figs.
4A, C), but not in the home cage (Fig. S9; SAM: t19 = 2.7, p ≤ 0.014; OF: t19 = 2.5, p ≤ 0.023).
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This phenotypic distinction is observed after Orx2R antagonism, but not Orx1R antagonism
(Figs. 4A, C; SAM.: t11 = 2.3, p ≤ 0.039) or Orx1R stimulation (Figs. 4B, D; SAM: t13 = 2.5, p ≤
0.026; OF: t13 = 2.5, p ≤ 0.028). However, the correlation of locomotive behavior in SAM and
OF is still present despite the reversal of the phenotypic divide (Orx1R Ant.: F2,3 = 15.9, p ≤
0.028).
Generalization of phenotypic behavior patterns are modulated by Orx receptors
As freezing and locomotion in response to social conflict are generalizable from SAM apparatus
to OF, we sought to understand whether the basic patterns of phenotypic response (Stay and
Escape), would be reflected in standard tests of anxious responsiveness, such as OF or EPM.
There was a generalization effect of phenotypic behavior in OF (Fig. 5; Antagonist groups,
SAM: Phenotype Effect, F1,43 = 7.4, p ≤ 0.010; OF: Phenotype Effect, F1,43 = 15.7; Stimulation
groups, SAM: Drug Effect, F3,45 = 5.5, p ≤ 0.003; OF: Phenotype Effect, F1,46 = 4.9, p ≤ 0.032).
However, for treated mice this transference was strictly dependent on movement patterns
learned during 4 days in the SAM. Escape mice, which used the edges of the SAM to locate
apical escape routes located on the edge, also favored edges in the OF (Figs. 5F top; ). In
contrast, Stay mice frequented the center of the SAM apparatus to avoid patrolling CD1
aggressors, and maintained that pattern in OF when treated with Orx1R or Orx2R antagonists or
an Orx2R agonist (Figs. 5E, F bottom, G, H; Orx1R Ant.: F1,8 = 16.8, p ≤ 0.003; Orx2R Ant.: F1,5
= 13.5, p ≤ 0.014; Orx2R Stim.: F1,4 = 40.2, p ≤ 0.003).
The EPM results following 4 days of SAM interaction did not produce a phenotypic
distinction between Escape and Stay mice for open arm, closed arm, or interaction zone times
(Figs. S11; Open Arms: Phenotype Effect, F1,46 = 7.5, p ≤ 0.009; Closed Arms: Phenotype
Effect, F1,46 = 8.5, p ≤ 0.005). Surprisingly, anxious, stress-vulnerable Stay mice [9, 24],
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exhibited significantly more time in open arms following OrxA treatment (t7 = 2.2, p ≤ 0.037),
and Orx1R stimulation (Figs. S11B, D; t13 = 2.2, p ≤ 0.044); opposite of the expected finding
relative to anxiety.

DISCUSSION
The process of phenotype development in the SAM requires numerous learning phases.
Decision-making for stress-vulnerable individuals (Stay) in the SAM paradigm shifts to resilient
(Escape) responses after anxiolytic drugs or behavioral modifications (such as exercise) are
administered [9, 13]. This is also true after intra-BLA Orx1R inhibition or icv Orx2R stimulation
[16, 17]. Conversely, decisions in the SAM switch from stress resilient responses to stress
susceptible responses in Escape phenotype animals following anxiogenic treatments that include
Orx2R antagonism [9, 17]. Furthermore, social aggression-based contextual and cued fear
conditioning are reduced by intra-BLA Orx1R antagonism and by icv Orx2R stimulation [16,
17], which suggested to us that amygdalar Orx receptors modify associative learning related to
fear behavior. Activation of the Orx system amends performance in novel object recognition,
while reducing social interaction following defeat [29], further suggesting that Orx and stressrelated behavior together modify the conditions for learning.
In the SAM, following the CS cue for fear conditioning, socially induced freezing in
response to aggressive contact also takes time to learn, and appears most consistently after 4
days of training (Fig. 2A). Importantly, SAM-induced behavioral changes, like freezing, after
acute pharmacological intervention (Day 3) are long-lasting, showing behavioral exhibiting
changes on the day of treatment but also later (Days 4 & 5) [9, 16, 17]. Social aggressioninduced, phenotype-dependent freezing behavior on Day 4 is bidirectionally correlated,
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positively for Escape with HCRTR1 and negatively for Stay with HCRTR2 gene expression in
the BLA (Figs. 2B & C). The locations of these receptors are distinctively organized primarily
with HCRTR1 expressed (> 60%) in glutamatergic pyramidal (Figs. 2D-F, S5D, F) and HCRTR2
in GABAergic neurons (Figs. 2G-I, S5E, F), suggesting separation of cellular function in the
stress circuits of the BLA that are dependent on learning. Simply put, the data suggest that, in
Escape mice, as Orx1R mRNA in BLA (mostly pyramidal neurons) increases, freezing also
increases. Additionally, the data suggest that as Orx2R mRNA increases in Stay BLA (mostly
GABA neurons), freezing also decreases. Pyramidal Orx1R-containing neurons in the BLA are
located in a larger pro-stress circuitry, and activate anxiogenic and pro-depressive behaviors and
conditioned fear learning [17, 30]. This circuitry is also innervated by noradrenergic neurons of
the locus coeruleus (LC), which are modulated by Orx1R and mediate cue-dependent fear
memories [31-33]. In the BLA, Orx2R-containing GABA neurons inhibit the pro-stress
circuitry, but also result in anxiolytic and anti-depressive behaviors and reduce conditioned-fear
learning [16, 24]. The data suggest that learned responses are not only tuned to the Orx receptor
type and particular neurocircuitry element in which they exist, but also reflected by the gene
expression changes that occur over the 4 days of training. Surprisingly, the coping strategies
learned in the SAM is transferred to other behavioral tests for anxiety, such as the open field
(OF; Figs. 3, 4, 5), but not the elevated plus maze (EPM; Fig. S11).
We have previously noted that Escape and Stay behavior both require learning social
behavioral patterns and associative cues, to efficiently minimize vulnerability from attack while
using the escape hole or remaining in the SAM arena [8, 14]. Escaping mice utilize one of the
two tunnels for egress with progressively reduced latency, while Stay mice display socially
induced conflict freezing with progressively increased duration (Fig. 2A). This suggests that
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both Stay and Escape animals utilize coping strategies that include learning how to minimize
vulnerability from aggression more efficiently with each trial. This means it is necessary to
monitor the patrolling patterns of the dominant aggressive male, to avoid those spaces while
freezing (for Stay animals), or to develop ballistic or secretive escape movements to safely
accomplish Escape. As such, our model demonstrates more than one learned and adaptive
reaction is possible in response to an unconditioned fearful stimulus in a fear conditioning
paradigm. Social defeat is replete with contextually rich stimuli, including the elements of
social rank dynamics, which in natural settings allows for more than one appropriate behavioral
response. Others have demonstrated that Orx activation during social defeat reduces both social
interaction and recognition learning in defeated mice [29], modifying appropriate behavioral
responses. Thus, the generalization or transference of responses (freezing, locomotion, center
preference in Stay vs. edge preference in Escape mice) from the SAM to the OF arena, suggests
behavioral plasticity in coping strategies linked to specific stress phenotypes.
Regardless of the eventual phenotype, Escape and Stay mice must learn the patrolling
routines of the novel, dominant, larger, aggressive (CD1) mice. These mice patrol the edges of
the SAM, because it is ecologically safer, and can easily block escape this way, since the tunnels
are located on the apical edge. Stress-vulnerable (Stay) mice learn to frequent the center of the
SAM arena, to avoid the aggressor. After 4 days of SAM training, these anxious, stressvulnerable Stay mice also frequent the center of the OF arena, just the opposite of what would
be expected, since susceptible animals demonstrate reduced social interaction [29] in the SIP test
[16, 34]. Conversely, Escape mice seek egress by following the edge of the arena to the tunnel,
and thus in the OF, these stress-resilient (Escape) mice also keep close to the edges. Finally, the
duration of socially induced freezing in the OF is correlated with prior freezing in the SAM,
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reflecting the learning that occurred there (Fig. 3E).
The behavioral transference or generalization learning observed here likely results from
distinctive Orx1R or Orx2R signaling within decision-making and anxiety/fear neurocircuitries
that are inextricably tied to learning systems [17, 31-33]. When decision-making coincides with
stress, recruitment of neural networks that define executive function, including the dorsolateral
prefrontal, anterior cingulate, and orbitofrontal cortices, utilize connections with the emotion
processing system of the amygdala [35, 36], which can be modified by other brain regions, such
as the LC [31-33]. Likewise, learning events prompted by fear are mediated through potentially
distinctive circuits involving hippocampus, lateral hypothalamus, LC, and amygdala [31-33]. In
this way, the gating of stress-induced learning behavior, like those associated with transference
and generalization, requires amygdalar engagement.
Importantly, we demonstrate transference or generalization is strongly modified by Orx
receptor actions in the BLA. Antagonism of Orx receptors in the BLA impacts spatial memory,
specifically during the consolidation/re-consolidation phase [37]. However, we report an
observed caveat that Orx influence over BLA-gated learning events may depend on the anxious
state of the individual. For example, in Stay mice, intra-BLA Orx1R antagonism promotes
learning to increase time in the center of the SAM arena (Figs. 5A, C, E, F). These Orx1R reside
predominantly in glutamatergic pyramidal cells of the BLA (Figs. 2A-F, S5F). Interestingly,
while Orx2R inhibition promotes activity in the center of the OF, and is suggestive of Stay
learning of center avoidance in the SAM (Figs. 5A, C, G), typically BLA Orx1R and Orx2R
inhibition have opposite effects on anxious behaviors in the SAM [17].
Stress-induced generalization learning requires integration of anxiety elements of
neurocircuitry [38, 39]. Stress-susceptible (Stay) mice exhibit enhanced socially induced
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freezing behavior in the SAM (Fig. 3A), which is carried over (generalized or possibly
overgeneralized) to the non-social OF Test arena (Fig. 3E). Uniquely, our behavioral design
incorporates conditioning over four days to a naturalistic fear in the form of social aggression
(US+). Our model captures fear generalization when mice are introduced to a new testing
context (i.e. OF Test), where the absence of the unconditioned stimulus (social aggressor)
should be more immediately distinguishable than the exclusion of a shock, as in less
ethologically relevant stress paradigms. While it is true that timing and layout of experimental
design may modify the intensity of the generalized behavior [40], the transferred fear response
observed in our study is tied to additional learned coping strategies (i.e. time in center and
locomotion) when mice are moved from the SAM to the OF Test. Thus, we posit that stressinduced generalization learning requires integration of both learning and anxiety elements of
neurocircuitry [38, 39].
Like learning how to move (Fig. 4) and identifying safe areas in the social context of the
SAM (Fig. 5), generalization of freezing behavior is influenced by Orx receptor activity in the
BLA (Fig. 3). Activity from distinct neuronal populations within the lateral amygdala (LA)
support the expression of generalized fear [41], and likely contribute to the observed
transference of freezing behavior reported here. While a relationship of the Orx system and
contextual fear response has been identified through indirect noradrenergic connections to the
LA from the LC [33], we provide evidence for a more direct influence of Orx in the amygdala
on fear generalization. In support of the relationship revealed between Orx2R expression in the
BLA and socially induced freezing in the SAM (Fig. 2C), Stay mice display enhanced freezing
behavior in both the SAM and OF Test environments after Orx2R antagonism (Figs. 3A, C), and
reduced freezing with Orx2R stimulation (Figs. 3B, D). Curiously, OrxA treatment, which
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activates both Orx1R and Orx2R, elevated SAM freezing behavior in both Escape and Stay mice
(Fig. 3B). As Orx1R are expressed at higher levels in the BLA compared to Orx2R (Fig. 2D), it
is reasonable to suggest that OrxA treatment would disproportionally activate Orx1R over Orx2R.
Further, while Orx1R antagonism had no effect on socially induced freezing in the SAM (Fig.
3A), it reduced freezing in the OF Test in Escape animals (Fig. 3C). Biased activation of Orx1R
enhanced freezing in both SAM and OF Test contexts in Stay animals (Figs. 3B, D). While
generalization of freezing behavior was apparent in vehicle-treated Stay mice (Fig. 3E),
manipulation of intra-BLA Orx receptor activity disrupted this behavior (Fig. S7). What is
clear, however, is that Orx receptors in the BLA mitigate freezing behavior as learned in a social
environment is carried over to a non-social context (Fig. 3), and these receptors appear to do so
in a phenotype-dependent way (Figs. 2B, C).
The EPM results testing for anxiety relationships in vehicle-treated animals do not show
socially induced phenotypic separation (Fig. S11). This was surprising at first, because both
SAM and SIP results suggest a strong correlation between Escape and resilience, as well as Stay
animals having high stress vulnerability. In the EPM, both Escape and Stay mice spend most of
their time in the closed arms, with significant excursions into the open arms, which were not
affected by either Orx1R or Orx2R antagonists (Figs. S11A, C), an observation consistent with
previous studies [42, 43]. Similarly, animals tested on the EPM before SAM trials, where
Escape and Stay phenotypes develop, also do not exhibit differences in open or closed arm times
[13]. It may simply be that social and environmental stressors provide radically dissimilar
results. However, with application of OrxA, Orx1R stimulation, or Orx2R stimulation,
phenotypic differences are again revealed (Figs. S11B, D). In the OF, stimulation of Orx1R
(OrxA and Orx1R stimulation) prompted Stay animals to spend more time in the open (and less
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in the closed) arms (Figs. S11B, D). Again, the results seem to have been modified by previous
experience in the SAM, which calls into question the value of both the OF and EPM tests. If the
results of the tests can be dramatically skewed, or reversed, by previous experience in the SAM,
they may also be slanted by additional, perhaps not obvious, environmental or social stresses in
other experimental paradigms, or by other life experiences before experimentation. The clinical
translatability of these tests has previously been called into question [10-12], and our results add
reason to question their validity. We urge caution for all those planning to use EPM or OF in
future experiments.
In conclusion, the Orx system interacts with BLA neurons to regulate fear learning and
generalization during social stress. Additionally, neurons that synthesize Orx1R and Orx2R in
the BLA are mostly distinct. While Orx1R are located primarily in glutamatergic neurons, a
smaller majority of Orx2R are found in GABAergic interneurons. Although learning strategies
are influenced by anxious state and behavioral phenotype, our results suggest that within the
BLA, Orx receptors modulate learning outcomes and generalization, while concomitantly
modifying stress-related behavior. The intra-BLA Orx receptors bidirectionally balance these
learning states with Orx1R inhibition and, alternatively, Orx2R stimulation contributing to
behavioral transference and a reduction in fear-induced generalization. While orexin’s effect
over learning extends beyond the BLA, including targets like the LC and hippocampus, we
demonstrate an important role for intra-BLA Orx receptors to influence learning in a receptorand anxious state-dependent manner.
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Figure 1. The Stress Alternatives Model (SAM) results in phenotype establishment after two days of
social stress. (A) The SAM is a 4-day paradigm in which test mice are conditioned to a tone (middle)
before an opaque cylinder is lifted and animals must decide whether to Escape (left) or submit (Stay,
right) to a large social aggressor. By the end of Day 2, test mice commit to the Escape or Stay behavioral
phenotype. (B) Experimental design for behavioral trials include stereotaxic surgeries for cannula
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implantation followed by a recovery and handling period before the beginning of the SAM. On Day 3, 1
hr before SAM exposure, mice were administered Orx receptor targeting drugs into the BLA. Following
SAM social interaction on Day 4, mice were exposed to the Open Field (OF) Test and on Day 5 they
were introduced to the Elevated Plus Maze (EPM).
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Figure 2. Stress-induced and phenotype-dependent freezing behavior is bidirectionally correlated with
Orx1R (HCRTR1), expressed predominantly in glutamatergic neurons, and Orx2R (HCRTR2), in
GABAergic neurons, gene expression in the BLA. (A) Phenotype (Escape & Stay) distinctions in SAMderived conflict freezing are significant and most pronounced on Day 4 (Phenotype Effect: F1,168 = 4.8, p
≤ 0.033; Time Effect: F3,168 = 4.2, p ≤ 0.007; Interaction Effect: F3,168 = 4.1, p ≤ 0.008; Day 4 Escape vs
Stay: t56 = 3.8, *p < 0.001). (B) In Escape mice, intra-BLA Orx1R (HCRTR1) transcription is positively
associated with socially induced freezing (social stress-related freezing) in the SAM (F1,8 = 7.8, R2 =
0.4946, p ≤ 0.0233). (C) Conversely, socially induced freezing behavior in the SAM is negatively related
to Orx2R (HCRTR2) mRNA levels in the BLA of Stay mice (F1,12 = 9.7, R2 = 0.4481, p ≤ 0.0088). While
Orx receptors are associated to phenotype and freezing behavior, (D) only a small percentage of the total
number of BLA cells contain Orx1R, Orx2R, or both receptor subtypes (F3,44 = 134.0, p < 0.001;
significance is by unique symbol, e.g. A is significantly different from B, C, & D). (E & F) In the BLA,
Orx1R (green), but not Orx2R (white), are highly co-expressed with the glutamatergic cell marker
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CamKIIα (red; some of the observed colocalizations are indicated with solid green arrows = Orx1R+ +
CamKIIα+, solid white arrow = Orx2R+ + CamKIIα+, and unfilled white arrows = Orx2R+ + CamKIIα-).
(G) The number of BLA Orx1R+ cells expressing CamKIIα is over 60% while Orx2R+ cells co-express
the glutamatergic marker ~30% of the time, and about 50% of the small proportion of BLA cells that
express both Orx1R and Orx2R also express CamKIIα. (H & I) Expression of Orx2R (white) overlaps
with GAD67 (red) more than Orx2R (green) in the BLA (a few observed colocalizations are identified
with unfilled green arrows = Orx1R+ + GAD67-, solid white arrow = Orx2R+ + GAD67+, and unfilled
white arrows = Orx2R+ + GAD67-). (J) Analyses reveal Orx2R are expressed in GABA neurons in a
greater proportion than Orx1R or cells that co-express Orx1R & Orx2R. _p ≤ 0.05 for comparisons to
CamKIIα-/GAD67- cells in the same receptor (Orx1R+ or Orx2R+) group; +p ≤ 0.05 for comparisons to
Orx1R+ of the same CamKIIα+/GAD67+ profile; #p ≤ 0.05 for comparisons to Orx2R+ of the same
CamKIIα+/GAD67+ profile. CeA = central amygdala; ITC = intercalated cells of the amygdala
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Figure 3. Socially induced freezing behavior in the SAM is transferred to the non-social OF Test in Stay
mice. (A) Stay mice treated with intra-BLA infusion of an Orx2R antagonist, but not an Orx1R
antagonist, exhibit enhanced freezing in the SAM. (B) Mice in OrxA and Orx1R stimulation groups
exhibit enhanced freezing, while animals treated with an Orx2R agonist demonstrate significantly reduced
freezing in the SAM. (C) Antagonism of Orx1R receptors in the BLA reduced generalized OF Test
freezing in Escape mice only, while Orx2R antagonist treatment increased OF freezing in Stay animals.
(D) Freezing in the OF Test was increased in Orx1R stimulation group mice, while intra-BLA agonism of
Orx2R reduced freezing in both phenotypes. (E) In vehicle-treated control Stay mice, conflict freezing in
the SAM is positively correlated to OF Test freezing (F1,11 = 8.7, R2 = 0.4423, p ≤ 0.0131). _p ≤ 0.05 for
comparisons between phenotypes in the same treatment group; +p ≤ 0.05 for comparisons to Vehicletreated mice of the same phenotype; #p ≤ 0.05 for comparisons to Orx1R Ant. group of the same
phenotype; !p ≤ 0.05 for comparisons to OrxA treatment animals of the same phenotype; %p ≤ 0.05 for
comparisons to mice in the Orx1R stimulation group of the same phenotype.
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Figure 4. Social stress-induced locomotion in SAM is generalized/transferred to a non-social OF Test
environment after intra-BLA manipulation of Orx receptor activity in Escape animals. (A) Escape mice
express higher locomotor activity compared to Stay animals during social stress in the SAM, but this
phenotype difference is not observed after intra-BLA Orx1R antagonism. (B) Infusion of an Orx2R
agonist into the BLA enhances locomotion in the SAM in Stay mice. (C) While Escape animals in the
vehicle control group display higher locomotion compared to Stay mice in the OF Test, this divergent
phenotype response is not observed after intra-BLA Orx1R or Orx2R antagonism. (D) Similarly, OrxA
and Orx2R stimulation eliminates the difference in locomotion between Escape and Stay mice in the OF
Test. (E) Unlike vehicle controls (gray dotted line represents linear regression line, F1,12 = , R2 = 0.0695,
p ≥ 0.5281), a significant positive relationship between SAM and OF Test locomotion is observed in
Escape mice treated with an Orx1R antagonist (F2,3 = 15.9, R2 = 0.8413, p ≤ 0.0282). (F) A significant
negative correlation is revealed between SAM and OF Test locomotion in Escape mice treated with an
Orx2R antagonist (F1,4 = 11.4, R2 = 0.7401, p ≤ 0.0279). Like Orx1R antagonism, significant positive
associations between locomotor activity in the SAM and OF Test for Escape mice treated with (G) OrxA
(F2,2 = 49.4, R2 = 0.9611, p ≤ 0.02) or (H) an Orx2R agonist (F2,1 = 351.5, R2 = 0.9972, p ≤ 0.034). _p ≤
0.05 for comparisons between phenotypes in the same treatment group; +p ≤ 0.05 for comparisons to
Vehicle-treated mice of the same phenotype; !p ≤ 0.05 for comparisons to OrxA treatment animals of the
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same phenotype; %p ≤ 0.05 for comparisons to mice in the Orx1R stimulation group of the same
phenotype.
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Figure 5. Treatments targeting Orx receptors in the BLA promote transfer learning from the SAM to the
OF Test in Stay mice. (A) In the SAM, the amount of time spent in the center of the arena is not different
between Escape and Stay animals in the vehicle control group, but phenotype divergence occurs after
intra-BLA Orx1R antagonism with Stay mice spending more time in the center. (B) Escape mice treated
with an Orx2R agonist display increased time in the center of the SAM arena. (C) While Escape and Stay
vehicle-treated mice did not show differences in the amount of time spent in the center of the OF Test,
both intra-BLA Orx1R antagonism and Orx2R antagonism prompted phenotype separation with Stay
animals spending more time in the center of the OF. (D) No differences in time spent in the center of the
OF Test were observed in Orx receptor stimulation groups. (E) Regression analysis revealed a
significant and positive relationship (F1,8 = 16.8, R2 = 0.6780, p ≤ 0.0034) between time spent in the
center of the SAM and time spent in the center of the OF Test after intra-BLA Orx1R antagonism in Stay
animals, but not in vehicle-treated Stay mice (dotted gray line represents regression line, F1,12 = 2.1, R2 =
0.1631, p ≥ 0.1712). (F) Examples of tracking software maps for Orx1R antagonist-treated Stay mice
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that prefer the edges of the SAM and OF Test (top) and those that bias the center regions (bottom). (G)
Significant and positive correlations exist for time spent in the center of the SAM and time spent in the
center of the OF Test for Stay mice treated with an Orx2R antagonist (F1,5 = 13.5, R2 = 0.7293, p ≤
0.0144) or (H) an Orx2R agonist (F1,4 = 40.2, R2 = 0.9096, p ≤ 0.0032). _p ≤ 0.05 for comparisons
between phenotypes in the same treatment group; !p ≤ 0.05 for comparisons to Vehicle-treated mice of
the same phenotype.
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COMPLETE MATERIALS & METHODS
Animals
Adult male C57BL/6NHsd mice (6-8 weeks old) weighing ~22-28 g were obtained from Envigo
(Indianapolis, IN; N=194) and acclimated for a 5-day period in groups five, after which animals
were singly housed in rooms held at 22°C and 35% relative humidity for the remainder of the
experiments. Food and water were provided ad libitum. For studies involving pharmacological
manipulations (N = 109), bilateral stereotaxic surgeries were performed where guide cannula (26
ga cut to 4.0 mm) were directed at the basolateral amygdala, or intra-BLA. A separate set of
retired male breeder Hsd:ICR mice (CD1, N = 30) weighing ~50 g (Envigo) were individually
housed, and used to initiate aggression in the Stress Alternatives Model (SAM; Fig. 1A).
Mice were subjected to a 12:12 light-dark cycle (with lights turning off at 6 p.m.), and
behavioral experiments were performed during the animals’ active phase (scotophase). Two
days (48 h) after surgeries, test subjects (C57BL/6NHsd mice) were handled daily for 7 days
before SAM exposure and behavioral testing the five proceeding days (Fig. 1B). All procedures
(surgery and behavioral testing) were performed in a manner that minimized suffering. The
number of animals used was in accordance with the National Institutes of Health’s Guide for the
Care and Use of Laboratory Animals (NIH Publications No. 80-23) and approved by the
Institutional Animal Care and Use Committee of the University of South Dakota.
Stereotaxic Surgeries
Mice were anesthetized using isoflurane (2% at 1.0 L/min flow rate) before bilateral intra-BLA
guide cannula (PlasticsOne, Roanoke, VA; 26 ga cut to 4.0 mm) implantation. Following
surgery, mice were provided a recovery period (7 days) before behavioral testing. Cannula
placement was performed using the following stereotaxic coordinates: -1.35 mm AP, ± 3.30 ML,
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and -4.90 mm DV. During surgery and for ~45 minutes post-surgery, mice were kept on a
warming pad to maintain core body temperature. Immediately following surgery and 24 hours
after surgical procedures, mice were provided pain relief in the form of subcutaneous injections
of the analgesic ketorolac (5 mg/kg).
Drugs & Drug Administration
As several drugs were used to activate or inhibit intra-BLA Orx receptors, we broke the
assessments into two broad categories: Orx receptor antagonist groups and Orx receptor
stimulation groups. The Orx receptor antagonist groups consisted of mice treated with the Orx1R
antagonist SB-674042 (N = 20; IC50 = 3.76 nM for Orx1R; MedChemExpress, Monmouth
Junction, NJ) and the Orx2R antagonist MK-1064 (N = 17; IC50 = 0.5 nM for Orx2R;
MedChemExpress). For Orx receptor stimulation groups, mice were administered OrxA (N = 13;
EC50 = 20 nM for Orx1R & Orx2R; ToCris, Minneapolis, MN), a concoction of OrxA & MK1064 (N = 19; for biased Orx1R activation), or the Orx2R agonist YNT-185 (N = 12; EC50 = 28
nM for Orx2R; Wako Chemicals, Richmond, VA). Drug effects were compared to vehicletreated (N = 28; artificial cerebrospinal fluid; aCSF + 25% DMSO) control animals that
underwent cannula implantation surgeries and were exposed to the same testing conditions and
procedures as drug-treated mice. On Day 3 of the behavioral design (Fig. 1B), mice were
infused bilaterally in the BLA (300 nL/side) with their designated treatment an hour before social
interaction in the SAM.
All drug treatments were diluted using a 3:1 ratio of aCSF to dimethylsulfoxide (DMSO);
and all treatments, excluding SB-674042 and YNT-185, were brought to a 0.1 nmol/0.3 μL
concentration. The dose for the Orx2R antagonist, MK-1064, was 3x lower than previously used
concentrations that produced anxiogenic effects when administered to the whole brain
(intracerebroventricularly; icv) [1]. Similarly, the intra-BLA dose for OrxA was selected and
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adjusted based on icv administrations that produced anxious behaviors in mice [2]. As the Orx1R
antagonist SB-674042 and the Orx2R agonist YNT-185 have lower binding affinities compared
to the Orx2R antagonist (MK-1064), we chose a slightly higher doses (0.3 nmol/0.3 μL for SB674042 and 10 nmol/0.3 µL for YNT-185) in order to compensate for these differences.
Artificial cerebrospinal fluid (aCSF; 8.59 g NaCl, 0.201 g KCl, 0.279 g, CaCl2, 0.16 MgCl2,
0.124 g NaH2PO4, 0.199 g Na2HPO4/L H2O) was mixed and brought to a physiological pH
(~7.33) using NaOH before being filtered, degassed, and stored at 4°C. Drugs were infused
using injector cannula (33 ga cut to 4.9 mm, extending 0.9 mm below each guide cannula) placed
into implanted guide cannulae, and injecting with a 1.0 µL digital syringe (Model 7101 Zero
Dead Volume, Knurled Hub 2.75”, 22GA Needle; Hamilton Company, Reno, NV) at a rate of
0.5 μL/min. After drug administration, the injector and syringe were left in place for 90 sec.
Home cage mobility was measured briefly (~3 min) after SAM interaction on Day 3 in order to
note changes in locomotion that resulted, not from social stress, but instead from drug
interactions.
Behavioral Design
Behavioral procedures were performed during the dark cycle when the animals are active, under
red light (~700 nm λ). Video cameras (GoPro Hero 3 & Hero 7) were used to record behavioral
measures for later analyses. To assess conflict freezing during the SAM (Figs. 2A, B), mice
from three separate cohorts (N = 73) were run through four days of the SAM. For
pharmacological experiments (Figs. 3-5), animal groups included mice treated with vehicle
(N=28, used for drug treatment comparisons), SB-674042 (Orx1R Ant.; N=20), MK-1064
(Orx2R Ant.; N=17), OrxA (N=13), OrxA + MK-1064 (Orx1R Stim.; N=19), and YNT-185
(Orx2R Stim.; N = 12).
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Each treatment group was subjected to 4 days of social stress in the SAM with intra-BLA
drug administration occurring on Day 3 an hour before SAM exposure (Fig. 1A, B). Day 4 of
the experimental design includes SAM social interaction followed immediately by Open Field
(OF) testing (Fig. 1B). On the final day (Day 5), mice were tested in the Elevated Plus Maze
(EPM; Fig. 1B). At the end of testing on Day 5, mice were briefly anesthetized using isoflurane
(5% at 1.0 min/L for ~2 min) and rapidly decapitated. Whole brains were collected, stored at 80°C, and sectioned to discern accurate placement of cannula and injections into the BLA. Only
animals in which the BLA was successfully targeted bilaterally (82 mice out of 109 total;
Vehicle = 21 [8 Escape & 13 Stay]; Orx1R Ant. = 15 [5 Escape & 10 Stay]; Orx2R Ant. = 13 [6
Escape & 7 Stay]; OrxA = 9 [4 Escape & 5 Stay]; Orx1R Stim. = 15 [6 Escape & 9 Stay]; Orx2R
Stim. = 9 [3 Escape & 6 Stay]) were used for behavioral analyses (Fig. S1)
Stress Alternatives Model (SAM)
The Stress Alternatives Model (SAM) (Fig. 1A) includes the use of a white box (91 cm x 22 cm
x 30 cm) with two concave dividers (r = 10.25 cm). In this way, the SAM apparatus consists of
three parts, which include an oval open field area (length = 71 cm, width = 22 cm, height = 30
cm) and two enclosed (safe) areas (10 cm x 22 cm x 30 cm) which are accessible only to smaller
C57BL/6N mice that choose to leave the open field area via provided escape tunnels (Fig. 1A).
At the beginning of the SAM paradigm, an opaque cylinder (diameter = 15 cm, width = 20 cm)
is placed in the center of the open field and an aggressive CD1 is positioned outside the cylinder
in the open arena of the SAM. A test mouse (C57BL/6N) is placed into the cylinder and
subjected to a fear conditioning paradigm, consisting sequentially of a 30 sec acclimation period,
a 5 second tone (2500 Hz at 75 dB; conditioned stimulus), a 10 second post-tone trace period,
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and finally removal of the cylinder resulting in aggressive social interaction with the CD1
(unconditioned stimulus) for a 5 min period.
During the first day of SAM exposure, the open field arena and the two escape routes on
both ends are novel, but over the course of four days, mice are allowed to choose to utilize the
escape route or remain in the SAM arena with the CD1 aggressor. Importantly, each test mouse
encounters a different and unfamiliar CD1 aggressor throughout the 4-day SAM paradigm. By
the end of Day 2 of the SAM, test mice will commit to one of two behavioral phenotypes that
will be consistent for the remaining days (Days 3 & 4) of the SAM protocol: mice that choose to
utilize the escape tunnels (escaping social aggression) are categorized as expressing the Escape
phenotype, and those that remain in the SAM arena and submit to social aggression express the
Stay phenotype (Fig. 1A). Earlier studies from our lab revealed that Escape mice exhibit
significantly reduced physiological and behavioral measurements of stress when compared to
Stay mice [1, 3-5]; however, both phenotypes receive equally high levels of social aggression
from CD1 mice.
At the end of 5-minute interactions in the SAM, both mice (test mice and CD1 mice) were
removed from the apparatus and placed into their home cages. When a test mouse escaped, they
were left in the enclosed area for the remainder of the 5 minutes, with a clear perforated sheet of
plastic being placed in front of the escape route. SAM interactions were recorded (GoPro Hero 3
& Hero 7) and analyzed using ANY-maze Video Tracking Software (Version 6.0, Stoelting Co.,
Wood Dale, IL). Between SAM trials, the apparatus was cleaned using 70 % ethanol,
disinfectant wipes, and dried using clean paper towels.
Animals were separated into phenotype groups after the first two days of the SAM: Escape if
they utilized the escape route on Days 1 and/or 2 and Stay if the mouse did not utilize the escape
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tunnel by the end of Day 2. For pharmacological studies, animals within a given phenotype
group were randomly assigned to receive treatments (vehicle, Orx1R Ant., Orx2R Ant., OrxA,
Orx1R Stim., or Orx2R Stim.) on Day 3. Behavioral measures on Day 4 (24 hours after drug
administration) were analyzed, including conflict freezing, time in the center of the SAM arena,
and social stress-induced locomotion.
Conflict freezing describes motionless behavior in the presence of the social aggressor, and is
defined as bouts of immobility, excluding normal breathing behavior, for one second or longer
during social interaction in the SAM [1] or OF Test. Conflict freezing includes freezing in
anticipation or in response to aggression, as well as contextual freezing in response to being in
the SAM open field where social aggression previously took place or the OF Test during
transference.
Time spent in the center of the SAM was defined as the amount of total time each mouse
spent inside the center of the SAM (48 cm x 9 cm). As this measure is often used as an indicator
of stress in the OF Test [6], we sought to compare time spent in the center of the SAM open field
to traditional OF testing. We further explored how this behavior may change with phenotype
expression: Stay and Escape.
Locomotor activity was measured in the SAM to compare social stress-induced locomotion
to that occurring subsequently in the OF Test, in which no social aggressor was present. Home
cage locomotion was also measured on Day 3 to assess whether behavioral measurements of
locomotor activity in the SAM and OF Test were not simply drug-induced responses.
Locomotion in the SAM, OF Test, and Home cage Mobility was calculated taking the total
distance the mice traveled and normalizing it to the amount of time spent in the SAM, OF, or
Home cage environment (cm/s).
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Validation of the SAM
As the SAM is a resource for describing anxious and depressive behaviors, it has been subjected
to validation testing, using criteria for Construct, Predictive, and Face Validities [7].
Incorporating aspects of social defeat and measures of active avoidance, the SAM construct
explores behavioral fear and anxiety [8-11], depression and stress [12, 13], but further the
mitigation of these stress-induced products via Escape, while being both ethologically and
ecologically applicable [3, 14, 15] and preserving comparisons to pertinent human disorders [16,
17], suggesting a degree of Construct Validity. In the SAM, predictive validation has been
confirmed through the induction of behavioral alterations, including the reversal of phenotypes,
using antidepressive, anxiolytic, or anxiogenic drugs (antalarmin, NPS, and yohimbine) [4, 5,
18]. Further, the SAM has been used in combination with, and produces analogous results to,
the Social Interaction/Preference (SIP) Test [1, 19], which has been validated as translationally
and predictively reliable in representing the efficacy of pharmacotherapies used to treat anxiety
(benzodiazepines) and depression (SSRIs) [20-24]. Additionally, raised glucocorticoid
concentrations exhibit an enhanced physiological stress response in animals facing social
aggression in the SAM, where Stay mice present the greatest increase [1, 3-5, 18, 25]. As far as
Face Validity, SAM exposure results in behavioral effects, largely examples of behavioral
inhibition (FC freezing, Conflict freezing), startle (Conflict Startle), and social avoidance
(Escape, Escape Latency, and SIP test), that imitate those seen in human depression and anxiety.
Open Field (OF) Test
On Day 4, after being subjected to 5 min of social aggression in the SAM, the OF Test [6] was
conducted in an opaque, white square box (40 cm3), under red lighting (Fig. 1B). Test mice
(C57BL/6N) were placed in the center of the arena at the beginning of testing and allowed to
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explore the open field area for 5 min while being video recorded (GoPro Hero 3 & Hero 7).
Videos were used to perform behavioral analyses (ANY-maze 6.0). Analyzed behaviors
included freezing time (as defined and measured in the SAM), time spent in the center (20 cm2)
of the apparatus, and locomotion (as defined and measured in the SAM and Home cage mobility
assessment). Between each trial, the arena was cleaned using 70% ethanol, disinfectant wipes,
and dried thoroughly with clean paper towels.
The OF Test has long been used as a model for anxiety in animal studies, specifically to
determine how treatments alter anxious behavior [6]. Behavioral analysis in the OF began as
soon as the animal was placed in the center of the arena, and continued for 5 min. Time spent in
the center of the OF arena (20 cm2) and time spent around the edges of the arena were recorded,
as more time spent in the center of the OF arena is typically interpreted as an animal
experiencing decreased anxious behavior, and more time around the border as an indication of
increased anxious behavior. For these experiments, it is important to note that we compared the
OF behavior of this classic OF Test with SAM OF behavior.
Elevated Plus Maze (EPM)
On Day 5, test mice (C57BL/6N) were exposed to the EPM [26], one day after SAM social
interactions (Fig. 1B). The EPM apparatus includes an elevated (74 cm tall) plus-shaped
platform with two open arms (50.5 cm x 10.5 cm x 1.5 cm edge height), two closed arms (50.5
cm x 10.5 cm x 40 cm wall height), and an intersection zone (10.5 cm2). Under red light, all
animals were placed in the center of the EPM, with their heads facing a corner between an open
and closed arm to avoid bias toward a specific arm. Trials were video recorded (GoPro Hero 3
& Hero 7) and behavioral measurements were scored by individuals blind to the treatment
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groups. Between all trials, the arena was cleaned sequentially using 70% ethanol, disinfectant
wipes, and thoroughly dried with paper towels.
Once mice were placed on the EPM apparatus, behavior was analyzed for 5 min. Time spent
in the open and closed arms of the EPM were measured, as they are typically thought to reflect
the anxious state of an animal. Increased time spent on the open arms is associated with less
anxiety, while increased time spent on the closed arms reflects more generalized anxious
behavior [26, 27]. Total time spent in intersection zone was also recorded. The results for a
single animal in the Orx1R Ant. Stay group is not included in the reported results as there was a
camera malfunction during behavioral testing and no video was available for analysis.
RNA Extraction
Fresh frozen brains of mice exposed to the 4-day SAM paradigm and cage control animals not
exposed to social stress (N = 30 Total; N = 6 Cage Controls, N = 10 Escape mice, & N = 14 Stay
mice) were cut (Leica Biosystems, Buffalo Grove, IL; Leica CM1850 Clinical Cryostat, Cat. No.
047131148) into 200 μm sections. Microdissection of the BLA (AP -1.00 mm to -2.45 mm
relative to Bregma) was performed on a cold plate using 25 GA punches (Stoelting Co., Wood
Dale, IL; Brain Punch Set, 0.25 to 1.25 mm; Cat. No. 57401) and submerged into 500 μL of
TRIzol reagent (Thermo Fisher Scientific, Waltham, MA; Invitrogen TRIzol Reagent, Cat. No.
15-596-018).
The TRIzol method as described previously [28] was used with some modifications. In
short, incubation of BLA tissue in 500 μL Trizol at room temperature took place for 5 min
followed by phase separation through the addition of 100 μL of 1-bromo-3-chloropropane and
centrifugation (4°C, 7,500xg, 15 min). The topmost aqueous layer was collected and RNA
precipitation through the addition of 250 μL of isopropanol and 1 μL glycol blue (Thermo Fisher
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Scientific, Waltham, MA; GlycoBlue Coprecipitant, Cat. No. AM9516) followed by
centrifugation (4°C, 12,000xg, 20 min) formed a visible RNA pellet. The excess alcohol around
the pellet was removed using a pipette, and the remaining RNA was washed with 75% ethanol
before being centrifuged (4°C, 16,000xg, 5 min). The majority of the ethanol was collected and
discarded and the samples were positioned in a hot plate oven set to 60°C for 20-40 min to
evaporate the remaining ethanol. A concentrated RNA sample was created by adding 25 μL
RNase-free water before quantification using a nanodrop (Implen Inc., Westlake Village, CA;
Nanophotometer N50 Spectrometer). Sample aliquots were diluted to 20 ng/μL and stored at 80°C for later PCR analyses.
Quantitative Reverse Transcription PCR (qRT-PCR)
Purchased assays (Thermo Fisher Scientific, Waltham, MA) for the PCR analyses included
HCRTR1 (4351370, Mm01185776_m1), HCRTR2 (4351370, Mm01179312_m1), and GAPDH
(4453320, Mm99999915_g1) as the housekeeping gene. A master mix for each PCR target was
created using a one-step qRT-PCR kit (Cat. No. 4392653) before being mixed with RNA
samples from BLA tissue in individual PCR tubes (MIDSCI, Valley Park, MO; Pryme
Ergonomic PCR Tubes; Cat. No. B77201). The PCR tubes were then loaded into Applied
Biosystems QuantStudio 3 No. B77201 thermal cycler (Thermo Fisher Scientific, Waltham, MA;
Cat. No. A28131) and, as per Taqman Assay vendor recommendations, were run through 40
cycles at the following conditions: reverse transcription (48°C, 15 min), DNA polymerase
activation (95°C, 10 min), denaturation (95°C, 15 sec), and annealing & extension (60°C, 1 min).
No enzyme and no template control PCR sample tubes were created to rule out the possibility
of contamination during PCR runs. Individual samples from non-stressed cage control mice (N
= 6), Escape mice (N = 10), and Stay mice (N = 14) were used for PCR analysis. Duplicates for
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each sample were run and the average Ct value was subtracted from the average housekeeping
gene (GAPDH) Ct to give the ΔCt for analysis. Determination of relative gene expression levels
was made using the 2-ΔΔCt method [29], which was then compared to the average ΔCt of the nonstressed cage controls. Regression curves were made for these data where average fold change is
correlated to SAM freezing behavior.
In situ Hybridization (RNAscope)
Fresh frozen brains (N = 12) of C57BL/6NHsd mice (9-10 weeks old) not exposed to social
stress or behavioral testing were sectioned into 20 µm coronal sections and positioned on slides
(Fisher Scientific, Pittsburgh, PA; Superfrost Plus, Cat. No. 12-550-15). Tissue that incorporated
the BLA from AP -1.50 to -1.80 relative to bregma was incubated in cold (4°C) 10% formalin
for 20 min and then washed (2x for 1 min) in 1x phosphate buffer solution (PBS). Dehydration
of tissue was performed by sequentially washing the sections in ethanol (50%, 70%, and 100%; 5
min each) followed by a final ethanol (100%) wash overnight in a -20°C freezer.
Proteins were digested in the tissue sections the next day with a protease treatment before
being rinsed in distilled H2O. Bathing of tissue in RNAscope (Advanced Cell Diagnostics,
Newark, CA) probes (HCRTR1, Cat. No. 466631; HCRTR2, Cat. No. 581631; GAD1, Cat No.
400951; CAMKIIα, Cat. No. 445231; PVALB, Cat. No. 421931) took place at 40°C for 2 h in a
specially designed hybridization oven (ACD HybEZ II oven, Cat. No. 321711). Next, sequential
washes (RNAscope Wash Buffer Reagents [310091]: Wash Buffer 50x diluted to 1x) and
bathing with amplification buffers (RNAscope Fluorescent Multiplex Detection Reagents
[320851]: AMP1 [320852], AMP2 [320853], AMP3 [320854], AMP4 ALT A [320855], AMP4
ALT B [320856]) was performed to bind fluorophores and enhance the signaling of target
mRNA. Lastly, the sections were stained with DAPI (20 sec) and a mounting medium (Fisher
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Scientific; Prolong Gold Antifade Mountant, Cat. No. P10144) before being coverslipped and
stored at 4°C in the dark until imaging.
Section visualization and image acquisition were performed using a confocal microscope
(Nikon NIE) and camera (Photometrics CoolSNAP MYO camera). Areas of interest were
selected from images and analyzed and counted for fluorescence using ImageJ software. The
colocalization of fluorescence-tagged mRNA were identified as overlap of signal or as puncta of
different fluorescence clustering on the same DAPI signaling, which would suggest that the
mRNA expression is in a single cell.
Statistical Analyses
Statistical analyses and experimental designs were based on a priori hypotheses. Two-way
ANOVA (Orx receptor targeting drug x Phenotype design) was used to examine the contribution
of drug effects relative to behavioral phenotype expression (Stay x Escape). Regression
analyses were used to investigate correlations of gene expression (HCRTR1 & HCRTR2) and
SAM conflict freezing responses. Further, regression analyses were used to identify
associations between SAM-dependent behavioral responses (Day 4) and OF Test behaviors (Day
4). Evaluations of locomotor activity in the home cage after drug treatment were assessed by
one-way ANOVA. Comparisons between two treatments (Vehicle, Orx1R Ant., Orx2R Ant.,
OrxA, Orx1R Stim, or Orx2R Stim.) within a given phenotype (Escape or Stay) were investigated
by Student’s t-tests.
Each animal provided only a singular datum for all analyses. Five assumptions of parametric
statistics were applied to the data, which were transformed, when necessary, but also compared
to non-parametric analyses, and graphed in their raw form. Analyses with both non-parametric
and parametric statistics were performed along with examination for multiple comparisons using
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the Holm-Sidak method, and when the statistical analyses match, as they do for the data herein,
we report the parametric results without α adjustment [30-35]. Significant effects between groups
for one-way analyses were examined with Student–Newman–Keuls post hoc analyses (to
minimize Type I error) and Duncan's Multiple Range Test (to minimize Type II error).

COMPLETE RESULTS
Socially induced conflict freezing response is positively correlated with BLA
transcriptional changes in Orx1R and negatively associated with changes in Orx2R
We previously demonstrated that Orx1R and Orx2R activity in the BLA bidirectionally effects
stress responsivity [25, 36]. To understand how these receptors in the basolateral amygdala
(BLA) might influence stress-sensitive phenotype development and learning, we first assessed
the relationship between Orx receptor transcription (HCRTR1 & HCRTR2) levels and conflict
freezing (Figs. 2A-C). In the Stress Alternatives Model (SAM; Fig. 1A), social stress-induced
conflict freezing is an indicator of fear-based behavioral inhibition and is most pronounced on
Day 4 of the SAM paradigm [36], where Stay mice express significantly elevated freezing
behavior (individual results combined from 3 cohorts: Phenotype Effect: F1,168 = 4.8, p ≤ 0.033;
Time Effect: F3,168 = 4.2, p ≤ 0.007; Interaction Effect: F3,168 = 4.1, p ≤ 0.008; Day 4 Escape vs
Stay: t56 = 3.825, p < 0.001) compared to Escape animals (Fig. 2A). Relative transcription levels
of Orx1R (HCRTR1) in Escape, but not Stay, mice were positively associated with Day 4
freezing behavior in the SAM (Figs. 2B, S2A; Escape: F1,8 = 7.8, p ≤ 0.0233; Stay: F1,12 = 0.3, p
≥ 0.6095). Alternatively, Orx2R (HCRTR2) mRNA levels in the BLA were negatively
correlated with SAM freezing behavior in only Stay mice (Figs. 2C, S2B; Stay: F1,12 = 9.7416, p
≤ 0.0088; Escape: F1,8 = 1.3, p ≥ 0.2840). These results indicate that Orx receptor activity in the
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BLA may be important for stress-related fear- and learning-based behaviors, but these
associations are closely linked to an animal’s stress responsive state (Escape or Stay).
In the BLA, Orx1R is primarily expressed on glutamatergic neurons and Orx2R on both
glutamatergic and GABAergic cells
In the BLA, approximately 25% of cells express Orx1R, while less than 20% contain Orx2R and
even fewer (< 3%) co-express both Orx1R and Orx2R (Fig. 2D; F3,44 = 134.0, p < 0.001; Orx1R+
vs Orx2R+, t22 = 2.1, p ≤ 0.050; Orx1R+ vs Orx1R+ & Orx2R+, t22 = 7.0, p < 0.001; Orx1R+ vs
Other, t22 = 9.6, p < 0.001; Orx2R+ vs Orx1R+ & Orx2R+, t22 = 7.9, p < 0.001; Orx2R+ vs Other,
t22 = 14.1, p < 0.001; Orx1R+ & Orx2R+ vs Other, t22 = 21.8, p < 0.001). To consider how Orx
receptors in BLA microcircuits influence behavioral states, we identified the relative
relationships of Orx1R (HCRTR1) and Orx2R (HCRTR2) expression in CamKIIα+
(glutamatergic) and GAD67+ (GABAergic) neurons. In the brain sections we sampled, ~70% of
cells were CamKIIα+ and ~20% expressed the GABA marker GAD67 (Fig. S5D; t9 = 16.8, p <
0.001). We have previously shown that Orx1R in the BLA are predominantly located in
glutamatergic neurons that do not express Orx2R [25].
To assess the cellular location of Orx2R and differences of Orx receptors in excitatory or
inhibitory neurons, we used RNAscope in situ hybridization techniques, and evaluated
proportional differences in Orx receptor-containing cells with respect to CamKIIα expression
(Figs. 2D-I, S3, S5). While >60% of Orx1R+ cells co-expressed CamKIIα (Receptor Effect: F2,30
= 0.0, p ≥ 0.9; CamKIIα Expression Effect: F1,30 = 0.7, p ≥ 0.398; Interaction Effect: F2,30 = 37.4,
p < 0.001; Orx1R+ CamKIIα+ vs CamKIIα-: t10 = 6.4, p < 0.001), less than 40% of Orx2R+ cells
were colocalized with the glutamatergic marker (Orx2R+ CamKIIα+ vs CamKIIα-: t10 = 5.8, p <
0.001), and ~51% of cells that colocalize both Orx receptors are glutamatergic (Fig. 2F).
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Further, the amount of CamKIIα+ neurons that express Orx2R were significantly lower than
those that produce Orx1R (t10 = 5.9, p < 0.001) or both receptor subtypes (Fig. 2G; t10 = 3.1, p ≤
0.004). Alternatively, a greater proportion of Orx2R+ cells do not express CamKIIα, while less
than 40% of Orx1R+ cells and under 50% of cells expressing both receptors do not house the
glutamate marker (Fig. 2G; CamKIIα- Orx1R+ vs Orx2R+: t10 = 6.3, p < 0.001; CamKIIα- Orx2R+
vs Orx1R+ & Orx2R+: t10 = 3.5, p ≤ 0.002; CamKIIα- Orx1R+ vs Orx1R+ & Orx2R+: t10 = 2.8, p ≤
0.009).
We next compared the proportion of Orx receptors with respect to GABA cells in the BLA,
which express the glutamate decarboxylase gene (GAD1) for GAD67 (Figs. 2H-J, S4, S5;
Receptor Effect: F2,24 = 0.0, p = 1.0; GAD67 Expression Effect: F1,24 = 322.9, p < 0.001;
Interaction Effect: F2,24 = 73.3, p < 0.001). Less than 20% of Orx1R+ cells are GABAergic,
which is significantly less than the number of Orx1R+ cells that do not contain GAD67 (t8 =
18.0, p < 0.001) and less than Orx2R+ cells that also express the GABA marker (t8 = 8.4, p <
0.001) or both receptor subtypes (Fig. J2; t8 = 2.9, p ≤ 0.008). The number of Orx2R+ BLA cells
that express GAD67 is not significantly lower than those that do not express this GABA marker
(t8 = 1.3, p ≥ 0.206), as nearly 50% of Orx2R+ cells produce GABA (Fig. 2J). Of the small
number of BLA neurons that co-express both Orx receptors, most (~70%) are not GABAergic
(Fig. 2J; Orx1R+ & Orx2R+ GAD67+ vs GAD67-: t8 = 12.3, p < 0.001; GAD67- Orx1R+ vs
Orx1R+ & Orx2R+: t8 = 2.9, p ≤ 0.008; GAD67- Orx2R+ vs Orx1R+ & Orx2R+: t8 = 5.5, p <
0.001).
We had previously predicted that the calcium-binding protein, parvalbumin (PV), which acts
as a marker for a specific subpopulation of GABAergic neurons, might be important for Orx
receptor activity in the BLA [1, 36], so we also looked for distributions of Orx receptors within
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this specific type of neuron (Fig. S6; Receptor Effect: F2,18 = 0.0, p = 1.0; PV Expression Effect:
F1,18 = 705.0, p < 0.001; Interaction Effect: F2,18 = 1.2, p ≥ 0.329). All Orx receptor-expressing
cells co-expressed PV at very low levels (Fig. S6F; Orx1R+ PV+ vs PV-: t6 = 22.4, p < 0.001;
Orx2R+ PV+ vs PV-: t6 = 16.1, p < 0.001; Orx1R+ & Orx2R+ PV+ vs PV-: t6 = 11.5, p < 0.001).
Interestingly, there appears to be a topographical organization of Orx1R in the BLA, with the
greatest expression being in the medial portion and very little in the lateral-most section of this
amygdalar region (Fig. S5A). The distribution of Orx2R in the BLA seems to be less organized
(Fig. S5B).
In order to fully consider the influence of Orx receptor activity on BLA neurons, we further
assessed the proportion of CamKIIα+ or GAD67+ BLA cells that expressed the genes for the Orx
receptors (Figs. S5D-F). In the brain sections we sampled, over 15% of glutamatergic neurons
also expressed Orx1R, while less than 10% expressed Orx2R, and under 5% co-expressed Orx1R
and Orx2R (Fig. S5D; F2,15 = 84.6, p < 0.001; Orx1R+ vs Orx2R+: t10 = 8.2, p < 0.001; Orx1R+ vs
Orx1R+ & Orx2R+: t10 = 12.8, p < 0.001; Orx2R+ vs Orx1R+ & Orx2R+: t10 = 5.8, p < 0.001).
Alternatively, very few GABAergic neurons express both Orx receptors and less than 10%
express Orx1R; however, ~25% of GAD67+ neurons co-express Orx2R (Fig. S5E; F2,12 = 84.0, p
< 0.001; Orx1R+ vs Orx2R+: t8 = 9.7, p < 0.001; Orx1R+ vs Orx1R+ & Orx2R+: t8 = 2.6, p ≤ 0.023;
Orx2R+ vs Orx1R+ & Orx2R+: t8 = 12.3, p < 0.001). These data suggest while the number of cells
expressing Orx receptors in the BLA is relatively small (Fig. 2D), ~16.25% of BLA cells house
Orx1R and are glutamatergic and ~7.5% of BLA cells are GABAergic and express Orx2R (Fig.
S5F). Collectively, these results propose Orx1R activity influences BLA signaling primarily
through glutamatergic pyramidal neurons while Orx2R receptors activate, through a small
majority, inhibitory interneurons in BLA microcircuits.
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Stress-induced freezing is ameliorated with acute intra-BLA Orx2R stimulation
In the SAM, longer periods of freezing are observed in Stay mice compared to Escape mice, and
this freezing behavior intensifies over the 4-day SAM paradigm [1], where we see the greatest
difference on Day 4 (Fig. 2A). We have previously demonstrated that single treatments before
Day 3 of SAM interaction, including drugs that target the Orx system, produce longer lasting
behavioral changes observed on Days 4 and 5 [1, 5, 25]. Here, we compared freezing behavior
on the last day of SAM exposure (Day 4) to freezing in the novel OF Test environment (also Day
4) where there is no social aggressor, to see if stress exposure leads to fear-related generalization
in a non-threatening environment. As reported previously [1] Stay mice experienced periods of
freezing in the SAM that were significantly increased relative to Escape mice under the control
conditions of vehicle treatment (Figs. 3A, B, white bars; t19 = 2.67, p ≤ 0.015).
Since Orx1R and Orx2R gene expression in the BLA are related to socially induced conflict
freezing behavior in a phenotype-dependent fashion (Figs. 2B, C), we assessed the influence of
pharmacologically inhibiting intra-BLA Orx receptors on freezing during conflict behavior in the
SAM (Fig. 3A; Drug Effect, F2,43 = 1.1, p ≥ 0.339; Phenotype Effect, F1,43 = 16.0, p < 0.001;
Interaction Effect, F2,43 = 2.2, p ≥ 0.126). Treatment with an Orx1R antagonist (SB-674042)
eliminated differences in conflict freezing between Escape and Stay mice (t13 = 0.9, p ≥ 0.365),
but did not result in significant differences compared to vehicle-treated controls (Fig. 3A, light
gray bars; Escape: Vehicle vs Orx1R Ant., t11 = 0.001, p ≥ 0.999; Stay: Vehicle vs Orx1R Ant.,
t21 = 1.3, p ≥ 0.212). Antagonizing Orx2R (MK-1064) resulted in an increase in freezing
behavior in Stay mice compared to vehicle-treated controls, though only significant at the p ≤
0.080 level (Fig. 3A, t18 = 1.9). Compared to Orx1R antagonist-treated mice, however, Stay
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animals in the Orx2R antagonist group exhibited elevated freezing behavior (Fig. 3A; t15 = 2.8, p
≤ 0.014).
To further assess the role of Orx receptors in the BLA on stress-induced conflict freezing
behavior, we pharmacologically stimulated intra-BLA Orx receptors (Fig. 3B; Drug Effect, F3,46
= 17.1, p < 0.001; Phenotype Effect, F1,46 = 9.1, p ≤ 0.004; Interaction Effect, F3,47 = 0.7, p ≥
0.561). Treatment with OrxA, which stimulates both Orx1R and Orx2R, significantly increased
freezing behavior in both Escape (t10 = 3.4, p ≤ 0.007) and Stay (t16 = 3.3, p ≤ 0.005) relative to
vehicle-treated control animals of the corresponding phenotype (Fig. 3B, black bars). While
biased stimulation of Orx1R (accomplished through a drug mixture of OrxA and the Orx2R
antagonist MK-1064) resulted in enhanced freezing in both Escape and Stay mice, only freezing
in Stay animals reached statistical significance compared to vehicle-treated controls (Fig. 3B,
light gray bars with dark gray outline; t21 = 3.0, p ≤ 0.008). Alternatively, agonizing Orx2R
(YNT-185) reduced stress-induced conflict freezing in Escape mice compared to those treated
with vehicle (t9 = 2.3, p ≤ 0.047) and OrxA (t5 = 3.2, p ≤ 0.023). In Stay animals, intra-BLA
Orx2R stimulation reduced freezing behavior (Fig. 3B, dark gray bars with light gray outline)
statistically below mice treated with vehicle (t17 = 3.3, p ≤ 0.004), OrxA (t9 = 8.7, p < 0.001), and
Orx1R stimulation (t13 = 8.5, p < 0.001). Together, these results suggest learned, phenotypedependent, freezing behavior is mediated and generalized through Orx receptor activity in the
BLA.
Stress-induced freezing in the SAM is transferred to the OF Test
Following four days of social aggression exposure, mice were subjected to the Open Field (OF)
Test (Fig. 1B) to determine how SAM-established behavioral phenotypes and Orx treatments
would impact behavior in a novel, anxiety-producing environment. As the OF Test was
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performed immediately following SAM social interaction on Day 4 of the behavioral
proceedings (Fig. 1B), we first assessed freezing behavior in the OF Test that may be a result of
fear-induced generalization (Figs. 3C, D). While there were no differences in freezing between
phenotypes in vehicle- and Orx1R antagonist-treated groups (Drug Effect, F2,43 = 4.1, p ≤ 0.024;
Phenotype Effect, F1,43 = 12.1, p < 0.001; Interaction Effect, F2,43 = 2.1, p ≥ 0.139; Vehicle:
Escape vs Stay, t20 = 1.0, p ≥ 0.320; Orx1R Ant.: Escape vs Stay, t13 = 1.8, p ≥ 0.093), Escape
mice that underwent acute Orx1R antagonism exhibited reduced freezing in the OF Test
compared to those mice administered vehicle treatment (Fig. 3C; t11 = 2.637, p ≤ 0.023). As
predicted, intra-BLA Orx2R inhibition elevated OF Test freezing behavior relative to Escape
mice that underwent the same treatment (Fig. 3C; t11 = 2.5, p ≤ 0.029). Further, these Stay mice
that were administered an Orx2R antagonist experienced increased freezing in the OF Test
compared to vehicle- (t19 = 3.0, p ≤ 0.008) and Orx1R Ant.-treated mice (Fig. 3C; t15 = 3.1, p ≤
0.008).
In intra-BLA Orx receptor stimulation studies, OrxA treatment did not result in a change in
freezing behavior in the OF Test that was different from vehicle-treated controls (Fig. 3D; Drug
Effect, F3,46 = 3.2, p ≤ 0.033; Phenotype Effect, F1,47 = 12.0, p < 0.001; Interaction Effect, F3,47 =
1.5, p ≥ 0.217; Escape: Vehicle vs OrxA, t10 = 0.2, p ≥ 0.814; Stay: Vehicle vs OrxA, t17 = 1.0, p ≥
0.336). However, Orx1R stimulation produced a robust freezing response in Stay mice that was
significantly different from Escape animals that experienced the same treatment (t13 = 3.8, p ≤
0.002) and vehicle-treated Stay mice (Fig. 3D; t21 = 3.4, p ≤ 0.003). Acute activation of intraBLA Orx2R resulted in reduced OF Test freezing in Escape mice compared to vehicle controls
(Fig. 3D; t9 = 3.4, p ≤ 0.008). While Stay animals infused with an Orx2R agonist were not
different from Escape mice administered the same treatment (t7 = 1.2, p ≥ 0.284) or vehicle
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controls (t18 = 0.5, p ≥ 0.635), they did experience reduced OF Test freezing compared to
animals that received the Orx1R stimulation treatment (Fig. 3D; t13 = 2.4, p ≤ 0.034).
To determine if freezing behavior in the OF Test was a result of generalization after social
stress exposure, we performed correlational analyses comparing freezing behavior in the SAM to
that of the OF Test (Figs. 3E, S7). There were no relationships observed in Escape mice
following any Orx receptor treatment (Figs. S7A-F). Further, a significant and positive
association was observed in vehicle-treated Stay animals (Fig. 3E; F1,11 = 8.7, p ≤ 0.0131), but
this relationship is lost in Orx1R antagonist treated mice (Fig. S7G). The lack of correlation
following Orx1R antagonist suggests that Orx1R activity in vehicle-treated mice allowed for
generalization of fear learning to be induced in these mice. Importantly, Stay animals in the
Orx2R antagonist or Orx1R stimulation groups displayed robust freezing behavior in both the
SAM and OF Test (Figs. 3A-D), and while regressions revealed no relationships in these mice
(Figs. S7H-J); a potential ceiling effect may have impaired the search for meaningful analyses.
Stress-induced locomotion in the SAM explains OF test locomotion after acute alteration
of intra-BLA Orx receptor activity in Escape mice
As the Orx system plays a role in arousal [39, 40] and may initiate locomotor functions [41], we
investigated locomotion in the SAM (Figs. 4A, B) and OF Test (Figs. 4C, D) as behaviors in
both SAM and OF Tests (socially induced freezing and time in center) may be influenced by
changes in locomotion. Importantly, the pharmacological manipulations of BLA Orx receptors
had no effect on home cage mobility (Fig. S9; F5,76 = 0.7, p ≥ 0.658; Escape: F5,26 = 1.3, p ≥
0.302; Stay: F5,44 = 1.0, p ≥ 0.433); however, several significant differences were observed
during social stress in the SAM (Figs. 4A, B; Antagonist groups: Drug Effect, F2,43 = 0.9, p ≥
0.423; Phenotype Effect, F1,43 = 9.0, p ≤ 0.005; Interaction Effect, F2,43 = 1.7, p ≥ 0.191;

209

Stimulation groups: Drug Effect, F3,46 = 2.7, p ≥ 0.059; Phenotype Effect, F1,46 = 8.2, p ≤ 0.006;
Interaction Effect, F3,46 = 0.7, p ≥ 0.564) and afterwards in the OF Test (Figs. 4C, D; Antagonist
groups: Drug Effect, F3,43 = 3.0, p ≥ 0.061; Phenotype Effect, F1,43 = 7.8, p ≤ 0.008; Interaction
Effect, F3,43 = 0.1, p ≥ 0.941; Stimulation groups: Drug Effect, F3,46 = 1.7, p ≥ 0.175; Phenotype
Effect, F1,46 = 9.7, p ≤ 0.003; Interaction Effect, F3,46 = 0.3, p ≥ 0.858).
In vehicle control animals, Escape mice displayed heightened locomotion compared to Stay
animals in both the SAM (Figs. 4A, B, white bars; t19 = 2.7, p ≤ 0.014) and OF Test (Figs. 4C,
D, white bars; t19 = 2.5, p ≤ 0.023). While not different from vehicle-treated mice, intra-BLA
Orx1R antagonism removes phenotypic separation of Escape and Stay locomotor activity in the
SAM (Fig. 4A, light gray bars; t13 = 0.2, p ≥ 0.864) and OF Test (Fig. 4C, light gray bars; t13 =
1.6, p ≥ 0.141). Acute inhibition of Orx2R in the BLA resulted in a maintained phenotype
separation in SAM locomotion, with Escape mice expressing higher locomotor activity than
Stay animals (Fig. 4A, dark gray bars; t11 = 2.3, p ≤ 0.039); however, this relationship was not
observed in the OF Test (Fig. 4C, dark gray bars; t11 = 1.1, p ≤ 0.314).
Similar to vehicle-treated mice, animals in the Orx1R stimulation group exhibited phenotype
differences in SAM (t13 = 2.5, p ≤ 0.026) and OF Test locomotion (Fig. 4B, light gray bars with
dark gray outline; t13 = 2.5, p ≤ 0.028). This divergent phenotype response was not observed
with OrxA or Orx2R stimulation treatments. However, agonism of BLA Orx2R resulted in Stay
mice expressing elevated locomotion in the SAM that was significantly greater than Stay
animals in vehicle (t18 = 2.9, p ≤ 0.010), OrxA (t9 = 2.7. p ≤ 0.009), and Orx1R stimulation (t13 =
3.0, p ≤ 0.005) treatment groups (Fig. 4B). This heightened locomotor response in Orx2R
agonist-treated Stay mice was not observed in the OF Test (Fig. 4D).
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Regression analyses comparing locomotion in the SAM to locomotor activity in the OF Test
revealed no associations in Stay mice (Figs. S8C-H). Further, no significant correlations were
observed for Escape animals in vehicle (F1,6 = 0.4, p ≥ 0.528) and Orx1R stimulation (F1,4 = 5.0,
p ≥ 0.090) treatment groups (Figs. S8A, B). Strong positive correlations between SAM and OF
Test locomotion in Escape mice were revealed with intra-BLA treatments of an Orx1R
antagonist (Fig. 4E; F2,3 = 15.9, p ≤ 0.028), OrxA (Fig. 4G; F2,2 = 49.4, p ≤ 0.02), and an Orx2R
agonist (Fig. 4H; F2,1 = 351.5, p ≤ 0.034). In contrast, a significant negative relationship was
observed between SAM and OF Test locomotor activity in Escape animals treated with an
Orx2R antagonist (Fig. 4F; F1,4 = 11.4, p ≤ 0.028). Together, these results suggest that Orx
receptors in the BLA influence generalization learning of stress-related locomotor activity,
transferred from SAM to OF.
Transient manipulation of Orx receptor activity in the BLA promotes learning
transference in Stay mice
As both the SAM and OF Test arenas comprise open field environments, on Day 4 we compared
behavior in the SAM arena to the behaviors exhibited in the OF Test, directly after the SAM
social interaction (Fig. 5). Mice of Escape and Stay behavioral phenotypes administered vehicle
treatments did not differ in the amount of time spent in the center of the SAM arena (Figs. 5A, B,
white bars; t19 = 0.5, p ≥ 0.699) or the OF Test (Figs. 5C, D, white bars; t19 = 1.3, p ≥ 0.213). In
the Orx receptor inhibition groups, there were no differences observed between animals
administered Orx receptor targeting drugs and those of the vehicle control group in the SAM
(Fig. 5A; Drug Effect, F2,43 = 0.02, p ≥ 0.978; Phenotype Effect, F1,43 = 7.4, p ≤ 0.010;
Interaction Effect, F2,43 = 1.7, p ≥ 0.197; Escape: Vehicle vs Orx1R Ant., t11 = 1.3, p ≥ 0.226;
Stay: Vehicle vs Orx1R Ant., t21 = 1.4, p ≥ 0.183; Escape: Vehicle vs Orx2R Ant., t12 = 0.9, p ≥
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0.380; Stay: Vehicle vs Orx2R Ant., t18 = 0.6, p ≥ 0.530) or OF Test behaviors (Fig. 5C; Drug
Effect, F2,43 = 0.4, p ≥ 0.679; Phenotype Effect, F1,43 = 15.7, p < 0.001; Interaction Effect, F2,43 =
1.4, p ≥ 0.268; Escape: Vehicle vs Orx1R Ant., t11 = 1.4, p ≥ 0.186; Stay: Vehicle vs Orx1R Ant.,
t21 = 0.4, p ≥ 0.699; Escape: Vehicle vs Orx2R Ant., t12 = 1.5, p ≥ 0.151; Stay: Vehicle vs Orx2R
Ant., t18 = 1.5, p ≥ 0.163). However, there was significant phenotype separation in mice that
received the Orx1R antagonist as Stay animals spent more time in the center of the SAM (Fig.
5A, light gray bars; t13 = 2.2, p ≤ 0.047) and OF Test (Fig. 5C, light gray bars; t13 = 2.2, p ≤ 0.05)
compared to Escape mice administered the same treatment. While Stay mice given the Orx2R
antagonist did not statistically spend more time than Escape animals in the center of the SAM
(Fig. 5A, dark gray bars; t11 = 1.6, p ≥ 0.144), phenotypic separation was clearly evident for time
in the center when mice were exposed to the OF Test after Orx2R antagonist treatment (Fig. 5C,
dark gray bars; t11 = 3.6, p ≤ 0.004).
In the Orx receptor stimulation groups, SAM (Fig. 5B; Drug Effect, F3,45 = 5.5, p ≤ 0.003;
Phenotype Effect, F1,45 = 0.4, p ≥ 0.516; Interaction Effect, F3,45 = 1.4, p ≥ 0.246) and OF Test
(Fig. 5D; Drug Effect, F3,46 = 0.4, p ≥ 0.779; Phenotype Effect, F1,46 = 4.9, p ≤ 0.032; Interaction
Effect, F3,46 = 0.4, p ≥ 0.750), targeting the BLA, OrxA infusion resulted in a reduction, though
not significant, in the amount of time spent in the center of the SAM in both Escape (t10 = 1.4, p
≥ 0.186) and Stay mice (t16 = 1.8, p ≥ 0.089) compared to vehicle controls (Fig. 5B, black bars).
Animals in the Orx1R stimulation group spent more time in the center of the SAM than those
mice treated with OrxA (Escape: t8 = 2.3, p ≤ 0.05; Stay: t12 = 2.4, p ≤ 0.033), but did not differ
from animals in the vehicle control group (Fig. 5B; Escape: t12 = 1.1, p ≥ 0.286; Stay: t20 = 1.6, p
≥ 0.132). Interestingly, a phenotype divergence was observed in mice treated with the Orx2R
agonist, where Escape animals spent more time in the center of the SAM compared to Stay mice
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(Fig. 5B, dark gray bars with light gray outline; t7 = 2.3, p ≤ 0.05). These Escape mice also spent
more time in the center of the SAM compared to OrxA-treated animals of the Escape phenotype
(Fig. 5B; t5 = 5.4, p ≤ 0.003). There were no significant differences in time spent in the center of
the OF Test between any of the Orx receptor stimulation groups (Fig. 5D; Drug Effect, F3,46 =
0.4, p ≥ 0.779; Phenotype Effect, F1,46 = 4.9, p ≤ 0.032; Interaction Effect, F3,46 = 0.4, p ≥ 0.750).
We next performed regression analyses to assess whether time spent in the center of the
SAM arena, where test mice primarily interact with a social aggressor, was being transferred to
the non-social and novel OF Test environment, and if Orx receptor activity might play a role in
transference learning (Figs. 5E-H). Significant positive regressions were revealed in Stay
animals between center time and treatment with an Orx1R antagonist (Fig. 5E, F; F1,8 = 16.8, p ≤
0.003), and an Orx2R agonist (Fig. 5H; F1,4 = 40.2, p ≤ 0.003). Curiously, there was also a
significant positive relationship observed after an Orx2R antagonist was administered (Fig. 5G;
F1,5 = 13.5, p ≤ 0.014). No significant correlations were observed in Escape mice in any
treatment group (Figs. S10A-F), nor Stay animals in the vehicle (Fig. S10G; F1,11 = 2.1, p ≥
0.171), OrxA (Fig. S10H; F1,3 = 3.5, p ≥ 0.157), and Orx1R stimulation groups (Fig. S10I; F1,7 =
1.3, p ≥ 0.296). These results seem to suggest Orx receptors play a role in regulating
phenotypically dependent behavioral transference in Stay animals during periods of stress,
perhaps by acting through alternate (such as locus coeruleus) pathways related to stress and
learning neurocircuitries [37, 38].
EPM results are muted by prior experience
On Day 5 of the experimental design, mice were exposed to the Elevated Plus Maze (EPM) to
assess behavioral measures of generalized anxiety as a comparator to SAM and OF Test results
observed the day prior (Day 4; Fig. 1B). In the Orx receptor antagonist groups, there were no
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phenotype differences nor differences with respect to vehicle-treated control mice for time in the
open (Fig. S11A, B; Drug Effect, F2,42 = 1.8, p ≥ 0.178; Phenotype Effect, F1,42 = 0.00006, p ≥
0.994; Interaction Effect, F2,42 = 0.07, p ≥ 0.933) or closed arms (Fig. S11C, D; Drug Effect,
F2,42 = 5.8, p ≤ 0.006; Phenotype, F1,43 = 0.2, p ≥ 0.671; Interaction Effect, F2,42 = 0.1, p ≥ 0.871)
of the EPM. Contrary to our predictions and behavioral results in the SAM (Fig. 3A), Stay mice
administered intra-BLA infusion of an Orx2R antagonist exhibited more time in the open arms
(t14 = 2.1, p ≤ 0.05) and less time in the closed arms (t14 = 3.1, p ≤ 0.008) compared to Stay
animals treated with an Orx1R antagonist (Figs. S11A, C). Further, in assessing time spent in
the intersection zone of the EPM (Drug Effect, F2,42 = 2.0, p ≥ 0.149; Phenotype Effect, F1,42 =
5.1, p ≤ 0.029; Interaction Effect, F2,42 = 1.2, p ≥ 0.313), Stay animals in the Orx2R antagonist
group spent more time in this area between the open and closed arms when compared to Escape
mice in the same treatment group (t11 = 2.5, p ≤ 0.018), as well as vehicle- (t18 = 2.3, p ≤ 0.028)
and Orx1R antagonist-treated Stay mice (Fig. S11E; t14 = 2.5, p ≤ 0.016).
In the Orx receptor stimulation groups, there were no effects observed for the amount of time
mice spent in the intersection zone of the EPM (Fig. S11F; Drug Effect, F3,46 = 0.7, p ≥ 0.533;
Phenotype Effect, F1,46 = 2.3, p ≥ 0.138; Interaction Effect, F3,46 = 0.9, p ≥ 0.461); however,
overall effects were observed for time in the open (Fig. S11B; Drug Effect, F3,46 = 2.0, p ≥
0.126; Phenotype Effect, F1,46 = 7.5, p ≤ 0.009; Interaction Effect, F3,46 = 1.3, p ≥ 0.296) and
closed arms (Fig. S11D; Drug Effect, F3,46 = 1.9, p ≥ 0.135; Phenotype Effect, F1,46 = 8.5, p ≤
0.005; Interaction Effect, F3,46 = 1.4, p ≥ 0.318). Stay mice treated with OrxA spent more time in
the open arms of the EPM than those of the Escape phenotype (Fig. S11B, black bars; t7 = 2.2, p
≤ 0.037), but this divergence of phenotypes was not observed for time in the closed arms (Fig.
S11D, black bars; t7 = 1.8, p ≥ 0.078). While Stay mice in the Orx1R stimulation group spent
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more time in the open arms compared to their Escape counterparts (t13 = 2.2, p ≤ 0.044), the
Escape animals in this treatment group spent less time in the open arms compared to vehicle
controls of the same phenotype (Fig. S11B, light gray bars with dark gray outline; t12 = 2.6, p ≤
0.024). The opposite result was observed for time in the closed arms of the EPM (Fig. S11D),
where Orx1R stimulation resulted in Escape mice spending more time in the closed arms
compared to Stay animals in the same treatment group (t13 = 2.7, p ≤ 0.020) and vehicle-treated
Escape mice (t12 = 2.7, p ≤ 0.021). Again, counter to our predictions, Escape mice infused with
an intra-BLA Orx2R agonist spent significantly less time in the open arms (Fig. S11B) and more
time in the closed arms (Fig. S11D) compared to Escape animals in the vehicle control (Open
Arms: t9 = 3.5, p ≤ 0.006; Closed Arms: t9 = 4.1, p ≤ 0.003) and OrxA treatment groups (Open
Arms: t5 = 3.6, p ≤ 0.015; Closed Arms: t5 = 2.9, p ≤ 0.034). Together, these results suggest that
anxiety-related learning in the SAM (or perhaps any environment) functionally modifies
behavioral responses to novel anxious conditions, such that standard ethological manifestations
no longer apply.
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Figure S1. Schematic shows successfully targeted intra-BLA injections of Escape and Stay mice treated
with Vehicle, Orx1R Antagonist (SB-674042), Orx2R Antagonist (MK-1064), OrxA, Orx1R Stimulation
(OrxA + MK-1064 combination), and Orx2R Stimulation (YNT-185) treatments. Escape mice are
identified as circles and Stay mice are symbolized with squares.
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Figure S2. (A) While relative expression levels of HCRTR1 are positively correlated with SAM-induced
conflict freezing in Escape mice (see Fig. 2B of main manuscript), correlation analyses in Stay mice does
not reveal this relationship (F1,12 = 0.3, R2 = 0.0224, p ≥ 0.6095). (B) Similarly, Escape mice conflict
freezing in the SAM is not associated with HCRTR2 transcription levels (F1,8 = 1.3, R2 = 0.1415, p ≥
0.2840); however, there is a negative relationship between freezing HCRTR2 expression in Stay animals
(see Fig. 2C of main manuscript).
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Figure S3. Expression of (A,a) HCRTR1 (green), (B, b) HCRTR2 (white), (C, c) CamKIIα (red), and (D,
d) DAPI (blue) in BLA cells. Images in a, b, c, & d are enlarged figures from square outlines in A, B, C,
& D. Note- images align with Figs. 2E & F of primary manuscript.

221

Figure S4. Expression of (A,a) HCRTR1 (green). (B, b) HCRTR2 (white), (C, c) GAD67 (red), and (D,
d) DAPI (blue) in BLA cells. Images in a, b, c, & d are enlarged figures from square outlines in A, B, C,
& D. Note- images align with Figs. 2H & I of primary manuscript.

222

Figure S5. (A) While Orx1R mRNA (HCRTR1) expression has a topographical organization in the BLA
(most abundant in medial portion - separated with white dotted line), (B) HCRTR2 does not exhibit an
obvious pattern of expression. (C) Approximately 70% of neurons in the BLA expressed the
glutamatergic marker CamKIIα, while only around 20% expressed GAD67 (t9 = 16.8, p < 0.001). (D) Of
CamKIIα-expressing cells, ~18% express Orx1R, less than 10% express Orx2R, and even less express
both Orx receptors (F2,15 = 84.6, p < 0.001). (E) Over 25% of GABA neurons in the BLA expressing
GAD67 also express Orx2R, while less than 10% express Orx1R or both Orx receptors (F2,12 = 84.0, p <
0.001). (F) A pie chart illustrates estimated proportions of BLA neurons and Orx receptors from reported
results.
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Figure S6. Orexin receptors in the BLA are expressed on PVALB+ GABA neurons at very low levels.
(A) Expression of HCRTR1 (green), (B) HCRTR2 (white), (C) PVALB (magenta), and DAPI (blue) when
(E) merged (some observed colocalizations are identified with filled green arrow = Orx1R+ + PVALB+,
solid white arrow = Orx2R+ + PVALB+, and unfilled magenta arrows = Orx1R- + Orx2R- + PVALB+)
reveals (F) low overlap of Orx receptor mRNA with PVALB+ GABA neurons (compared to PVALBcells in the same receptor [Orx1R+, Orx2R+, or Orx1R+ & Orx2R+] group, _p ≤ 0.05). CeA = central
amygdala
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Figure S7. (A-F) No significant correlations exist between freezing behavior in the SAM and freezing
response in the OF Test for Escape mice in any treatment group. Further, no freezing relationships were
observed for Stay animals in the (G) Orx1R Antagonist (F1,8 = 2.0, p ≥ 0.1912), (H) Orx2R Antagonist
(F1,5 = 2.2, p ≥ 0.1989), (I) OrxA (F1,3 = 0.1, p ≥ 0.7535), (J) Orx1R Stimulation (F1,7 = 0.2, p ≥ 0.6364),
and (K) Orx2R Stimulation (F1,4 = 0.3, p ≥ 0.607) groups.
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Figure S8. (A) For Escape mice under control conditions (vehicle administration) there is no significant
correlation between locomotion in the SAM and locomotion in the OF Test (F1,6 = 0.4, p ≥ 0.5281). (B)
Similarly, there is no significant relationship between SAM and OF Test locomotion for Escape animals
in the Orx1R Stimulation group (F1,4 = 5.0, p ≥ 0.09). (C-H) No significant correlations exist between
locomotor activity in the SAM and locomotion in the OF Test for Stay mice in any treatment group;
although, regression analyses for those (E) animals treated with an Orx2R antagonist exposed a positive
relationship between SAM and OF Test locomotion that is significant at the p < 0.06 level (F1,5 = 6.1, p ≤
0.057).
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Figure S9. While locomotion in the SAM and OF Test are altered by Orx receptor-targeting drugs,
home cage mobility is not affected (F5,76 = 0.7, p ≥ 0.658; Escape: F5,26 = 1.3, p ≥ 0.302; Stay: F5,44 = 1.0,
p ≥ 0.433). Circles represent Escape animals in the designated treatment group and squares signify Stay
mice.
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Figure S10. (A-F) In animals exhibiting the Escape phenotype, there were no significant correlations
between time in the center of the SAM arena and time in the center of the OF Test. Additionally, there
were no relationships observed in Stay mice for those in the (G) Vehicle (F1,11 = 2.1, p ≥ 0.1712), (H)
OrxA (F1,3 = 3.5, p ≥ 0.1572), or (I) Orx1R Stimulation (F1,7 = 1.3, p ≥ 0.2955) treatment groups.
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Figure S11. Phenotype separation is observed after Orx receptor manipulation in post-SAM EPM, but
results are not consistent with anxious state. (A) Stay mice treated with an intra-BLA Orx2R antagonist
spent more time in the open arms of the EPM than Stay animals treated with an Orx1R antagonist. (B)
Escape mice in Orx1R and Orx2R stimulation groups spent significantly less time in the open arms of the
EPM compared to vehicle-treated control animals. (C) Administration of an Orx2R antagonist into the
BLA or Stay mice resulted in less time in the closed arms of the EPM compared to animals of the same
phenotype that were treated with an Orx1R antagonist. (D) Stimulation of Orx1R or Orx2R in the BLA
promoted Escape animals to spend more time in the closed arms of the EPM compared to vehicle
controls. (E) Antagonizing intra-BLA Orx2R led to more time spent in the intersection zone of the EPM.
(F) No differences in time in the intersection zone of the EPM were observed for the Orx receptor
stimulation groups. #p ≤ 0.05 for comparisons to mice in the Orx1R antagonist group of the same
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phenotype; *p ≤ 0.05 for comparisons to Escape phenotype in the same treatment group; +p ≤ 0.05 for
comparisons to Vehicle-treated mice of the same phenotype; !p ≤ 0.05 for comparisons to OrxA treatment
animals of the same phenotype.
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Chapter 4: Female social defeat avoidance is modified by orexin 2 receptor activity

ABSTRACT
Stress responsive states require signaling balance in brain regions associated with the promotion
of pro- and anti-stress behavioral output. Biases in these circuits shift behavioral patterns and
define phenotypes that exhibit stress resilience or vulnerability. The Stress Alternatives Model
(SAM) is a behavioral paradigm that separates mice into social stress-induced behavioral
phenotypes: active avoidance (Escape) and accepting confrontation (Stay). Manipulation of
intra-BLA orexin 2 receptor (Orx2R) activity shifted phenotype-specific behaviors. As the
orexin system mediates stress responses in a sex-dependent fashion, we developed a model for
investigating social stress in female mice using shock-induced aggression (SIA). Unlike males
exposed to the SAM paradigm, all females display Escape behavior, which can be altered by
changing the paradigm to enhance the stress state. Further, female mice possess more BLA cells
that express Orx2R mRNA (HCRTR2) compared to males. Antagonizing Orx2R subcutaneously
at a low dose (30 nmol) in female animals resulted in phenotype divergence with a proportion of
mice displaying slower escape (EscapeS), a result replicated in all females administered
yohimbine (α2 receptor antagonist). Like yohimbine-treated mice, females of the EscapeS
phenotype also showed reduced social preference and enhanced cued fear freezing.
Additionally, EscapeS animals had more HCRTR2-positive cells in the BLA. These results
suggest that Orx2R mediate stress responsivity, likely by balancing pro- and anti-stress circuitry.
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INTRODUCTION
Females are reported as having twice the rates of affective disorder diagnoses compared to males
[1-3]. As stress prompts affective dysfunction and initiates disorder development, possibly in a
sex-dependent manner [4], understanding behavioral and neurophysiological consequences of
stress in female populations is paramount. Models incorporating social defeat, while potent
tools for delineating differential outcomes of stress-induced behavior and neurophysiology [5],
are limited in their ability to provoke equivalent stress states in female populations. In this way,
much of our current understanding of stress neurocircuitry is biased toward the physiology and
behavior of males.
An impediment to understanding the heightened propensity of females to exhibit stressrelated psychiatric conditions such as anxiety and depression is an animal model with highly
translatable results. As the major impetus for developing such disorders is social stress, three
recently developed models of social defeat for females have been put forth [6-8]. While these
models proved to be important advances, they had limited effectiveness in producing social
defeat in females, because the rate of aggression from males was low. We report that our model
of social stress, the Stress Alternatives Model (SAM), can be utilized to produce aggressive
interaction in females. This paradigm pits aggressive CD1 males with smaller female C57Bl/6
test mice, and occurs in an oval arena provided with escape routes that allow for escape. Four
daily trials with a novel aggressor produces two behavioral phenotypes in males: Escape and
Stay [9, 10]. Pharmacological treatments are given on Day 3, with anxiogenic drugs (such as the
α2 antagonist yohimbine) reversing Escape (become Stay), and anxiolytic drugs (such as the
CRF1 antagonist antalarmin) allow Stay animals to Escape [11].
Hypothalamus-derived orexins mediate stress responsive states in a sex-dependent fashion
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[12, 13]. The end result of post-translational processing in orexinergic neurons is the production
of two similar, yet distinct, neuromodulators: Orexin A (OrxA) and Orexin B (OrxB). Targeted
cells express type 1 and 2 orexin receptor subtypes (Orx1R and Orx2R) which, upon activation
by OrxA (EC50 = 30 nM for Orx1R and 38 nM for Orx2R) or OrxB (EC50 = 2,500 nM for Orx1R
and 36 nM for Orx2R), initiate Gq signaling pathways [14]. Orexinergic innervation is
widespread and influences reward and arousal, but also motivation and stress [15-17]. Blocking
Orx1R in the fear learning region of the brain, the basolateral amygdala (BLA), reduces anxious
behavior (changes Stay to Escape), fear conditioning, and increases resilient behavior and
motivation to Escape [18].
We adapted the SAM paradigm to include classical conditioning (a brief shock during
anogenital sniffing) for the CD1 aggressor mice to effectively induce male aggression towards
females. With CD1 male mice behaving aggressively toward females, we were able to evaluate
the behavioral profile of socially stressed females, the phenotypes that were produced, and how
the relationship of exhibited behaviors to balanced pro- and anti-stress neurocircuitries of the
BLA. Females and males have been demonstrated to react differently to stressors, which
involves distinct neurochemistry, including that of orexin [12, 13]. Those differences are
reflected in unique female orexin signaling and behavior.

METHODS & MATERIALS
Animals
Adult (6–12 weeks) female (N = 117) and male (N = 144) C57BL/6N mice (Envigo,
Indianapolis) were briefly group housed (4–5 per cage for 5 days) before being individually
housed on a 12:12 light-dark cycle (lights off at 6 P.M.) at 22°C, with ad libitum food and water.
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Male Hsd:ICR (CD1) retired breeder mice (N = 50) were singly housed and used as aggressor
mice in behavioral paradigms. Test mice (C57BL/6N) were exposed to daily handling for 7 days
prior to behavioral trials. Procedures were performed in ways that minimized suffering and the
use of animals, and were in accordance with the NIH's Guide for the Care and Use of Laboratory
Animals (NIH Publications No. 80-23) and approved by the IACUC of USD.
Surgeries and intra-BLA injections
Stereotaxic surgeries were performed on a cohort of male C57BL/N mice (N = 50) where guide
cannulae were positioned bilaterally above the basolateral amygdala (relative to bregma: AP, 1.5 mm; ML, +/-3.3 mm; DL, 4.5 mm). Mice were allowed to recover for 7 days and were
provided pain relief (ketorolac, sc, 5 mg/kg) for 48 h following surgeries. On the day of drug
delivery (Day 3), injector cannula (4.8 mm) were inserted into the guide cannula and drugs were
infused at a rate of 1 µl/min for 20 s to deliver 300 nL, after which the injector cannula was left
in position for 90 s.
Drugs
For intra-BLA manipulation of Orx2R receptor, an Orx2R antagonist (MK-1064, IC50 = 18 nM for
Orx2R; MedChemExpress, Monmouth Junction, NJ), Orx2R agonist (YNT-185 for fear response
test, EC50 = 28 nM for Orx2R and [Ala11,ᴅ-Leu15]-OrxB for Social Interaction/Preference (SIP)
test, EC50 = 0.13 nM for Orx2R; Tocris, Minneapolis, MN), and Vehicle, mixed in a 25% DMSO
solution (75% artificial cerebrospinal fluid [aCSF; 8.59 g NaCl, 0.201 g KCl, 0.279 g, CaCl2, 0.16
g MgCl2, 0.124 g NaH2PO4, 0.199 g Na2HPO4/L H2O brought to a pH of 7.3]), were administered
on Day 3 of the experimental plan (Fig. 2a). For subcutaneous (sc) pharmacological experiments,
an Orx2R antagonist (MK-1064), an α2 receptor antagonist (yohimbine), and vehicle (1:3, Saline
to DMSO ratio) were similarly delivered on Day 3 (Fig. S2). Doses for drugs infused into the
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BLA (0.1 nmol/300 nL/side for MK-1064 and [Ala11,ᴅ-Leu15]-OrxB; 10 nmol/300 nL/side for
YNT-185) were selected and adjusted based on previous experiments from our laboratory [18,
19]. As we were unsure which dose of MK-1064 to use systemically on female mice, for sc studies
we performed a dose response, where our high dose (1 µmol) was chosen to be lower than that
necessary to induce sleep in mice [20]. For our yohimbine control group, a dose of 5 mg/kg,
which blocked escape in male mice [11], was used for pharmacological studies in females.
Shock-induced aggression (SIA)
Classical Pavlovian conditioning was used to train male CD1 mice to behave aggressively
toward female C57BL/6N mice. Male CD1 mice, investigating (specifically anogenital sniffing)
female mice introduced into the males’ home cage, were delivered a brief mild shock (1 mA, <1
s) to the rump region, resulting in intense aggression directed toward the female mice. Once
aggression was displayed by the CD1, mice were separated. Typical interactions lasted under 5
min, as aggression was often immediately obtained through the pairing of the female with a mild
shock. This procedure was repeated for 4 days prior to the use of the male CD1 mice in
behavioral paradigms. In the actual experiments, CD1 mice trained to associate a female mouse
(scent) with a mild shock, seldom required shock to display aggression. In cases where the CD1
mouse did not behave aggressively toward the female during experimentation, a mild shock was
applied to produce aggressive behavior.
Behavioral paradigms
The primary behavioral paradigm used in these studies utilized the SAM. The SAM involves a
4-day (5 min/day) experimental plan that starts with test animals (C57BL/6N mice) being
introduced to an opaque cylinder in the center of an oval-shaped, open field arena (Fig. 1). An
aggressor (male CD1 mouse) roams the arena outside of the cylinder. After a 30 s resting
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period, a 5 s tone (conditioned stimulus, CS) and 10 s trace proceed the lifting of the cylinder
divider allowing the aggressive CD1 mouse to attack (unconditioned stimulus, US) the test
animal. Importantly, no test mouse encounters the same CD1 mouse twice throughout the 4Day paradigm. In the SAM arena, two escape routes existing on opposite apical ends of the
open field space allow the smaller test mouse to escape aggressive encounters. In male mice, the
end of the second day marks a commitment to one of two stable behavioral phenotypes: Escape
and Stay. This commitment allows for pharmacological intervention on Day 3, which may
reverse the chosen phenotype. Anxiogenic drugs delay escape time and promote Stay behavior,
whereas, anxiolytic drugs initiate escape behaviors in Stay mice. A purpose of the following
studies was to investigate how female behavior in the SAM differs from that in males.
To explore female behavior with our SIA method, we exposed female C57BL/6N mice to
several unique paradigms (Fig. S1). A group of female mice (N = 22) were presented with the
standard 4-Day SAM paradigm. A separate cohort (N = 10) were introduced into a SAM-like
setting, but without escape routes for four days (Inescapable Social Stress group). In
preliminary trials, all females introduced into the 4-Day SAM escaped. We next tested an
experimental plan in which a cohort of females (N = 16) was presented with a shorter SAM
protocol (2-Day SAM group) to determine if Escape and Stay phenotypes could be differentiated
in females. Finally, to see how elevated stress levels might affect SAM behavior, we tested a
group of females (N = 20) that were presented with brief bouts of aggression (less than 1 min) in
a male CD1 home cage for four days preceding the standard 4-Day SAM paradigm (Prior Stress
+ 4-Day SAM). A separate experimental design, involving both female (N = 41) and male (N =
17) mice, utilized the standard 4-Day SAM paradigm with sc drug administration on Day 3.

236

In all experiments, the behavioral paradigms were followed with the Social
Interaction/Preference (SIP) and Fear Response tests as previously described [10, 18, 19, 21]. In
brief, the SIP test involves introduction of a test mouse to a square (40 cm2) open field
environment. An empty perforated jar (Novel target) is positioned alongside on wall and the test
mouse is allowed to explore this area, including the Novel target, for 1.5 min. The mouse is
briefly removed and the empty jar is replaced by an identical jar that contains an aggressive CD1
mouse (Social target) not previously used in preceding behavioral trials. Again, the test mouse
is allowed to explore the environment and social target for 1.5 min. More time spent within 3
cm of the Social target compared to the Novel target is considered social preference behavior,
and increased time spent in the corners when the Social target is social avoidance behavior. Fear
Response is tested by placing test mice within the same cylinder divider used during daily fear
conditioning (context, CS-) and measuring freezing for 30 s. Afterwards, freezing is measured
during a 5 s tone and 10 s trace period (cue, CS+). Importantly, during the fear response test, no
CD1 aggressor is present. At the end of the Fear Response test, mice were briefly anesthetized
(5% isoflurane, 2 min) and rapidly decapitated. Trunk blood was spun down (5 min) in
heparinized tubes and plasma was collected. Brains were extracted and flash frozen in cold
isopentane on dry ice.
All behavioral paradigm was performed during the animals’ awake period (Dark hours)
under red light. Each behavioral trial was recorded using GoPro (Hero 7) cameras. Videos were
analyzed using ANY-maze (version 6.0) software.
Estrous cycle
Vaginal lavages were performed daily based on a previously described protocol [22] with
modifications. In brief, 50 µL of distilled water (dH2O) was gently flushed 3-6 times into the
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vaginal cavity and the contents were placed onto microscope slides. Samples were dried under a
heat lamp and stained for 1 min with Cresyl violet (0.1 g/100 mL dH2O), 1 min dH2O twice, and
air dried. The samples were viewed under a microscope and the stages of estrous were
identified by the abundance of three distinct cell types (Fig. S3): proestrus samples included
mostly round nucleated epithelial cells, estrus samples were characterized by dense clusters of
cornified squamous epithelial cells, metestrus samples contained predominantly leukocytes with
few cornified epithelial cells, and diestrus samples involved a mix of all cell types and was
distinguished from metestrus by the presence of nucleated epithelial cells. As our preliminary
results do not definitively expose whether the stage of the estrous cycle might impact stressrelated behaviors, for drug treatment studies (Fig. S2) we only started female animals through
behavioral the paradigm when they were in proestrus.
In situ hybridization - RNAscope
Sections of fresh frozen brains (coronal; 20 µm; relative to bregma AP -1.40 to -2.0) were placed
in cold (4°C) 10% formalin for 20 min and subsequently washed (2x for 1 min) in 1x phosphate
buffer solution (PBS), before dehydration with ethanol (50% x 1, 70% x 1, and 100% x 3; 5 min
each with the final ethanol being kept at -20°C overnight). The following day, proteins were
digested using a protease treatment and rinsed with dH2O. Brain sections were incubated for two
hours in RNAscope (Advanced Cell Diagnostics, Newark, CA) probes (HCRTR2, Cat. No.
460881) in a hybridization oven (ACD HybEZ II oven) set to 40°C. Fluorophores were linked to
probes and signaling was enhanced through application of a series of amplification buffers
(RNAscope Fluorescent Multiplex Detection Reagents). Finally, tissue was briefly stained with
DAPI (20 sec) and coverslipped. Image acquisition was performed fluorescence microscope
(Nikon A1; 10x/0.30 Plan Fluor and 20x/0.75 Plan Apo VC Nikon objectives) and NIS Elements
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software. The BLA was identified from images and analyzed using QuPath 3.0 and ImageJ
programs.
Statistics
Experimental design and analyses were based on a priori hypotheses. For comparisons that
involved SAM (and other behavioral paradigm) trials across days, SIP test results for Novel and
Social target, and Fear Response test (CS- & CS+) analyses, we utilized two-way repeated
measures ANOVA. For changes occurring across treatment/experimental groups we applied a
one-way ANOVA. Non-stressed cage controls were added for comparisons of corticosterone
levels, in situ hybridization results, and home cage mobility measurements, in which one-way
ANOVA was used. Assessments between two treatments/experimental conditions were
performed by Student’s two-tailed t-tests. To determine differences in percentage of escape or
estrous cycle stage, chi-square and Fischer Exact statistical analyses were utilized. Each mouse
provided a single unit for analyses involving a priori hypotheses. The five assumptions of
parametric statistics were applied to the data, transformed when necessary, compared to nonparametric analyses, and graphed in raw form. Analyses for parametric and non-parametric
statistics were used along with an examination for multiple comparisons applying the HolmSidak method. If the statistical analyses match, as they do for the data herein, we report the
parametric results without α adjustment [23-28]. Effects between groups for one-way analyses
were examined with Student–Newman–Keuls post hoc analyses (to minimize Type I error) and
Duncan's Multiple Range Test (to minimize Type II error).
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RESULTS
Pharmacological manipulation of intra-BLA Orx2R activity modifies stress-related
behavior
The Stress Alternatives Model (SAM) is a 4-day social stress paradigm in which male mice
diverge into distinguishable behavioral phenotypes, by actively avoiding (Escape) or accepting
(Stay) confrontation (Fig. 1). As the BLA appears to be important for SAM-promoted
phenotype development [18], we targeted this area (intra-BLA) with Orx2R-targeting drugs to
see if we could influence phenotype-specific behaviors in Social Interaction/Preference (SIP)
and Fear Response tests (Figs. 2A, B, C). In both Escape and Stay male mice, Orx2R
antagonism reduced social preference (Figs. 2D, E; Treatment Effect: F2,30 = 8.1, p ≤ 0.002;
Target Effect: F1,30 = 22.7, p < 0.001; Social, Vehicle vs Orx2R Antagonist, t19 = 2.4, p ≤ 0.02;
Vehicle, Novel vs Social, t10 = 2.9, p ≤ 0.02; Treatment Effect: F2,14 = 10.4, p ≤ 0.002; Target
Effect: F1,14 = 20.0, p < 0.001; Interaction Effect: F2,14 = 15.2, p < 0.001; Social, Vehicle vs
Orx2R Antagonist, t10 = 2.5, p ≤ 0.02). Agonism of Orx2R increased preference for both the
novel and social target in Escape and Stay mice (Figs. 2D, E; Escape: Novel, Vehicle vs Orx2R
Agonist, t21 = 2.1, p ≤ 0.05; Novel, Orx2R Antagonist vs Orx2R Agonist, t20 = 4.1, p < 0.001;
Social, Orx2R Antagonist vs Orx2R Agonist, t20 = 2.6, p ≤ 0.016; Orx2R Agonist, Novel vs
Social, t11 = 3.8, p ≤ 0.003; Stay: Novel, Orx2R Antagonist vs Orx2R Agonist, t11 = 3.2, p ≤
0.009; Social, Vehicle vs Orx2R agonist, t7 = 2.9, p ≤ 0.01; Social, Orx2R Antagonist vs Orx2R
Agonist, t11 = 6.1, p < 0.001; Orx2R Agonist, Novel vs Social, t4 = 14.3, p < 0.001). While
Orx2R antagonism increased social avoidance in Escape mice (Fig. 2F; Treatment Effect: F2,30 =
4.9, p ≤ 0.01; Social, Vehicle vs Orx2R Antagonist, t19 = 2.5, p ≤ 0.02; Social, Orx2R Antagonist
vs Orx2R Agonist, t20 = 2.7, p ≤ 0.01), there was no effect in Stay animals (Fig. 2G). Curiously,
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both Orx2R antagonism and agonism reduced cued fear freezing and eliminated the learning
response (more freezing post-tone than pre-tone) in Escape mice (Fig. 2H; Treatment Effect:
F2,13 = 5.9, p ≤ 0.02; CS Effect: F1,13 = 9.6, p ≤ 0.008; Interaction Effect: F2,13 = 4.6, p ≤ 0.03;
Post-Tone, Vehicle vs Orx2R Antagonist, t11 = 2.5, p < 0.001; Post-Tone, Vehicle vs Orx2R
Agonist, t8 = 3.7, p < 0.001; Vehicle, Pre- vs Post-Tone, t7 = 4.8, p < 0.001). However, intraBLA agonism of Orx2R diminished both contextual and cued fear freezing in Stay animals (Fig.
2I; Treatment Effect: F2,22 = 7.2, p ≤ 0.004; CS Effect: F1,22 = 37.2, p < 0.001; Pre-Tone, Vehicle
vs Orx2R Agonist, t16 = 2.3, p ≤ 0.03; Pre-Tone, Orx2R Antagonist vs Orx2R Agonist, t11 = 2.9, p
≤ 0.02; Post-Tone, Vehicle vs Orx2R Agonist, t16 = 3.9, p < 0.001; Post-Tone, Orx2R Antagonist
vs Orx2R Agonist, t11 = 3.6, p < 0.001;Vehicle, Pre- vs Post-Tone, t13 = 4.8, p < 0.001; Orx2R
Antagonist, Pre- vs Post-Tone, t8 = 4.7, p < 0.001; Orx2R Agonist, Pre- vs Post-Tone, t5 = 2.9, p
≤ 0.04).
Orx2R expression is higher in female vs male BLA
In the BLA, Orx2R are expressed at low levels in male mice [18]. Male and female mice differ
in the amount of BLA cells that express Orx2R mRNA (HCRTR2) with females having higher
levels (>20%) compared to male (~10%) mice (Fig. 3; t11 = 3.5, p ≤ 0.005).
Shock-induced aggression (SIA) initiates attacks toward female mice
In order to investigate the effects of social stress on female populations, we developed a method
for producing male CD1 retired breeder mice that act aggressively toward female mice (Fig.
4A). As males investigated (including anogenital sniffing) female mice, a mild shock (1 mA, <1
s) was applied to the rump region, which resulted in intense attacks of female conspecifics. The
number of shocks necessary to promote aggression varies (average = 2.85). However, all males
introduced to our protocol successfully exhibited aggression toward female mice (Fig. 4B).
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Surprisingly, all females subjected to the SAM choose to avoid social aggression by the end
of Day 3, which is different from males, in which ~45% escape (Fig. 4C; Day 1: Χ2 = 18.6, p <
0.001; Day 2: Χ2 = 16.3, p < 0.001; Day 3 & 4: Χ2 = 19.5, p < 0.001). However, manipulating
the stress state of females by exposing them to brief bouts of social aggression for 4-Days prior
to SAM exposure, the percentage of Escape mice can be reduced (Fig. 4D; Day 1: Χ2 = 4.9, p ≤
0.03; Day 2: Χ2 = 3.2, p ≤ 0.04). The escape latency of males of the Escape phenotype mimics
that of females, except for Day 1 where male mice utilize the escape routes at a slower rate (Fig.
4E; Day Effect: F3,141 = 51.8, p < 0.001; Day 1: t47 = 2.4, p ≤ 0.02). Interestingly, females of the
Prior Stress + 4-Day SAM experimental conditions, display enhanced latency to escape times on
Days 1-3; however, the learning profile, as indicated by the curve of the plot, remains similar
(Fig. 4F; Paradigm Effect: F1,120 = 12.9, p < 0.001; Day Effect: F3,120 = 51.0, p < 0.001; Day 1:
t40 = 4.3, p < 0.001; Day 2: t40 = 2.8, p < 0.001; Day 2: t40 = 2.6, p ≤ 0.01). Importantly, while
males of the Stay phenotype encounter greater levels of aggression in the SAM compared to
both females and Escape males (Phenotype Effect: F2,192 = 42.9, p < 0.001; Day Effect: F3,192 =
5.1, p ≤ 0.002), there is no difference in aggression received when comparing female and males
that avoid social aggression (Fig. 4G). Further, no differences in the amount of aggression
received exist between females exposed only to the SAM or those that encountered prior stress
before the SAM; however, females presented with an inescapable social stress environment
using SIA experience the greatest amount of aggression (Fig. 4H; Paradigm Effect: F2,147 = 32.4,
p < 0.001), which resembles that of Stay male mice.
Social preference and avoidance in female mice is affected by stress state
As male mice of the Escape phenotype tend to show more social preference and less avoidance
compared to Stay animals in the SIP test [19] (Figs. 2D-G), we wanted to examine how females
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subjected to various SIA paradigms (Fig. S1) would behave in this context (Fig. 5). Female
mice exposed to the standard 4-Day SAM paradigm (Fig. S1) exhibited social preference (Fig.
5A; Paradigm Effect: F3,64 = 41.3, p < 0.001; Target Effect: F1,64 = 37.6, p < 0.001; Interaction
Effect: F3,64 = 5.8, p < 0.001; 4-Day SAM, Novel vs Social, t21 = 7.1, p < 0.001) and reduced
social avoidance (Fig. 5B; Paradigm Effect: F3,64 = 9.4, p < 0.001; Target Effect: F1,64 = 12.2, p
< 0.001; Interaction Effect: F3,64 = 3.3, p ≤ 0.03; 4-Day SAM, Novel vs Social, t21 = 3.0, p ≤
0.007). Animals subjected to inescapable social stress, a 2-Day SAM paradigm, or prior stress
before 4-Day SAM exposure displayed reduced social preference (Fig. 5A; Novel, 4-Day SAM
vs Inescapable Social Stress, t30 = 4.0, p < 0.001; Novel, 4-Day SAM vs 2-Day SAM, t36 = 6.6, p
< 0.001; Novel, 4-Day SAM vs Prior Stress + 4-Day SAM, t40 = 7.1, p < 0.001; Social, 4-Day
SAM vs Inescapable Social Stress, t30 = 5.7, p < 0.001; Social, 4-Day SAM vs 2-Day SAM, t36 =
9.8, p < 0.001; Social, 4-Day SAM vs Social Stress + 4-Day SAM, t40 = 10.3, p < 0.001; Social,
Inescapable Social Stress vs 2-Day SAM, t26 = 2.6, p ≤ 0.01; Social, Inescapable Social Stress vs
Prior Stress + 4-Day SAM, t28 = 2.6, p ≤ 0.01; Inescapable Social Stress, Novel vs Social, t9 =
2.6, p ≤ 0.01) and enhanced social avoidance (Fig. 5B; Novel, 4-Day SAM vs Inescapable Social
Stress, t30 = 3.7, p < 0.001; Novel, 4-Day SAM vs 2-Day SAM, t36 = 2.7, p ≤ 0.01; Novel, 4-Day
SAM vs Prior Stress + 4-Day SAM, t40 = 3.5, p < 0.001; Social, 4-Day SAM vs Inescapable
Social Stress, t30 = 4.8, p < 0.001; Social, 4-Day SAM vs 2-Day SAM, t36 = 3.4, p < 0.001;
Social, 4-Day SAM vs Social Stress + 4-Day SAM, t40 = 5.3, p < 0.001; Inescapable Social
Stress, Novel vs Social, t9 = 2.0, p ≤ 0.05; 2-Day SAM, Novel vs Social, t15 = 2.1, p ≤ 0.04; Prior
Stress + 4-Day SAM, Novel vs Social, t19 = 3.4, p < 0.001).
As hormonal changes associated with the estrous cycle may further modify stress-related
behaviors [32], we investigated whether behaviors exhibited in the SIP test were related to the
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stage of the estrous cycle (Figs. 5C-D, S2). Mice in proestrus exhibited the highest amount of
social preference (Fig. 5C; Stage Effect: F3,49 = 6.7, p < 0.001; Target Effect: F1,49 = 34.8, p <
0.001; Interaction Effect: F3,49 = 7.6, p < 0.001; Novel, Proestrus vs Diestrus, t28 = 3.1, p ≤
0.005; Social, Proestrus vs Estrus, t21 = 3.5, p < 0.001; Social, Proestrus vs Metestrus, t18 = 4.5, p
< 0.001; Social, Proestrus vs Diestrus, t28 = 5.7, p < 0.001; Proestrus, Novel vs Social, t9 = 5.9, p
< 0.001; Estrus, Novel vs Social, t12 = 3.5, p < 0.001), while animals in diestrus showed the
greatest amount of social avoidance (Fig. 5D; Interaction Effect: F3,49 = 3.1, p ≤ 0.04; Social,
Proestrus vs Diestrus, t28 = 3.1, p ≤ 0.002; Diestrus, Novel vs Social, t19 = 3.0, p ≤ 0.004).
Fear response in female mice is impacted by stress responsive state
While male mice of the Stay phenotype display enhanced contextual and cued fear freezing
behavior relative to both male Escape animals and female mice (all of which escape in the SAM
paradigm), male Escape animals exhibit enhanced cued fear freezing compared to females (Fig.
6A; Phenotype Effect: F2,82 = 19.9, p < 0.001; CS Effect: F1,82 = 72.5, p < 0.001; Pre-Tone, Male
Stay vs Male Escape, t61 = 3.5, p < 0.001; Pre-Tone, Male Stay vs Female, t56 = 4.8, p < 0.001;
Post-Tone, Male Stay vs Male Escape, t61 = 2.5, p ≤ 0.02; Post-Tone, Male Stay vs Female, t56 =
6.1, p < 0.001; Post-Tone, Male Escape vs Female, t57 = 3.5, p < 0.001). Importantly, both
phenotypes from male mice as well as female mice show cued fear learning, characterized by
elevated freezing post-tone compared to pre-tone (Fig. 6A; Male Stay, t35 = 5.8, p < 0.001; Male
Escape, t26 = 6.5, p < 0.001; Female, t21 = 2.9, p ≤ 0.005). Female mice presented with our
various stress paradigms (Fig. S1) all display cued fear learning (Fig. 6B; Paradigm Effect: F3,64
= 8.1, p < 0.001; CS Effect: F1,64 = 87.6, p < 0.001; Interaction Effect: F3,64 = 5.1, p ≤ 0.003; 4Day SAM, Pre-Tone vs Post-Tone, t21 = 2.6, p ≤ 0.01; Inescapable Social Stress, Pre-Tone vs
Post-Tone, t9 = 6.2, p < 0.001; 2-Day SAM, Pre-Tone vs Post-Tone, t15 = 5.2, p < 0.001; Prior
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Stress + 4-Day SAM, Pre-Tone vs Post-Tone, t19 = 4.1, p < 0.001). However, mice introduced
to the experiments involving inescapable social stress, 2-Day SAM, and prior stress before 4Day SAM demonstrate increased cued fear relative to standard 4-Day SAM animals (Fig. 6B; 4Day SAM vs Inescapable Social Stress, t30 = 5.5, p < 0.001; 4-Day SAM vs 2-Day SAM, t36 =
3.9, p < 0.001; 4-Day SAM vs Prior Stress + 4-Day SAM, t40 = 3.9, p < 0.001). Further, those
mice in the prior stress + 4-Day SAM experimental group display enhanced contextual fear
freezing (Fig. 6B; 4-Day SAM vs Prior Stress + 4-Day SAM, t40 = 3.4, p ≤ 0.002). Interestingly,
mice in proestrus do not display fear learning and exhibit reduced cued freezing relative to
animals in metestrus and diestrus (Fig. 6C; Stage Effect: F3,49 = 4.3, p ≤ 0.009; CS Effect: F1,49 =
30.2, p < 0.001; Post-Tone, Proestrus vs Metestrus, t18 = 2.7, p ≤ 0.008; Post-Tone, Proestrus vs
Diestrus, t28 = 3.7, p < 0.001; Estrus, Pre-Tone vs Post-Tone, t12 = 2.9, p ≤ 0.005; Metestrus,
Pre-Tone vs Post-Tone, t9 = 2.6, p ≤ 0.01; Diestrus, Pre-Tone vs Post-Tone, t19 = 5.2, p < 0.001).
Systemic administration of an Orx2R antagonist reveals stress-related phenotypes in
female mice
As it is unclear whether the hormonal fluctuations associated with stages of the estrous cycle are
responsible for shifts in stress-related behaviors, we controlled for potential influence by
selecting only female animals in proestrus for systemic (subcutaneous) pharmacological
experiments (Figs. 7-9, S3). Pharmacological treatments, while not statistically significant,
seemed to shift the stage of the estrous cycle (Fig. S3). Treatment with yohimbine, an α2
adrenergic receptor antagonist known for anxiogenic effects, increased escape latency in females
on the day of drug administration (Fig. 7B; Day Effect: F3,108 = 17.2, p < 0.001; Day 3, Vehicle
vs Yohimbine, t11 = 4.9, p < 0.001; Day 3, MK-1064 – 1 µmol vs Yohimbine, t12 = 5.8, p <
0.001), an effect that is similarly seen in male mice [11]. While minor deviations in latency to
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escape were observed with low doses of an Orx2R antagonist (300 nmol & 30 nmol), there was
no significant differences compared to vehicle-treated animals (Fig. 7B). However, in the 30
nmol-treated group, we observed disparities in how female mice responded to drug treatment,
where we defined a distinct separation phenotypes: Slow Escape (EscapeS) and Fast Escape
(EscapeF). The females in the EscapeS classification exhibited delayed escape behavior similar
to that observed in our yohimbine control mice (Fig. 7C; Treatment Effect: F3,66 = 3.9, p ≤ 0.02;
Day Effect: F3,66 = 11.0, p < 0.001; Day 3, Vehicle vs MK-1064 – 30 nmol – EscapeS, t9 = 2.6, p
≤ 0.03; Day 3, MK-1064 – 30 nmol – EscapeF vs MK-1064 – 30 nmol – EscapeS, t11 = 3.0, p ≤
0.01). Escape males administered the same dose (30 nmol) of the Orx2R antagonist did not
display the phenotype emergence observed in female mice (Fig. 7D), however, males already
display distinct phenotypes (Fig. 4C). Further, on the day of drug delivery (Day 3), home cage
locomotion was impaired in yohimbine-treated mice, but not animals given MK-1064 at varying
doses (Fig. S4A; F5,38 = 3.0, p ≤ 0.021; Cage Control vs Yohimbine, t8 = 6.3, p < 0.001; Vehicle
vs Yohimbine, t11 = 4.6, p < 0.001; MK-1064: 1 µmol, t12 = 3.7, p ≤ 0.003; 300 nmol, t13 = 3.3, p
≤ 0.006; 30 nmol, t18 = 3.1, p ≤ 0.006). Importantly, home cage locomotion was restored to
normal levels in the yohimbine treatment group 24 hours after treatment (Fig. S4B)
Systemic delivery of Orx2R antagonist reduces social preference
While female mice administered vehicle treatment, as well as low doses of an Orx2R antagonist
(300 nmol & 30 nmol), displayed social preference in the SIP test, yohimbine-treated animals
exhibited a decrease in social preference (Fig. 8A; Target Effect: F1,36 = 27.8, p < 0.001; Social,
Vehicle vs Yohimbine, t11 = 3.1, p ≤ 0.003; Vehicle, Novel vs Social, t5 = 3.8, p < 0.001; MK1064 – 300 nmol, Novel vs Social, t7 = 2.1, p ≤ 0.045; MK-1064 – 30 nmol, Novel vs Social, t12
= 3.0, p ≤ 0.005). However, mice of the EscapeS phenotype displayed a reduction in social
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preference similar to that observed after yohimbine treatment (Fig. 8B; Target Effect: F1,16 =
24.1, p < 0.001; Social, Vehicle vs MK-1064 – 30 nmol – EscapeS, t9 = 2.7, p ≤ 0.01; MK-1064
– 30 nmol – EscapeF, Novel vs Social, t7 = 2.8, p ≤ 0.01). Only vehicle-treated mice, similar to
untreated females (Fig. 5B), saw a reduction in social avoidance (Figs. 8C, D; t5 = 2.5, p ≤ 0.05).
Fear response is enhanced in females with Orx2R antagonism
All treatment groups exhibited fear learning behavior (Fig. 9A; CS Effect: F1,36 = 42.0, p <
0.001; Vehicle, Pre-Tone vs Post-Tone, t5 = 2.5, p ≤ 0.05; MK-1064 – 1 µmol, Pre-Tone vs
Post-Tone, t6 = 2.4, p ≤ 0.02; MK-1064 – 300 nmol, Pre-Tone vs Post-Tone, t7 = 2.5, p ≤ 0.02;
MK-1064 – 30 nmol, Pre-Tone vs Post-Tone, t12 = 4.7, p < 0.001; Yohimbine, Pre-Tone vs PostTone, t6 = 4.2, p < 0.001); however, low dose (30 nmol) Orx2R antagonism promoted increased
contextual freezing behavior while yohimbine-treated female mice demonstrated enhanced
freezing to the cue (Fig. 9A; Pre-Tone, MK-1064 – 1 µmol vs MK-1064 – 30 nmol, t18 = 2.4, p
≤ 0.03; Post-Tone, Vehicle vs Yohimbine, t11 = 2.5, p ≤ 0.03). After low dose Orx2R antagonist
treatment, mice exhibited the EscapeS phenotype experienced elevated cued freezing compared
to vehicle-treated control animals, an effect mimicking yohimbine treatment (Fig. 9B; CS
Effect: F3,22 = 44.7, p < 0.001; Post-Tone, Vehicle vs MK-1064 – 30 nmol – EscapeS, t9 = 2.8, p
≤ 0.009; MK-1064 – 30 nmol – EscapeS, Pre-Tone vs Post-Tone, t4 = 4.0, p < 0.001; MK-1064 –
30 nmol – EscapeF, Pre-Tone vs Post-Tone, t7 = 3.5, p ≤ 0.002).
HCRTR2 expression is distinct in pharmacologically induced phenotypes
The number of cells in the BLA expressing Orx2R mRNA is higher in EscapeS mice compared
to EscapeF animals (Fig. 10; t8 = 2.3, p ≤ 0.048). This suggests the presence of a physiological
difference in these phenotypes, which may define the stress responsive state.
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DISCUSSION
Pro- and anti-stress neurocircuitries are divided functionally into prelimbic (PrL) prefrontal
cortical connections to anterior BLA and infralimbic (IL) connections to posterior regions
(pBLA), which correspond to non-overlapping cells with genetic markers Rspo2 (coding for the
protein R-spondin 2) and Ppp1r1b (coding for the protein DARPP-32) (29, 31). In the male
BLA, Orx1R are found in a minority of cells, which are primarily glutamatergic (CamKIIexpressing) pyramidal cells [18]. Balancing pro- and anti-stress systems appears to involve
BLA microcircuits, but the relationship of Orx2R in these circuits is largely unexplored, with
related studies providing only a glimpse into this complicated system. For example, oral
administration of an Orx2R antagonist in a clinical setting improves sleep, but in the process also
produces antidepressive effects [33]. In contrast, systemic brain delivery
(intracerebroventricular injection) of Orx2R agonists produces anxiolytic and antidepressive
effects in an animal model of social defeat and avoidance [19]. Additionally, Orx2R null mice
display enhanced behavioral despair [34] and reduced contextual freezing [35], as Orx2R
knockout decreases stress responsivity [36]. While inhibition of Orx2R in the BLA diminished
cued freezing in male Escape mice (Fig. 2H), we have previously revealed a possible anxiogenic
outcome of blocking receptor function [21]. Inhibiting Orx1R reduces fear/panic-induced
freezing [37-40], however, Orx2R antagonism directed at the BLA appears to eliminate fear
learning in Escape mice (Fig. 2H) and agonism reduces fear freezing in Stay mice (Fig. 2I),
suggesting a phenotype-dependent effect. This response may further be specific to the BLA, as
Orx2R activity in the nucleus accumbens shell, PrL, and paraventricular thalamus may enhance
anxious behavior [41-44]. These collective qualities of Orx2R action suggest this receptor
subtype, unlike Orx1R activity which is consistently linked to pro-stress outcomes [37, 38, 45],
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differentially regulates behavioral responses in a way that reflects the initial, possibly innate,
stress state [46].
In the BLA, Orx2R expressing cells are more abundant in females compared to males (Fig.
3), and female mice exposed to the SAM arena always escape and do so faster than males on
Day 1 (Figs. 4E). Further, females show greater social preference and diminished fear responses
compared to males (Figs. 5A, 6A). These sexually dimorphic responses may be altered by
manipulating the female stress state (Figs. 5A-B, 6B), suggesting, like males [10, 11, 18, 19],
SAM-induced escape behavior in females is linked to anti-stress outcomes.
We suspected these behavioral differences in females and males might be associated with
Orx2R function, and attempted to manipulate escape-related behaviors by pharmacologically
inhibiting Orx2R activity. In our dose response, the highest concentration (1 µmol) of MK-1064,
selected to be slightly under the amount necessary to promote sleep [20], produced minimal
changes to female behavior; however, the lowest dose (30 nmol) modified behaviors more
noticeably (Figs. 8, 9). Closer examination revealed a divergence in behavioral outcomes after
treatment of low dose MK-1064 (Fig. 7C): animals exhibiting delayed escape (EscapeS) and
mice showing normal escape (EscapeF). Female mice defined as EscapeS animals further
displayed pro-stress responses, which mimicked those of the anxiogenic α2 receptor antagonist
yohimbine, in SIP and Fear Response tests (Figs. 8B, 9B). We postulate the prominent effect of
the lowest dose of MK-1064 to be a result of enhanced biased signaling of Orx2R, over Orx1R,
as a result of limiting the drug load. Interestingly, this low dose of Orx2R had no effect on male
Escape mice, further highlighting sex differences in stress behavioral responses.
The orexin system is plastic, and the number of hypothalamic cells that produce orexins
fluctuate diurnally [47] and during dependency [48, 49]. We demonstrate a mechanism for
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potential plasticity of Orx2R-expressing cells in the BLA that may define an animals’ stress
responsive state as EscapeS mice have more of these cells (Fig. 10). Importantly, it is unclear
from the results reported here if the higher expression of HCRTR2-postive cells in EscapeS mice
precedes drug administration. If this were true, however, it would establish a
neurophysiological difference that may explain phenotype emergence after drug administration.
In males, antagonism of intra-BLA Orx2R in Escape animals lowers cued freezing behavior (Fig.
2H); however, male Escape mice have higher HCRTR2 expression in the BLA compared to Stay
animals [18]. In females, high Orx2R-expressing cells appears to be the stable state (Fig. 3);
however, phenotype emergence promotes neurophysiological adaptations and plasticity within
the BLA-contained orexin system. If this is true, higher HCRTR2-expressing cells in the BLA
acts as a homeostatic mechanism to help establish balance to counteract a bias in pro-stress
signaling.
Conclusions
Shifts in microcircuits regulate stress responsivity and higher reactive states (Stay). In males,
these stress responsive states are modified by Orx2R activity in the BLA, where sex-defined
differences in intra-BLA HCRTR2 may help explain sexual dimorphism in stress-induced
behaviors. By manipulating Orx2R activity in females, behavioral phenotypes emerge. These
phenotypic differences are further defined by the number of HCRTR2-expressing cells in the
BLA. Together, these results suggest the balance of Orx2R activity in the BLA is important for
mediating stress responsivity in both males and females.
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Figure 1. The Stress Alternatives Model (SAM) is a 4-Day social stress paradigm in which mice are
conditioned (Tone, CS+) to social aggression (US) and commit to a behavioral phenotype by the end of
Day 2: Escape (active avoidance of social aggression) and Stay (accepting confrontation from aggressor).
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Figure 2. Administration of intra-BLA Orx2R-targeting drugs alters stress-related behavior in SIP and
Fear Response tests. (A) Experimental design for experiment pharmacologically targeting male intraBLA Orx2R. (B) Social Interaction/Preference (SIP) test measures social preference (bottom left) and
avoidance (bottom right). (C) Fear Response test indicates if fear learning takes place and whether fear
responses are observed in response to the context (CS-) or cue (CS+). (D) Escape mice treated with an
Orx2R antagonist exhibit reduced social preference (n = 33, Treatment Effect: F2,30 = 8.1, p ≤ 0.002;
Target Effect: F1,30 = 22.7, p < 0.001; Novel, Vehicle vs Orx2R Agonist, t21 = 2.1, +p ≤ 0.05; Novel,
Orx2R Antagonist vs Orx2R Agonist, t20 = 2.6, ^p ≤ 0.016; Social, Vehicle vs Orx2R Antagonist, t19 = 2.4,
!p ≤ 0.02; Social, Orx2R Antagonist vs Orx2R Agonist, t20 = 4.1, ^p < 0.001; Vehicle, Novel vs Social, t10
= 2.9, #p ≤ 0.02; Orx2R Agonist, Novel vs Social, t11 = 3.8, #p ≤ 0.003). (E) In Stay mice, social
preference is enhanced after Orx2R agonist treatment and reduced after administration of an Orx2R
antagonist (n = 17, Treatment Effect: F2,14 = 10.4, p ≤ 0.002; Target Effect: F1,14 = 20.0, p < 0.001;
Interaction Effect: F2,14 = 15.2, p < 0.001; Novel, Orx2R Antagonist vs Orx2R Agonist, t11 = 3.2, ^p ≤
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0.009; Social, Vehicle vs Orx2R Antagonist, t10 = 2.5, $p ≤ 0.02; Social, Vehicle vs Orx2R agonist, t7 =
2.9, +p ≤ 0.01; Social, Orx2R Antagonist vs Orx2R Agonist, t11 = 6.1, ^p < 0.001; Orx2R Agonist, Novel
vs Social, t4 = 14.3, #p < 0.001). (F) Social avoidance is enhanced in Orx2R antagonist-treated Escape
mice (n = 33, Treatment Effect: F2,30 = 4.9, p ≤ 0.01; Social, Vehicle vs Orx2R Antagonist, t19 = 2.5, !p ≤
0.02; Social, Orx2R Antagonist vs Orx2R Agonist, t20 = 2.7, ^p ≤ 0.01). (G) There is no effect of
treatment on social avoidance behavior in Stay mice. (H) Cued fear freezing is reduced in Escape mice
following either Orx2R antagonism or agonism (n = 16, Treatment Effect: F2,13 = 5.9, p ≤ 0.02; CS Effect:
F1,13 = 9.6, p ≤ 0.008; Interaction Effect: F2,13 = 4.6, p ≤ 0.03; Post-Tone, Vehicle vs Orx2R Antagonist,
t11 = 2.5, $p < 0.001; Post-Tone, Vehicle vs Orx2R Agonist, t8 = 3.7, +p < 0.001; Vehicle, Pre- vs PostTone, t7 = 4.8, #p < 0.001). (I) Agonism of intra-BLA Orx2R reduces both contextual and cued fear
freezing in Stay animals (n = 29, Treatment Effect: F2,22 = 7.2, p ≤ 0.004; CS Effect: F1,22 = 37.2, p <
0.001; Pre-Tone, Vehicle vs Orx2R Agonist, t16 = 2.3, +p ≤ 0.03; Pre-Tone, Orx2R Antagonist vs Orx2R
Agonist, t11 = 2.9, +p ≤ 0.02; Post-Tone, Vehicle vs Orx2R Agonist, t16 = 3.9, +p < 0.001; Post-Tone,
Orx2R Antagonist vs Orx2R Agonist, t11 = 3.6, !p < 0.001;Vehicle, Pre- vs Post-Tone, t13 = 4.8, #p <
0.001; Orx2R Antagonist, Pre- vs Post-Tone, t8 = 4.7, #p < 0.001; Orx2R Agonist, Pre- vs Post-Tone, t5 =
2.9, #p ≤ 0.04).
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Figure 3. Expression of Orx2R mRNA in the BLA is higher in female compared to male mice. (A)
Representative image of female BLA with Orx2R mRNA (HCRTR2) expression (red = HCRTR2, blue =
DAPI). (B) Expression of HCRTR2 in male BLA. (C) Female mice have more BLA cells that express
Orx2R mRNA compared to males (n = 13, t11 = 3.5, *p ≤ 0.005).
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Figure 4. Female social stress and behavioral phenotype development is distinct from that in male mice.
(A) Shock-induced aggression (SIA) involves applying a mild shock (1 mA, <1 s) to male (CD1 retired
breeder) mice as they perform anogenital sniffing of female conspecifics. (B) The number of shocks
needed to promote aggression varies, but all preliminary trials (n = 40) resulted in aggressive
interactions. (C) Female mice experiencing social aggression in the SAM all escaped by Day 3; whereas,
~45% of male mice committed to the Escape phenotype by the end of Day 2 (n = 85, Day 1: Χ2 = 18.6,
*p < 0.001; Day 2: Χ2 = 16.3, *p < 0.001; Day 3 & 4: Χ2 = 19.5, *p < 0.001). (D) Female mice that
experienced 4-Days of social stress prior to SAM introduction exhibited more Stay behavior (n = 42, Day
1: Χ2 = 4.9, *p ≤ 0.03; Day 2: Χ2 = 3.2, *p ≤ 0.04). (E) Male mice that chose the Escape phenotype
experienced a slower latency to escape on Day 1 compared to female animals (n = 49, Day Effect: F3,141 =
51.8, p < 0.001; Day 1: t47 = 2.4, *p ≤ 0.02; unique letters indicate differences from other Days, e.g. A is
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different from B, p ≤ 0.02). (F) Latency to escape in females that experienced social stress prior to SAM
exposure displayed slower escape times on Days 1-3 (n = 42, Paradigm Effect: F1,120 = 12.9, p < 0.001;
Day Effect: F3,120 = 51.0, p < 0.001; Day 1: t40 = 4.3, *p < 0.001; Day 2: t40 = 2.8, *p < 0.001; Day 2: t40 =
2.6, *p ≤ 0.01; unique letters indicate differences from other Days, e.g. A is different from B, p < 0.001).
(G) Male Stay mice experience more aggression than Escape mice, which receive similar levels of
aggression as Female mice in the SAM arena (n = 85, Phenotype Effect: F2,192 = 42.9, p < 0.001; Day
Effect: F3,192 = 5.1, p ≤ 0.002). (H) Females in an inescapable social stress paradigm receive more
aggression than females exposed to the SAM where they can avoid aggressive encounters (n = 52,
Paradigm Effect: F2,147 = 32.4, p < 0.001).
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Figure 5. Female stress state impacts results in SIP test. (A) Enhanced stress in females reduces
preference for both novel and social targets (n = 68, Paradigm Effect: F3,64 = 41.3, p < 0.001; Target
Effect: F1,64 = 37.6, p < 0.001; Interaction Effect: F3,64 = 5.8, p < 0.001; Novel, 4-Day SAM vs
Inescapable Social Stress, t30 = 4.0, *p < 0.001; Novel, 4-Day SAM vs 2-Day SAM, t36 = 6.6, *p < 0.001;
Novel, 4-Day SAM vs Prior Stress + 4-Day SAM, t40 = 7.1, *p < 0.001; Social, 4-Day SAM vs
Inescapable Social Stress, t30 = 5.7, *p < 0.001; Social, 4-Day SAM vs 2-Day SAM, t36 = 9.8, *p < 0.001;
Social, 4-Day SAM vs Social Stress + 4-Day SAM, t40 = 10.3, *p < 0.001; Social, Inescapable Social
Stress vs 2-Day SAM, t26 = 2.6, ^p ≤ 0.01; Social, Inescapable Social Stress vs Prior Stress + 4-Day
SAM, t28 = 2.6, ^p ≤ 0.01; 4-Day SAM, Novel vs Social, t21 = 7.1, _p < 0.001; Inescapable Social Stress,
Novel vs Social, t9 = 2.6, _p ≤ 0.01). (B) In females, social avoidance is increased in paradigms involving
inescapable social stress, 2-Day SAM, and prior stress before 4-Day SAM (n = 68, Paradigm Effect: F3,64
= 9.4, p < 0.001; Target Effect: F1,64 = 12.2, p < 0.001; Interaction Effect: F3,64 = 3.3, p ≤ 0.03; Novel, 4Day SAM vs Inescapable Social Stress, t30 = 3.7, *p < 0.001; Novel, 4-Day SAM vs 2-Day SAM, t36 =
2.7, *p ≤ 0.01; Novel, 4-Day SAM vs Prior Stress + 4-Day SAM, t40 = 3.5, *p < 0.001; Social, 4-Day
SAM vs Inescapable Social Stress, t30 = 4.8, *p < 0.001; Social, 4-Day SAM vs 2-Day SAM, t36 = 3.4, *p
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< 0.001; Social, 4-Day SAM vs Social Stress + 4-Day SAM, t40 = 5.3, *p < 0.001; 4-Day SAM, Novel vs
Social, t21 = 3.0, _p ≤ 0.007; Inescapable Social Stress, Novel vs Social, t9 = 2.0, _p ≤ 0.05; 2-Day SAM,
Novel vs Social, t15 = 2.1, _p ≤ 0.04; Prior Stress + 4-Day SAM, Novel vs Social, t19 = 3.4, _p < 0.001).
(C) Mice in proestrus exhibit enhanced social preference compared to other stages of the estrous cycle (n
= 53, Stage Effect: F3,49 = 6.7, p < 0.001; Target Effect: F1,49 = 34.8, p < 0.001; Interaction Effect: F3,49 =
7.6, p < 0.001; Novel, Proestrus vs Diestrus, t28 = 3.1, *p ≤ 0.005; Social, Proestrus vs Estrus, t21 = 3.5,
*p < 0.001; Social, Proestrus vs Metestrus, t18 = 4.5, *p < 0.001; Social, Proestrus vs Diestrus, t28 = 5.7,
*p < 0.001; Proestrus, Novel vs Social, t9 = 5.9, _p < 0.001; Estrus, Novel vs Social, t12 = 3.5, _p < 0.001).
(D) Animals in diestrus display higher social avoidance behavior (n = 53, Interaction Effect: F3,49 = 3.1, p
≤ 0.04; Social, Proestrus vs Diestrus, t28 = 3.1, *p ≤ 0.002; Diestrus, Novel vs Social, t19 = 3.0, _p ≤
0.004).
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Figure 6. Fear response in female mice is dependent on stress state. (A) Male Stay mice exhibit the
greatest amount of contextual and cued freezing, but male Escape animals freeze more to the cue than
females (n = 85, Phenotype Effect: F2,82 = 19.9, p < 0.001; CS Effect: F1,82 = 72.5, p < 0.001; Pre-Tone,
Male Stay vs Male Escape, t61 = 3.5, *p < 0.001; Pre-Tone, Male Stay vs Female, t56 = 4.8, +p < 0.001;
Post-Tone, Male Stay vs Male Escape, t61 = 2.5, *p ≤ 0.02; Post-Tone, Male Stay vs Female, t56 = 6.1, +p
< 0.001; Post-Tone, Male Escape vs Female, t57 = 3.5, +p < 0.001; Male Stay, Pre-Tone vs Post-Tone, t35
= 5.8, #p < 0.001; Male Escape, Pre-Tone vs Post-Tone, t26 = 6.5, #p < 0.001; Female, Pre-Tone vs PostTone, t21 = 2.9, #p ≤ 0.005). (B) In female mice, enhancing the stress state promotes increased freezing
in the fear response test (n = 68, Paradigm Effect: F3,64 = 8.1, p < 0.001; CS Effect: F1,64 = 87.6, p <
0.001; Interaction Effect: F3,64 = 5.1, p ≤ 0.003; Pre-Tone, 4-Day SAM vs Prior Stress + 4-Day SAM, t40
= 3.4, *p ≤ 0.002; Post-Tone, 4-Day SAM vs Inescapable Social Stress, t30 = 5.5, *p < 0.001; Post-Tone,
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4-Day SAM vs 2-Day SAM, t36 = 3.9, *p < 0.001; Post-Tone, 4-Day SAM vs Prior Stress + 4-Day SAM,
t40 = 3.9, *p < 0.001; 4-Day SAM, Pre-Tone vs Post-Tone, t21 = 2.6, _p ≤ 0.01; Inescapable Social Stress,
Pre-Tone vs Post-Tone, t9 = 6.2, _p < 0.001; 2-Day SAM, Pre-Tone vs Post-Tone, t15 = 5.2, _p < 0.001;
Prior Stress + 4-Day SAM, Pre-Tone vs Post-Tone, t19 = 4.1, _p < 0.001). (C) Female mice in metestrus
and diestrus display elevated cued fear freezing behavior (n = 53, Stage Effect: F3,49 = 4.3, p ≤ 0.009; CS
Effect: F1,49 = 30.2, p < 0.001; Post-Tone, Proestrus vs Metestrus, t18 = 2.7, *p ≤ 0.008; Post-Tone,
Proestrus vs Diestrus, t28 = 3.7, *p < 0.001; Estrus, Pre-Tone vs Post-Tone, t12 = 2.9, _p ≤ 0.005;
Metestrus, Pre-Tone vs Post-Tone, t9 = 2.6, _p ≤ 0.01; Diestrus, Pre-Tone vs Post-Tone, t19 = 5.2, _p <
0.001).
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Figure 7. Systemic antagonism of Orx2R reveals female phenotype formation. (A) Experimental design
for pharmacological experiments. (B) Yohimbine, an α2 receptor antagonist, significantly increases
latency to escape, while low doses of an Orx2R antagonist (MK-1064) moderately alter latency to escape
(n = 41, Day Effect: F3,108 = 17.2, p < 0.001; Day 3, Vehicle vs Yohimbine, t11 = 4.9, *p < 0.001; Day 3,
MK-1064 – 1 µmol vs Yohimbine, t12 = 5.8, +p < 0.001). (C) Phenotype separation in female mice after
low dose (30 nmol) treatment of an Orx2R antagonist (MK-1064) reveals fast (EscapeF) and slow
(EscapeS) escapers, where EscapeS animals express an enhanced latency to escape comparable to that
observed after yohimbine treatment (n = 26, Treatment Effect: F3,66 = 3.9, p ≤ 0.02; Day Effect: F3,66 =
11.0, p < 0.001; Day 3, Vehicle vs MK-1064 – 30 nmol – EscapeS, t9 = 2.6, *p ≤ 0.03; Day 3, MK-1064 –
30 nmol – EscapeF vs MK-1064 – 30 nmol – EscapeS, t11 = 3.0, !p ≤ 0.01). (D) Male Escape mice
administered MK-1064 at 30 nmol did not display increased latency to escape.
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Figure 8. Pharmacologically revealed phenotypes in females show different responses in SIP test. (A)
Social preference is reduced with Yohimbine treatment (n = 41, Target Effect: F1,36 = 27.8, p < 0.001;
Social, Vehicle vs Yohimbine, t11 = 3.1, *p ≤ 0.003; Vehicle, Novel vs Social, t5 = 3.8, _p < 0.001; MK1064 – 300 nmol, Novel vs Social, t7 = 2.1, _p ≤ 0.045; MK-1064 – 30 nmol, Novel vs Social, t12 = 3.0, _p
≤ 0.005). (B) Female mice treated with MK-1064 at the 30 nmol dose that exhibited slow escape
behavior (EscapeS) displayed reduced social preference comparable to that observed in yohimbine-treated
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mice (n = 26, Target Effect: F1,16 = 24.1, p < 0.001; Social, Vehicle vs MK-1064 – 30 nmol – EscapeS, t9
= 2.7, *p ≤ 0.01; MK-1064 – 30 nmol – EscapeF, Novel vs Social, t7 = 2.8, #p ≤ 0.01). (C-D) Only
vehicle-treated mice exhibited reduced social avoidance behavior (t5 = 2.5, _/#p ≤ 0.05).
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Figure 9. Systemic antagonism of Orx2R affects fear response in females mice in a phenotypedependent fashion. (A) Yohimbine increases cued fear freezing (n = 41, CS Effect: F1,36 = 42.0, p <
0.001; Pre-Tone, MK-1064 – 1 µmol vs MK-1064 – 30 nmol, t18 = 2.4, +p ≤ 0.03; Post-Tone, Vehicle vs
Yohimbine, t11 = 2.5, *p ≤ 0.03; Vehicle, Pre-Tone vs Post-Tone, t5 = 2.5, _p ≤ 0.05; MK-1064 – 1 µmol,
Pre-Tone vs Post-Tone, t6 = 2.4, _p ≤ 0.02; MK-1064 – 300 nmol, Pre-Tone vs Post-Tone, t7 = 2.5, _p ≤
0.02; MK-1064 – 30 nmol, Pre-Tone vs Post-Tone, t12 = 4.7, _p < 0.001; Yohimbine, Pre-Tone vs PostTone, t6 = 4.2, _p < 0.001). (B) Female EscapeS phenotype displays elevated cued freezing behavior
similar to yohimbine-treated female mice (n = 26, CS Effect: F3,22 = 44.7, p < 0.001; Post-Tone, Vehicle
vs MK-1064 – 30 nmol – EscapeS, t9 = 2.8, *p ≤ 0.009; MK-1064 – 30 nmol – EscapeS, Pre-Tone vs
Post-Tone, t4 = 4.0, #p < 0.001; MK-1064 – 30 nmol – EscapeF, Pre-Tone vs Post-Tone, t7 = 3.5, #p ≤
0.002).
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Figure 10. Cells in BLA expressing Orx2R are unique in antagonist-induced phenotypes. (A) Image
representing HCRTR2 expression in BLA cells of mice defined as EscapeF (red = HCRTR2, blue = DAPI)
and (B) EscapeS. (C) Mice exhibiting the EscapeS phenotype have more Orx2R mRNA expression
compared to EscapeF animals (n = 10, t8 = 2.3, *p ≤ 0.048).
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Figure S1. Social stress paradigm outlines used for exploring female social stress.
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Figure S2. Lavage samples were collected daily to determine the stage of the estrous cycle for NonStressed Cage Control mice and those of experimental groups: 4-Days SAM & Prior Stress + 4-Days
SAM.
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Figure S3. While all animals started experimental trials in the proestrus stage of the estrous cycle,
variation was observed in the number of animals in a particular stage of the cycle after drug treatment
(Yohimbine or MK-1064).
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Figure S4. (A) Yohimbine reduces home cage locomotion on Day 3, 1 hr after drug administration (F5,38
= 3.0, p ≤ 0.021). Differences are observed relative to cage control (t8 = 6.3, ^p < 0.001), vehicle- (t11 =
4.6, *p < 0.001), and MK-1064-treated mice (1 µmol: t12 = 3.7, +p ≤ 0.003; 300 nmol: t13 = 3.3, #p ≤
0.006; 30 nmol: t18 = 3.1, !p ≤ 0.006). (B) There were, however, no effects on home cage mobility on
Day 4 (24 hr after) drug treatment (F5,38 = 0.7, p ≥ 0.647).
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